data_2l16_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2l16 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.442 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo . . . . . 0 N--CA 1.496 1.674 0 N-CA-C 111.211 -0.342 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.466 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 22' ' ' GLY . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.403 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo . . . . . 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.702 0.209 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.459 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo . . . . . 0 N--CA 1.497 1.688 0 CA-C-O 120.693 0.205 . . . . 0.0 111.906 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m . . . . . 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.473 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.406 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.451 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.5 Cg_exo . . . . . 0 N--CA 1.493 1.453 0 CA-C-O 121.107 0.378 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.013 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 HD12 ' A' ' 16' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo . . . . . 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.746 0.228 . . . . 0.0 111.708 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.488 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.439 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.42 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.42 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.45 ' HB3' HH12 ' A' ' 31' ' ' ARG . 11.8 Cg_exo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.93 -0.45 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.45 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.6 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.492 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 13' ' ' ILE . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.428 HG21 HD13 ' A' ' 19' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.543 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo . . . . . 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.543 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo . . . . . 0 N--CA 1.48 0.735 0 CA-C-O 120.929 0.304 . . . . 0.0 111.953 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.491 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo . . . . . 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 121.081 0.367 . . . . 0.0 111.464 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.42 HD13 HG23 ' A' ' 29' ' ' ILE . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.435 ' CD1' ' HZ2' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.435 ' HZ2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.464 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo . . . . . 0 N--CA 1.496 1.666 0 CA-C-O 121.296 0.457 . . . . 0.0 111.518 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.46 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.423 ' O ' ' N ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo . . . . . 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.438 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.0 Cg_exo . . . . . 0 N--CA 1.494 1.503 0 CA-C-O 120.961 0.317 . . . . 0.0 111.575 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.401 HG22 HD13 ' A' ' 29' ' ' ILE . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.49 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_exo . . . . . 0 N--CA 1.497 1.715 0 CA-C-O 121.116 0.382 . . . . 0.0 111.438 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.492 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo . . . . . 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 37.5 Cg_exo . . . . . 0 N--CA 1.491 1.369 0 CA-C-O 121.242 0.434 . . . . 0.0 111.601 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo . . . . . 0 N--CA 1.498 1.779 0 CA-C-O 121.166 0.402 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.621 0 N-CA-C 112.045 -0.422 . . . . 0.0 112.045 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.462 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.41 HG23 HD13 ' A' ' 16' ' ' ILE . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.404 HG12 ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.404 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo . . . . . 0 N--CA 1.499 1.802 0 CA-C-O 120.719 0.216 . . . . 0.0 112.103 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.445 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.445 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo . . . . . 0 N--CA 1.495 1.589 0 CA-C-O 121.182 0.409 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.505 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.401 HG23 HD13 ' A' ' 13' ' ' ILE . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.423 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 CA--C 1.547 1.131 0 CA-C-O 120.729 0.22 . . . . 0.0 111.561 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.445 ' N ' ' CD1' ' A' ' 11' ' ' ILE . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo . . . . . 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.474 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 29.1 Cg_exo . . . . . 0 N--CA 1.498 1.783 0 CA-C-O 121.22 0.425 . . . . 0.0 112.103 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo . . . . . 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo . . . . . 0 N--CA 1.504 2.115 0 N-CA-C 113.267 0.449 . . . . 0.0 113.267 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.454 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.405 ' O ' ' N ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo . . . . . 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.404 ' CG ' ' O ' ' A' ' 23' ' ' PRO . 19.1 Cg_endo . . . . . 0 N--CA 1.492 1.386 0 N-CA-C 111.344 -0.291 . . . . 0.0 111.344 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.405 HG23 HD12 ' A' ' 13' ' ' ILE . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 17' ' ' ALA . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo . . . . . 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.463 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 7.4 Cg_endo . . . . . 0 N--CA 1.505 2.175 0 CA-C-O 121.37 0.488 . . . . 0.0 112.218 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m . . . . . 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.44 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.411 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 120.917 0.299 . . . . 0.0 112.361 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.507 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.404 ' O ' ' N ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 HG23 HD12 ' A' ' 19' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.432 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 30.2 Cg_exo . . . . . 0 N--CA 1.494 1.548 0 CA-C-O 121.214 0.422 . . . . 0.0 111.233 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.4 HD13 HG22 ' A' ' 29' ' ' ILE . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.499 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo . . . . . 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.444 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.2 Cg_endo . . . . . 0 N--CA 1.492 1.404 0 N-CA-C 111.384 -0.276 . . . . 0.0 111.384 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.414 HG21 HD11 ' A' ' 13' ' ' ILE . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.409 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.403 HG22 HD12 ' A' ' 16' ' ' ILE . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo . . . . . 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_exo . . . . . 0 N--CA 1.492 1.415 0 N-CA-C 111.113 -0.38 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.489 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.415 HG21 HD11 ' A' ' 16' ' ' ILE . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.403 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.436 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.436 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.403 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.959 0.316 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.401 ' HG3' ' N ' ' A' ' 42' ' ' SER . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' SER . . . . . 0.401 ' N ' ' HG3' ' A' ' 41' ' ' LYS . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.5 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 16' ' ' ILE . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.409 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo . . . . . 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.466 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo . . . . . 0 N--CA 1.503 2.068 0 CA-C-O 120.767 0.236 . . . . 0.0 111.9 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.466 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.463 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo . . . . . 0 N--CA 1.497 1.698 0 CA-C-O 121.208 0.42 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.496 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.4 HD11 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.433 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.427 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 16.4 Cg_exo . . . . . 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.1 Cg_exo . . . . . 0 N--CA 1.493 1.48 0 CA-C-O 121.239 0.433 . . . . 0.0 111.706 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.46 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo . . . . . 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 CA-C-O 121.017 0.34 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.443 ' CD1' ' HZ3' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.443 ' HZ3' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.442 ' N ' ' CD1' ' A' ' 11' ' ' ILE . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.436 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.436 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 10.7 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.704 0.21 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.488 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.424 HG21 HD13 ' A' ' 19' ' ' ILE . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.488 1.179 0 CA-C-O 120.988 0.328 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.452 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.897 0.29 . . . . 0.0 111.422 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.503 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.458 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.4 Cg_exo . . . . . 0 N--CA 1.496 1.673 0 CA-C-O 121.156 0.398 . . . . 0.0 111.678 . . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.471 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo . . . . . 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.5 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 21.4 Cg_endo . . . . . 0 N--CA 1.498 1.766 0 CA-C-O 120.789 0.245 . . . . 0.0 111.756 . . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.485 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.485 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.485 1.026 0 CA-C-O 120.636 0.182 . . . . 0.0 112.066 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . 0.461 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.437 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo . . . . . 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.411 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 38.1 Cg_exo . . . . . 0 N--CA 1.494 1.507 0 CA-C-O 121.156 0.398 . . . . 0.0 111.353 . . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.431 ' CD1' ' HZ2' ' A' ' 41' ' ' LYS . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . 0.431 ' HZ2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t . . . . . 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.496 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo . . . . . 0 N--CA 1.494 1.559 0 CA-C-O 121.079 0.366 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.439 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo . . . . . 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 14.6 Cg_endo . . . . . 0 N--CA 1.492 1.394 0 CA-C-O 120.756 0.232 . . . . 0.0 112.249 . . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.461 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo . . . . . 0 N--CA 1.498 1.789 0 CA-C-O 120.603 0.168 . . . . 0.0 112.12 . . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo . . . . . 0 N--CA 1.494 1.547 0 CA-C-O 121.07 0.362 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.685 ' N ' HD21 ' A' ' 4' ' ' ASN . 99.3 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -87.29 -3.22 59.03 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.699 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -101.98 -23.64 14.09 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.685 HD21 ' N ' ' A' ' 1' ' ' MET . 51.0 m-80 -76.74 -14.43 59.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.742 -179.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -64.36 -43.99 97.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.006 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.72 -137.79 34.78 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.531 -1.028 . . . . 0.0 110.531 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.527 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -65.86 -47.67 64.15 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.711 179.496 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.442 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 95.2 Cg_exo -39.48 -38.61 1.58 Allowed 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 121.487 1.458 . . . . 0.0 112.114 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.81 -29.96 60.33 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.527 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.442 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -69.59 -16.26 38.18 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -94.19 0.89 56.04 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.478 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.51 -35.86 9.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.543 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.3 mt -68.95 -43.26 25.82 Favored Pre-proline 0 N--CA 1.446 -0.635 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.564 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 23.5 Cg_exo -67.17 -32.98 32.58 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.292 1.995 . . . . 0.0 111.211 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -75.75 -31.97 59.79 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.9 mt -70.49 -44.13 68.29 Favored 'General case' 0 N--CA 1.455 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.782 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.74 -40.29 69.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.428 ' OG ' ' OD1' ' A' ' 51' ' ' ASP . 40.3 t -60.94 -44.38 97.34 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.479 -179.332 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 42.38 31.45 0.99 Allowed Glycine 0 CA--C 1.521 0.447 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.428 ' OD1' ' OG ' ' A' ' 49' ' ' SER . 53.9 p-10 -172.28 178.41 2.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.85 0.357 . . . . 0.0 110.605 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.756 179.836 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.681 ' N ' HD21 ' A' ' 4' ' ' ASN . 96.9 mtp . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.423 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.0 m-85 -85.12 -3.09 58.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.612 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.71 -24.48 13.74 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.602 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.681 HD21 ' N ' ' A' ' 1' ' ' MET . 55.4 m-80 -77.79 -13.65 59.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.658 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.423 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -61.25 -47.83 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.531 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.45 -118.89 6.22 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.687 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.8 tp -105.59 -17.85 0.17 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.687 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 62.0 Cg_endo -72.45 -54.19 0.13 Allowed 'Trans proline' 0 N--CA 1.499 1.853 0 C-N-CA 122.133 1.889 . . . . 0.0 112.912 -178.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.14 -21.63 32.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.466 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 22' ' ' GLY . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.403 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo -83.88 -15.48 6.96 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.78 -18.23 15.23 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 112.859 -1.973 . . . . 0.0 109.045 -179.431 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 55.8 mmtt -96.44 -13.77 22.89 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.444 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 3.2 mt -82.37 -63.36 0.28 Allowed Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.574 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 21.4 Cg_endo -58.88 -32.27 96.98 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 122.168 1.912 . . . . 0.0 111.676 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t -75.51 -32.78 60.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.7 mt -70.35 -43.47 70.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.978 0.418 . . . . 0.0 110.714 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.22 -28.99 26.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.784 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -60.46 -43.85 96.49 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.717 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 148.96 41.62 0.03 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -125.09 107.92 11.28 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.734 0.302 . . . . 0.0 110.751 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.625 179.838 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.723 ' H3 ' HD21 ' A' ' 4' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 98.1 m-85 -79.73 -2.0 41.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -101.93 -24.14 14.05 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.485 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.723 HD21 ' H3 ' ' A' ' 1' ' ' MET . 37.6 m-80 -73.59 -16.14 61.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.551 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.43 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.0 pt -63.71 -47.59 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.34 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.86 -119.79 6.55 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.685 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.6 tp -104.4 -17.68 0.18 Allowed Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 177.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.685 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 60.0 Cg_endo -71.84 -56.33 0.11 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.95 1.767 . . . . 0.0 113.116 -178.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -54.71 -21.31 21.75 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.459 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo -70.8 -20.29 30.13 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.5 m -93.35 -23.54 18.42 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.82 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -81.99 -29.67 31.99 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 110.526 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.448 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 6.7 mt -64.55 -59.22 11.11 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.039 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo -57.26 -32.15 92.83 Favored 'Trans proline' 0 N--CA 1.497 1.688 0 C-N-CA 122.266 1.977 . . . . 0.0 111.906 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.409 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m -77.2 -28.57 53.96 Favored 'General case' 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 48' ' ' VAL . 66.2 mt -72.36 -21.44 61.3 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.747 0.308 . . . . 0.0 111.465 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.592 ' C ' ' H ' ' A' ' 50' ' ' GLY . 4.9 m -55.88 -154.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.261 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 72.0 m -67.68 32.83 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.747 179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.592 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 51.88 36.9 42.94 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -157.41 175.45 13.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.808 0.337 . . . . 0.0 110.783 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.681 -179.996 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.529 ' O ' ' N ' ' A' ' 3' ' ' SER . 76.5 mtm . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 38.48 23.43 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.924 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.977 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.529 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -120.39 -33.28 3.91 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.175 0.512 . . . . 0.0 109.851 179.665 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -71.85 -14.3 61.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.268 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.1 pt -60.66 -50.38 80.68 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.484 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 94.64 -120.36 6.39 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.642 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.5 tp -102.79 -21.37 0.2 Allowed Pre-proline 0 CA--C 1.551 1.005 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 55.8 Cg_endo -69.71 -30.07 23.11 Favored 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 121.602 1.535 . . . . 0.0 112.245 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.3 73.63 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.473 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.402 ' O ' HG23 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.406 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.45 -16.99 34.73 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.9 m -95.61 -6.19 40.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.62 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -99.45 -23.47 15.11 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.417 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -76.66 -47.49 3.06 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.933 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.529 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.5 Cg_exo -56.32 -39.16 93.11 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.537 2.158 . . . . 0.0 111.434 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -75.68 -34.04 60.43 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.18 -42.51 72.33 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.047 0.451 . . . . 0.0 111.119 -179.447 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.56 -28.51 31.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.249 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.503 ' C ' ' H ' ' A' ' 51' ' ' ASP . 54.5 p -60.16 -23.11 63.66 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.307 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.95 38.74 0.94 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.503 ' H ' ' C ' ' A' ' 49' ' ' SER . 54.9 p-10 -83.28 170.77 14.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 110.59 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.632 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.0 mmm . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -79.8 -2.54 43.77 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.657 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -98.17 -23.44 15.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.298 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -68.55 -27.2 65.87 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.405 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.46 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 pt -62.09 -48.47 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.674 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 66.18 -136.35 34.87 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.555 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -57.76 -53.65 63.5 Favored Pre-proline 0 C--O 1.22 -0.475 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.596 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -44.81 -23.77 1.0 Allowed 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.495 2.13 . . . . 0.0 112.233 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -91.15 -26.94 20.13 Favored Glycine 0 C--N 1.345 1.066 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 176.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.555 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.432 HG22 HD12 ' A' ' 16' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo -70.34 -21.64 30.52 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -92.25 -31.6 15.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.924 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -77.92 -33.6 51.69 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 121.121 0.486 . . . . 0.0 110.557 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.426 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.5 mt -58.1 -61.45 7.44 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.043 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo -58.37 -30.44 91.27 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.206 1.937 . . . . 0.0 111.708 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.488 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.416 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -84.27 -32.95 24.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.452 ' CD1' ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.07 -48.6 28.74 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.494 0.664 . . . . 0.0 110.682 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 11.1 p -51.45 -20.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.426 -0.807 . . . . 0.0 110.073 -178.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.0 p -61.52 -23.7 66.11 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.517 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.429 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 71.86 36.07 61.51 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.72 37.06 1.44 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.937 0.399 . . . . 0.0 110.736 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.485 -179.902 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.741 ' H1 ' HD21 ' A' ' 4' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.29 -0.54 37.01 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.832 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -103.72 -23.77 13.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.269 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.741 HD21 ' H1 ' ' A' ' 1' ' ' MET . 55.0 m-80 -76.25 -14.29 60.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.537 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.3 pt -62.52 -50.49 79.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.465 -179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.13 -145.55 32.28 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -58.15 -54.76 52.34 Favored Pre-proline 0 C--O 1.225 -0.229 0 CA-C-O 118.855 -0.593 . . . . 0.0 109.73 179.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 38.0 Cg_exo -34.01 -38.86 0.14 Allowed 'Trans proline' 0 N--CA 1.487 1.124 0 C-N-CA 121.598 1.532 . . . . 0.0 111.932 178.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -75.73 -34.85 47.65 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.992 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.547 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.439 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.42 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.42 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.73 -13.04 31.91 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.2 t -87.14 -7.55 57.88 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -91.98 -26.4 18.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.3 -178.492 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.491 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.1 mt -67.08 -50.8 39.67 Favored Pre-proline 0 N--CA 1.445 -0.717 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 178.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.8 Cg_exo -43.52 -49.72 7.48 Favored 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 121.01 1.14 . . . . 0.0 110.93 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.45 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m -76.99 -28.3 55.02 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.93 -34.56 71.62 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.04 0.448 . . . . 0.0 111.102 -179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.487 ' CG2' ' N ' ' A' ' 49' ' ' SER . 2.5 m -43.46 -45.35 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.67 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.487 ' N ' ' CG2' ' A' ' 48' ' ' VAL . 7.5 t -78.63 -39.82 36.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.18 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.23 31.75 2.86 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.279 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.407 ' H ' ' C ' ' A' ' 49' ' ' SER . 54.4 t0 -93.53 110.92 22.49 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.767 0.317 . . . . 0.0 110.661 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.603 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.597 ' O ' ' N ' ' A' ' 3' ' ' SER . 3.5 ttt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 36.79 21.63 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.126 0.489 . . . . 0.0 111.843 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.597 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.5 OUTLIER -122.31 -28.35 4.33 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.817 179.821 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -76.79 -13.96 59.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.752 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 pt -58.97 -51.8 68.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.919 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.93 -135.76 12.91 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -178.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.568 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -81.37 -39.45 1.0 Allowed Pre-proline 0 CA--C 1.553 1.093 0 CA-C-O 118.967 -0.54 . . . . 0.0 112.27 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.568 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 8.7 Cg_endo -47.56 -30.34 11.98 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 CA-C-N 121.142 1.444 . . . . 0.0 112.567 177.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -80.59 -26.71 53.55 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.499 -178.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.492 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.413 HG21 HD12 ' A' ' 13' ' ' ILE . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.428 HG21 HD13 ' A' ' 19' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.543 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo -53.72 -28.95 49.49 Favored 'Trans proline' 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.9 m -78.07 -11.41 59.91 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.731 -178.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -93.01 -23.41 18.69 Favored 'General case' 0 C--O 1.22 -0.483 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.513 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 19.3 mt -69.05 -53.82 13.29 Favored Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 119.435 -0.906 . . . . 0.0 109.248 178.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.543 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo -36.72 -53.69 1.09 Allowed 'Trans proline' 0 N--CA 1.48 0.735 0 C-N-CA 123.161 2.574 . . . . 0.0 111.953 175.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.36 -32.42 60.84 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 94.0 mt -70.2 -44.03 69.51 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.09 0.472 . . . . 0.0 110.572 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.45 -26.92 22.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.837 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -58.01 -42.74 85.87 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.249 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.77 59.16 4.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -84.65 112.76 20.75 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.859 0.361 . . . . 0.0 110.827 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.647 179.958 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttm . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -84.74 8.68 16.29 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.785 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.06 -25.94 13.56 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.25 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 54.6 m-80 -75.46 -14.86 60.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.866 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -65.31 -43.81 94.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.025 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.49 -135.15 24.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -72.58 -44.7 9.59 Favored Pre-proline 0 C--N 1.327 -0.386 0 O-C-N 122.866 -0.197 . . . . 0.0 110.738 179.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.478 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 82.2 Cg_exo -41.82 -30.72 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 C-N-CA 121.382 1.388 . . . . 0.0 111.208 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.24 -27.38 33.61 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.491 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo -48.65 -23.5 5.58 Favored 'Trans proline' 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -88.8 -7.65 55.81 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.953 0.406 . . . . 0.0 111.202 -177.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.5 mptt -99.3 -37.77 9.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.701 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.492 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.8 OUTLIER -59.63 -48.64 94.98 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.062 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo -56.61 -36.49 98.06 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.833 2.355 . . . . 0.0 111.464 179.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.42 HD13 HG23 ' A' ' 29' ' ' ILE . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.435 ' CD1' ' HZ2' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.435 ' HZ2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -77.21 -30.86 54.87 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.4 mt -70.23 -36.84 74.8 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.364 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' A' ' 48' ' ' VAL . 6.1 m -41.2 114.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.547 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.9 t 38.65 74.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -69.15 36.34 0.31 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.547 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.3 m-20 -103.01 138.49 39.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 110.459 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.417 -179.851 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.7 ' N ' HD21 ' A' ' 4' ' ' ASN . 95.9 mtp . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 92.8 m-85 -77.93 -0.04 26.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.51 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -101.42 -23.48 14.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.732 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.7 HD21 ' N ' ' A' ' 1' ' ' MET . 51.3 m-80 -76.96 -14.9 59.8 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.72 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 2.7 pt -59.69 -58.18 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.458 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.42 ' H ' ' CG1' ' A' ' 5' ' ' ILE . . . 97.79 -139.77 14.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.625 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -55.9 -53.22 65.49 Favored Pre-proline 0 C--O 1.222 -0.35 0 CA-C-O 118.364 -0.827 . . . . 0.0 109.751 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.456 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 14.0 Cg_exo -33.12 -32.51 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 121.859 1.706 . . . . 0.0 111.175 175.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -80.07 -35.3 27.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 179.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.625 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.464 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.07 -17.4 40.72 Favored 'Trans proline' 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 t -93.93 3.34 55.52 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.666 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -103.05 -34.57 8.85 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.528 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.598 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 5.0 mt -67.61 -40.67 26.38 Favored Pre-proline 0 C--N 1.325 -0.461 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.724 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.6 Cg_exo -60.27 -40.43 59.21 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 C-N-CA 122.799 2.332 . . . . 0.0 111.518 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m -76.01 -27.44 57.38 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -72.51 -22.06 61.1 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.932 0.396 . . . . 0.0 110.999 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.9 m -61.95 -27.68 42.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.643 -178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 37.6 m -58.35 -40.46 82.28 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.197 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.56 35.44 62.77 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -84.84 115.16 22.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.754 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.879 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.678 ' N ' HD21 ' A' ' 4' ' ' ASN . 96.0 mtp . . . . . 0 N--CA 1.488 1.44 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -83.84 -2.19 55.91 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.534 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -102.16 -23.65 14.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.57 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.678 HD21 ' N ' ' A' ' 1' ' ' MET . 64.1 m-80 -82.22 -13.07 57.66 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 8.0 pt -59.96 -43.17 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.425 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.46 -136.81 34.41 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.543 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -67.1 -47.14 52.35 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 178.539 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.489 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.2 Cg_exo -39.34 -36.68 0.97 Allowed 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 121.611 1.541 . . . . 0.0 112.212 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.91 -27.93 57.58 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.46 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.423 ' O ' ' N ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo -71.3 -17.05 31.2 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 m -96.94 -3.61 41.45 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.962 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -101.28 -22.34 14.65 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.225 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.19 -47.17 2.12 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.539 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.0 Cg_exo -56.0 -40.9 82.11 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.499 2.133 . . . . 0.0 111.575 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.401 HG22 HD13 ' A' ' 29' ' ' ILE . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -76.01 -33.4 59.69 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 mt -70.21 -43.61 70.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.007 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.91 -25.1 23.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.718 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.2 t -59.52 -43.58 93.4 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.658 -179.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -112.87 34.81 4.91 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -149.67 113.29 5.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.703 0.287 . . . . 0.0 110.56 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.562 179.918 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.493 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 89.4 m-85 -77.44 -2.92 37.73 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.602 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -102.18 -22.85 14.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.264 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -77.13 -14.53 59.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.493 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.0 pt -62.51 -51.99 65.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.964 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.16 -136.11 13.07 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -178.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -83.1 -38.84 0.76 Allowed Pre-proline 0 CA--C 1.552 1.051 0 CA-C-O 118.254 -0.879 . . . . 0.0 112.51 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.54 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 9.7 Cg_endo -48.36 -28.88 12.22 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.0 1.8 . . . . 0.0 112.389 177.386 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -82.65 -25.26 50.93 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 119.984 -1.103 . . . . 0.0 112.267 -178.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.49 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -70.83 -13.2 31.8 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 t -96.73 4.49 51.78 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.352 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -105.98 -30.16 9.49 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.368 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.4 mt -71.91 -40.93 8.5 Favored Pre-proline 0 C--N 1.324 -0.534 0 C-N-CA 120.524 -0.471 . . . . 0.0 110.374 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.5 Cg_exo -61.11 -37.34 75.96 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 122.805 2.337 . . . . 0.0 111.438 179.635 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.34 -32.53 60.91 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.38 -44.4 68.12 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.038 0.447 . . . . 0.0 110.606 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.33 -35.49 57.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.827 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -59.26 -43.57 92.45 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.483 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -97.37 36.28 4.01 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -148.94 120.04 7.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.808 0.337 . . . . 0.0 110.731 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.582 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.683 ' N ' HD21 ' A' ' 4' ' ' ASN . 77.6 mtm . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -77.44 2.17 16.92 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-O 120.93 0.395 . . . . 0.0 110.511 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 m -99.91 -24.11 14.75 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.637 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.683 HD21 ' N ' ' A' ' 1' ' ' MET . 44.0 m-80 -69.97 -22.66 63.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.494 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.2 pt -63.19 -45.47 98.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.27 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.7 -132.77 14.55 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.981 -0.847 . . . . 0.0 110.981 -179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.608 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.1 mp -73.75 -44.2 6.83 Favored Pre-proline 0 C--N 1.325 -0.495 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 177.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.608 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.5 Cg_exo -41.67 -31.05 1.16 Allowed 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.526 2.151 . . . . 0.0 111.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.56 -23.96 37.82 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.492 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo -72.55 -14.01 27.53 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -98.24 -6.27 31.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.376 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.8 mptt -98.78 -16.01 19.08 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.837 178.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.547 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -83.77 -47.95 0.73 Allowed Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.038 0.447 . . . . 0.0 110.193 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.5 Cg_exo -57.19 -39.33 91.24 Favored 'Trans proline' 0 C--N 1.302 -1.868 0 C-N-CA 122.907 2.405 . . . . 0.0 111.601 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m -76.99 -28.19 54.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 89.5 mt -72.25 -22.11 61.28 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.977 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.2 m -58.08 -25.61 26.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.625 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.7 t -63.0 -17.64 62.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.442 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.39 38.25 10.08 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.7 t0 -90.1 109.36 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.785 0.326 . . . . 0.0 110.496 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.641 179.828 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.5 ttp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.17 -1.53 23.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.782 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 m -102.64 -23.54 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.152 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.7 m-80 -77.41 -14.21 59.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -63.84 -45.43 97.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 62.9 -142.5 47.78 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.585 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -53.72 -54.37 47.03 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 119.417 -0.325 . . . . 0.0 110.626 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -43.01 -22.38 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 120.879 1.053 . . . . 0.0 111.837 178.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -90.77 -29.1 13.97 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -68.92 -18.28 41.1 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -89.54 -2.82 58.46 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.575 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -100.34 -7.36 24.56 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.841 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.582 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.0 mt -80.7 -41.07 1.2 Allowed Pre-proline 0 C--N 1.325 -0.46 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.43 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 25.1 Cg_exo -64.24 -34.23 57.06 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.764 2.309 . . . . 0.0 111.466 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -76.51 -28.63 56.47 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.1 mt -70.12 -36.58 74.93 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.989 0.423 . . . . 0.0 110.953 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.49 ' C ' ' H ' ' A' ' 50' ' ' GLY . 3.1 m -44.38 150.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.432 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.426 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.0 m 55.19 7.73 0.22 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.506 -179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.49 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -78.43 38.7 1.87 Allowed Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.976 -0.849 . . . . 0.0 110.976 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.426 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.9 t0 40.91 68.82 0.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.996 0.427 . . . . 0.0 111.018 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.21 179.801 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.548 ' H2 ' HD21 ' A' ' 4' ' ' ASN . 97.5 mmm . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.435 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.2 m-85 -78.27 -2.95 40.39 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.669 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -100.63 -23.6 14.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.31 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.548 HD21 ' H2 ' ' A' ' 1' ' ' MET . 43.5 m-80 -68.89 -24.0 64.27 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.519 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.435 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.4 pt -61.29 -48.19 90.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.671 -179.055 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.0 -112.0 3.47 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -92.62 -57.31 0.23 Allowed Pre-proline 0 CA--C 1.541 0.618 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.979 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 7' ' ' ILE . 24.3 Cg_exo -28.83 -43.42 0.08 OUTLIER 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.524 2.149 . . . . 0.0 112.726 178.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.23 -35.7 70.34 Favored Glycine 0 CA--C 1.524 0.621 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.045 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.462 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.41 HG23 HD13 ' A' ' 16' ' ' ILE . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.404 HG12 ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.404 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.82 -15.89 37.05 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.9 t -90.6 -8.63 49.62 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.514 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.9 mmmt -90.88 -24.87 20.09 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.05 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.519 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.2 mt -68.23 -50.3 30.14 Favored Pre-proline 0 N--CA 1.445 -0.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.518 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 27.0 Cg_endo -58.55 -31.57 94.74 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 C-N-CA 121.644 1.562 . . . . 0.0 112.103 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.408 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.0 -31.66 59.05 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.463 ' O ' ' O ' ' A' ' 48' ' ' VAL . 58.2 mt -72.33 -21.75 61.27 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.216 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.658 ' O ' ' N ' ' A' ' 50' ' ' GLY . 20.0 m -40.26 162.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -51.62 72.65 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 O-C-N 123.409 0.443 . . . . 0.0 111.534 -178.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.658 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -81.31 37.71 2.41 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 54.0 p-10 -171.4 81.28 0.07 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.392 179.931 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.697 ' N ' HD21 ' A' ' 4' ' ' ASN . 77.6 mtm . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.4 m-85 -83.48 1.01 43.83 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-O 120.935 0.398 . . . . 0.0 110.664 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -100.37 -24.18 14.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.533 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.697 HD21 ' N ' ' A' ' 1' ' ' MET . 42.9 m-80 -70.93 -21.07 62.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.4 pt -62.72 -45.33 99.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.926 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.03 -135.67 19.23 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -73.38 -43.57 7.25 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 178.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.527 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 86.6 Cg_exo -43.44 -29.82 2.22 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 121.458 1.438 . . . . 0.0 111.488 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.77 -27.48 31.84 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' N ' ' O ' ' A' ' 7' ' ' ILE . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.445 ' CG2' ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.445 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.83 -15.86 33.06 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.5 t -94.56 -0.29 54.67 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.893 0.377 . . . . 0.0 110.587 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -102.81 -8.31 20.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.407 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.59 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -84.68 -41.3 0.69 Allowed Pre-proline 0 N--CA 1.45 -0.439 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.17 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 28.0 Cg_exo -62.41 -34.86 75.34 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.793 2.329 . . . . 0.0 111.569 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.424 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -78.88 -32.98 46.07 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.462 ' CD1' ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.02 -48.73 28.09 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.512 0.672 . . . . 0.0 110.397 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.0 p -58.73 -31.66 44.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.214 -178.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.8 p -66.55 -18.97 65.66 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.612 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 73.34 39.69 50.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -81.11 109.62 15.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.794 0.331 . . . . 0.0 110.563 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.682 -179.875 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.682 ' N ' HD21 ' A' ' 4' ' ' ASN . 78.4 mtm . . . . . 0 N--CA 1.488 1.466 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -84.84 -2.68 58.06 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.015 0.436 . . . . 0.0 110.746 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.71 -23.57 13.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.619 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.682 HD21 ' N ' ' A' ' 1' ' ' MET . 56.2 m-80 -78.95 -13.9 59.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.817 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 pt -63.18 -43.78 98.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.083 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.88 -135.59 28.4 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.94 -44.82 11.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.867 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.459 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.3 Cg_exo -41.43 -31.53 1.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.309 1.34 . . . . 0.0 111.139 178.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.03 36.09 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.505 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.401 HG23 HD13 ' A' ' 13' ' ' ILE . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.423 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -71.98 -24.37 20.82 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.86 -6.73 55.54 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.496 -176.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -93.51 -23.56 18.31 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.003 -0.999 . . . . 0.0 111.846 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.517 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.4 mt -69.97 -54.05 10.48 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.611 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.517 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -39.14 -50.73 2.68 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 121.732 1.621 . . . . 0.0 111.561 176.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -77.05 -28.96 54.95 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.6 mt -71.25 -28.3 64.07 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.25 -179.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.7 m -55.87 -31.04 29.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.244 -178.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.522 ' C ' ' H ' ' A' ' 51' ' ' ASP . 43.0 t -162.87 97.19 0.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.305 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.48 35.63 0.82 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 -120.64 106.11 11.43 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.682 0.277 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.677 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.589 ' O ' ' N ' ' A' ' 3' ' ' SER . 65.4 mmm . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 38.73 19.89 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.338 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.589 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.9 OUTLIER -115.86 -40.2 3.37 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.174 0.511 . . . . 0.0 110.405 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -76.79 -13.49 60.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.833 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.413 HG13 ' N ' ' A' ' 6' ' ' GLY . 19.3 pt -61.6 -41.42 90.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.413 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 74.65 -134.22 17.17 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.495 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -76.38 -44.17 3.43 Favored Pre-proline 0 CA--C 1.54 0.594 0 C-N-CA 121.124 -0.231 . . . . 0.0 111.083 179.794 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 84.1 Cg_exo -42.13 -39.62 6.02 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 121.683 1.588 . . . . 0.0 112.505 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -75.0 -27.61 64.1 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.45 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.445 ' N ' ' CD1' ' A' ' 11' ' ' ILE . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo -52.46 -19.73 10.46 Favored 'Trans proline' 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 t -96.79 -15.6 21.25 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.541 0.686 . . . . 0.0 110.5 -178.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 41.8 mmtm -101.32 -12.06 18.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.073 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.511 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.8 mt -86.6 -43.84 0.56 Allowed Pre-proline 0 CA--C 1.541 0.605 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.783 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.511 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 29.1 Cg_exo -60.36 -42.54 40.85 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.633 2.222 . . . . 0.0 112.103 179.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.512 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t -75.79 -31.22 59.37 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.24 -32.74 70.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.298 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.2 m -57.85 -27.78 31.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.147 -178.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.53 ' C ' ' H ' ' A' ' 51' ' ' ASP . 17.4 p -173.17 97.73 0.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.254 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.67 37.02 0.59 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.0 m-20 -78.44 150.86 32.96 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.869 0.366 . . . . 0.0 110.755 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.706 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.668 ' N ' HD21 ' A' ' 4' ' ' ASN . 95.8 mtp . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -79.56 3.98 17.24 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.458 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -99.95 -24.38 14.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.361 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.668 HD21 ' N ' ' A' ' 1' ' ' MET . 44.1 m-80 -69.22 -22.98 63.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.67 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.1 pt -63.6 -44.91 98.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.072 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.01 -135.88 23.39 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.559 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.95 -44.85 15.03 Favored Pre-proline 0 CA--C 1.532 0.286 0 O-C-N 122.871 -0.193 . . . . 0.0 110.566 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.486 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -42.32 -31.24 1.69 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 121.297 1.331 . . . . 0.0 111.268 178.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.38 -26.8 34.98 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.438 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -72.59 -6.39 18.95 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.0 t -105.76 -17.67 14.31 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.135 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 3.0 mmmm -96.12 -15.5 22.11 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.1 mt -83.54 -59.27 0.37 Allowed Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.834 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -55.39 -33.15 84.6 Favored 'Trans proline' 0 N--CA 1.504 2.115 0 C-N-CA 122.33 2.02 . . . . 0.0 113.267 178.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.71 -31.98 59.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.6 mt -70.43 -43.68 69.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.018 0.437 . . . . 0.0 110.831 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.57 -35.49 56.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.831 179.735 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 40.3 t -60.22 -43.15 96.24 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.361 -179.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -98.46 58.1 0.98 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.8 t0 -66.01 135.45 54.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.851 0.357 . . . . 0.0 110.646 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 79.7 mm-40 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.487 ' H3 ' HD21 ' A' ' 4' ' ' ASN . 93.0 mmm . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.413 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.2 m-85 -80.48 -1.7 42.8 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.686 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.3 m -102.34 -23.25 13.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.292 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.487 HD21 ' H3 ' ' A' ' 1' ' ' MET . 70.3 m-80 -75.91 -14.49 60.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.814 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.413 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.5 pt -65.16 -43.92 95.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.004 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.13 -134.38 27.02 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -70.41 -46.96 19.61 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.463 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.7 Cg_exo -39.43 -38.1 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.695 1.597 . . . . 0.0 112.312 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.38 -27.87 58.8 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.454 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.405 ' O ' ' N ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo -68.75 -13.0 36.06 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.4 t -107.33 4.15 26.13 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 13.2 mptt -106.92 -27.71 10.53 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.659 0.266 . . . . 0.0 110.682 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.455 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mp -80.5 -63.53 0.34 Allowed Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.684 -0.235 . . . . 0.0 110.615 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -58.14 -28.46 83.88 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.053 1.835 . . . . 0.0 111.344 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.63 -31.97 60.06 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.85 -44.31 66.67 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.924 0.392 . . . . 0.0 110.818 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.7 p -71.11 -43.18 75.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.89 179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 40.5 t -62.33 -43.74 98.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.608 -179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.73 32.31 70.6 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' A' ' 52' ' ' GLU . 99.8 m-20 -69.84 142.61 53.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 51' ' ' ASP . 82.1 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.564 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.9 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.1 m-85 -81.62 -1.97 48.53 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.518 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -102.1 -23.28 14.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.49 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -75.12 -14.81 60.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.3 pt -65.76 -44.05 93.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.8 -138.16 31.21 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -67.07 -46.88 52.99 Favored Pre-proline 0 CA--C 1.539 0.531 0 C-N-CA 120.926 -0.31 . . . . 0.0 110.746 179.642 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.437 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 97.1 Cg_exo -40.25 -37.14 1.79 Allowed 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.516 1.477 . . . . 0.0 112.158 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.45 -29.41 58.13 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.406 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.405 HG23 HD12 ' A' ' 13' ' ' ILE . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' A' ' 17' ' ' ALA . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.463 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo -54.07 -29.64 56.22 Favored 'Trans proline' 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.4 t -74.93 -36.71 62.15 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 6.6 tptt -89.75 -7.42 54.51 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -177.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.483 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 7.7 tp -76.06 -55.2 1.89 Allowed Pre-proline 0 CA--C 1.554 1.131 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 7.4 Cg_endo -55.0 -47.22 27.78 Favored 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.748 2.299 . . . . 0.0 112.218 176.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -76.51 -29.69 56.9 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.471 ' O ' ' N ' ' A' ' 50' ' ' GLY . 58.7 mt -70.2 -35.47 73.94 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.93 0.395 . . . . 0.0 111.062 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.539 ' C ' ' H ' ' A' ' 50' ' ' GLY . 4.1 m -41.45 142.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.531 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.7 t 54.18 5.93 0.09 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.603 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -95.18 38.6 3.07 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -143.54 125.18 14.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.811 0.339 . . . . 0.0 110.529 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.5 tp10 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.459 -179.827 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 ttp . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -78.41 -2.47 38.48 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.851 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.52 -23.37 13.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.266 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -79.15 -13.6 59.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.83 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.7 pt -63.18 -43.5 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.878 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.6 -137.73 39.76 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.53 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -64.75 -48.0 73.99 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.538 179.226 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.474 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.9 Cg_exo -38.75 -37.67 0.84 Allowed 'Trans proline' 0 N--CA 1.49 1.274 0 C-N-CA 121.549 1.5 . . . . 0.0 112.226 179.806 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.66 -29.04 58.27 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.498 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.53 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.477 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.44 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.44 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.411 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -71.31 -12.31 29.67 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.25 -7.22 22.31 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 110.557 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.4 mmmt -101.92 -22.43 14.32 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.803 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.412 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -77.62 -50.74 1.96 Allowed Pre-proline 0 C--N 1.328 -0.329 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.085 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -62.83 -29.31 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.231 1.954 . . . . 0.0 112.361 -179.74 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.94 -31.52 59.13 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -69.68 -36.5 76.06 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.873 0.368 . . . . 0.0 111.112 -179.331 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.5 m -43.26 141.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.437 -179.482 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.511 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.3 m 48.17 29.94 2.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.421 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -70.95 40.16 0.54 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.511 ' H ' ' C ' ' A' ' 49' ' ' SER . 38.5 t70 -85.92 111.24 20.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.831 0.348 . . . . 0.0 110.682 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.663 -179.93 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.682 ' N ' HD21 ' A' ' 4' ' ' ASN . 96.3 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -85.08 -2.36 57.91 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 120.981 0.42 . . . . 0.0 110.552 -179.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.18 -23.39 14.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.569 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.682 HD21 ' N ' ' A' ' 1' ' ' MET . 47.8 m-80 -76.85 -14.39 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.711 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.1 pt -64.96 -43.73 96.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.123 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.81 -137.1 36.2 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.387 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.45 -46.44 48.42 Favored Pre-proline 0 C--N 1.327 -0.392 0 O-C-N 122.659 -0.318 . . . . 0.0 110.939 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.0 Cg_exo -40.56 -32.28 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 121.372 1.381 . . . . 0.0 111.209 178.493 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.12 35.83 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.507 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.404 ' O ' ' N ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 HG23 HD12 ' A' ' 19' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -69.62 -13.7 35.41 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.9 t -96.92 -6.29 36.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.691 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -100.92 -15.81 17.41 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.812 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -83.34 -47.34 0.8 Allowed Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.778 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.2 Cg_exo -60.52 -32.97 94.23 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.233 179.013 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.4 HD13 HG22 ' A' ' 29' ' ' ILE . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -75.86 -31.78 59.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.1 mt -70.72 -43.55 68.69 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-O 120.907 0.384 . . . . 0.0 110.603 -179.641 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.54 -28.92 29.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.1 t -61.13 -43.62 98.6 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.584 -179.348 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 146.81 35.33 0.06 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -103.49 110.76 22.91 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.685 0.279 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.607 179.86 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.677 ' N ' HD21 ' A' ' 4' ' ' ASN . 76.4 mtp . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -75.22 0.66 15.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.533 -179.728 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -102.34 -23.77 13.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.46 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.677 HD21 ' N ' ' A' ' 1' ' ' MET . 57.3 m-80 -77.45 -14.3 59.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.73 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.6 pt -63.69 -43.48 98.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.732 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 67.19 -135.85 32.11 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -68.86 -46.01 32.15 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 178.604 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.5 Cg_exo -40.18 -31.42 0.54 Allowed 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 121.415 1.41 . . . . 0.0 111.521 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.73 -27.99 30.53 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.54 ' N ' ' O ' ' A' ' 7' ' ' ILE . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.499 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo -70.76 -15.97 33.37 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -93.51 -26.08 17.32 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.803 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -72.85 -40.52 65.64 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.14 0.495 . . . . 0.0 109.986 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.445 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.1 mp -56.69 -62.75 4.43 Favored Pre-proline 0 C--N 1.319 -0.738 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.571 -179.671 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.445 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 18.2 Cg_endo -57.13 -35.32 98.88 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.037 1.824 . . . . 0.0 111.384 -179.576 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.417 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t -76.76 -31.68 57.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 70.2 mt -70.8 -20.58 62.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.204 -179.227 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 4.5 m -56.22 -41.02 68.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.647 -178.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.47 ' C ' ' H ' ' A' ' 51' ' ' ASP . 4.3 m -99.85 -8.58 23.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.436 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.54 40.16 1.1 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.696 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.47 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 43.06 93.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.841 -179.932 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.572 ' H3 ' ' ND2' ' A' ' 4' ' ' ASN . 93.8 mmm . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -82.89 -1.56 52.48 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.522 179.995 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -98.43 -22.24 16.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.153 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.572 ' ND2' ' H3 ' ' A' ' 1' ' ' MET . 68.2 m-80 -67.45 -30.66 70.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.466 179.925 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.49 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.4 pt -59.68 -53.86 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.464 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 94.5 -125.66 8.39 Favored Glycine 0 CA--C 1.53 0.981 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.636 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 11.2 tp -91.87 -26.16 0.28 Allowed Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 113.257 0.836 . . . . 0.0 113.257 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.636 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 33.8 Cg_exo -57.69 -35.15 98.91 Favored 'Trans proline' 0 N--CA 1.5 1.879 0 C-N-CA 122.263 1.976 . . . . 0.0 112.443 179.326 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.88 -30.71 76.5 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.414 HG21 HD11 ' A' ' 13' ' ' ILE . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.409 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.403 HG22 HD12 ' A' ' 16' ' ' ILE . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -72.9 -25.17 16.88 Favored 'Trans proline' 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.46 7.88 36.61 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.848 -178.168 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.1 mptt -104.86 -42.02 5.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.754 179.696 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.567 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mt -58.21 -41.3 88.88 Favored Pre-proline 0 C--N 1.322 -0.612 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.435 -179.111 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.6 Cg_exo -62.15 -45.99 14.11 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.335 2.024 . . . . 0.0 111.113 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -76.01 -32.12 59.25 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.46 ' O ' ' N ' ' A' ' 51' ' ' ASP . 56.6 mt -69.55 -38.44 77.46 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.818 0.342 . . . . 0.0 111.25 -179.209 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.486 ' O ' ' N ' ' A' ' 50' ' ' GLY . 4.2 m -38.36 129.1 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.647 -179.434 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.506 ' C ' ' H ' ' A' ' 51' ' ' ASP . 1.5 m 66.24 -57.45 0.36 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.368 -179.71 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -78.18 28.46 1.97 Allowed Glycine 0 CA--C 1.52 0.35 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.506 ' H ' ' C ' ' A' ' 49' ' ' SER . 44.0 t0 -83.01 110.4 17.93 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.441 -0.379 . . . . 0.0 110.282 179.464 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tp10 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.451 -179.752 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.6 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -82.47 -3.18 55.32 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 120.97 0.414 . . . . 0.0 110.488 -179.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.57 -23.29 13.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.421 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -76.71 -14.35 59.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.751 -179.827 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -64.98 -43.81 96.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.006 -179.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.98 -137.4 36.11 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 -179.298 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.26 -46.48 50.52 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 119.49 -0.29 . . . . 0.0 110.816 179.444 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.437 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 88.0 Cg_exo -40.81 -30.93 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.076 1.184 . . . . 0.0 111.251 178.5 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -84.73 -28.33 32.42 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 178.927 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.489 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.415 HG21 HD11 ' A' ' 16' ' ' ILE . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.403 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.436 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.436 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.403 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.95 -14.93 32.62 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 t -87.01 -10.91 51.96 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -93.19 -20.41 20.49 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.337 -179.459 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.503 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.6 mt -70.4 -54.32 9.04 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.146 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.503 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.1 Cg_exo -38.09 -52.28 1.84 Allowed 'Trans proline' 0 N--CA 1.489 1.24 0 C-N-CA 122.507 2.138 . . . . 0.0 111.329 176.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.401 ' HG3' ' N ' ' A' ' 42' ' ' SER . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' SER . . . . . 0.401 ' N ' ' HG3' ' A' ' 41' ' ' LYS . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.428 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -77.99 -34.72 50.72 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.438 ' CD1' ' C ' ' A' ' 47' ' ' LEU . 2.2 tm? -73.45 -47.58 40.39 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 121.564 0.697 . . . . 0.0 110.871 -179.615 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 9.9 p -62.71 -30.93 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.21 -179.032 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -60.9 -42.64 98.42 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.337 179.782 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 80.43 38.46 17.59 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.789 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 59.3 t0 -89.28 110.16 20.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.74 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.332 179.92 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mmm . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -79.28 -3.35 45.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.553 -179.889 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.4 -23.09 13.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.391 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -74.79 -14.95 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.65 -179.808 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.4 pt -66.21 -44.0 91.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.049 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.52 -137.08 28.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.286 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.02 -45.26 22.46 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 119.688 -0.196 . . . . 0.0 110.745 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.453 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.6 Cg_exo -41.64 -30.52 1.03 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 121.19 1.26 . . . . 0.0 111.289 178.831 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.59 -27.35 32.72 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 178.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.5 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 16' ' ' ILE . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.409 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -71.89 -12.13 28.2 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.9 t -96.86 -15.95 20.98 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.381 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.56 -17.97 30.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.86 179.579 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 mp -78.11 -55.15 1.18 Allowed Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 120.625 -0.43 . . . . 0.0 109.865 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.466 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo -57.47 -30.38 87.99 Favored 'Trans proline' 0 N--CA 1.503 2.068 0 C-N-CA 122.04 1.827 . . . . 0.0 111.9 179.113 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.466 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -75.52 -32.12 60.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.38 -43.58 69.78 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.011 0.434 . . . . 0.0 110.836 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.76 -31.94 38.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.906 179.643 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -59.82 -43.6 94.44 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.528 -179.337 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.435 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 69.87 35.77 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.281 -0.727 . . . . 0.0 111.281 179.596 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.84 36.34 1.32 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.019 0.438 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 . . . . . 0 C--N 1.325 -0.492 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 179.96 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.407 ' H2 ' HD21 ' A' ' 4' ' ' ASN . 91.1 mmm . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -82.88 -0.14 46.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.721 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.0 -23.21 14.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.433 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.407 HD21 ' H2 ' ' A' ' 1' ' ' MET . 69.7 m-80 -75.69 -14.65 60.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.882 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.5 pt -65.86 -43.91 92.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.31 -135.72 27.69 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.562 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -70.52 -45.17 18.54 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-O 119.7 -0.19 . . . . 0.0 110.528 178.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.7 Cg_exo -41.15 -31.32 0.83 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 121.32 1.347 . . . . 0.0 111.417 178.698 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.57 -26.79 31.63 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 178.987 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.562 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.463 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.411 ' O ' ' N ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.7 -18.29 53.28 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -85.85 -3.1 58.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.594 -179.875 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.1 mptt -101.27 -1.85 32.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.807 179.752 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.613 ' N ' ' CD2' ' A' ' 26' ' ' LEU . 1.1 mm? -84.4 -38.29 0.66 Allowed Pre-proline 0 N--CA 1.452 -0.341 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.487 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 24.4 Cg_exo -65.29 -33.84 46.96 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.356 2.037 . . . . 0.0 111.031 178.2 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -76.26 -30.81 57.99 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -70.03 -32.59 70.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.964 0.411 . . . . 0.0 111.258 -179.626 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 5.1 m -41.48 -37.35 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.732 -179.233 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.506 ' C ' ' H ' ' A' ' 51' ' ' ASP . 98.4 p -173.04 98.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.262 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.2 35.13 1.3 Allowed Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.852 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.506 ' H ' ' C ' ' A' ' 49' ' ' SER . 42.8 p-10 -154.62 111.12 3.27 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.838 0.351 . . . . 0.0 110.725 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.607 179.816 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.7 ttp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -74.49 -0.04 16.26 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.753 -179.866 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -104.2 -23.58 13.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.283 179.664 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -83.93 -13.99 52.08 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.979 -179.792 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 17.8 pt -65.71 -42.38 92.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.018 179.926 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.47 -132.73 12.3 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.059 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -79.17 -42.56 1.66 Allowed Pre-proline 0 C--N 1.326 -0.416 0 O-C-N 122.785 -0.244 . . . . 0.0 110.57 179.094 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 82.9 Cg_exo -43.11 -31.5 2.49 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 121.564 1.509 . . . . 0.0 111.398 179.773 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -84.93 -25.94 39.35 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.037 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.496 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.4 HD11 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.433 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.427 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 16.4 Cg_exo -74.8 -19.5 18.3 Favored 'Trans proline' 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.28 -7.95 25.66 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 113.884 -1.507 . . . . 0.0 110.739 -177.004 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -100.11 -20.94 15.76 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.495 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.513 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.5 -48.11 1.87 Allowed Pre-proline 0 CA--C 1.534 0.35 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.513 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.1 Cg_exo -56.3 -39.45 91.19 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.513 2.142 . . . . 0.0 111.706 179.763 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -77.45 -28.8 52.53 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.577 ' O ' ' N ' ' A' ' 49' ' ' SER . 1.6 tm? -70.8 -43.54 68.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 -179.472 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.485 ' C ' ' O ' ' A' ' 47' ' ' LEU . 15.5 m -25.61 -40.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-O 121.16 0.505 . . . . 0.0 111.505 -179.446 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.577 ' N ' ' O ' ' A' ' 47' ' ' LEU . 35.7 p -157.28 -40.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.162 178.735 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.419 ' N ' ' HG ' ' A' ' 49' ' ' SER . . . 61.24 37.66 94.37 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.835 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 54.0 p-10 -66.69 144.21 56.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.048 0.451 . . . . 0.0 110.616 -179.67 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.687 -179.955 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -89.16 7.92 32.75 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.941 -179.653 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.93 -24.08 13.29 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.069 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.2 m-80 -80.44 -14.01 58.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.056 -179.72 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 9.8 pt -65.51 -42.97 94.39 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.914 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.26 -134.8 21.73 Favored Glycine 0 CA--C 1.525 0.719 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.338 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.503 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.5 OUTLIER -73.2 -45.14 8.03 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.649 179.24 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.467 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -40.67 -37.97 2.45 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.746 1.63 . . . . 0.0 112.551 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.48 -28.03 60.35 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 179.363 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.46 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -69.97 -16.91 36.86 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -92.6 -0.42 57.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.637 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.6 mptt -101.57 -8.38 21.92 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.811 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.583 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -83.49 -41.24 0.8 Allowed Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.442 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 27.2 Cg_exo -63.99 -35.74 52.96 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.716 2.277 . . . . 0.0 111.258 179.095 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.443 ' CD1' ' HZ3' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.443 ' HZ3' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -76.7 -30.52 56.73 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.6 mt -69.97 -35.57 74.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.883 0.373 . . . . 0.0 111.191 -179.494 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.1 m -41.6 130.5 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 -179.449 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.531 ' C ' ' H ' ' A' ' 51' ' ' ASP . 20.1 m 42.43 47.67 4.35 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.589 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.4 37.48 0.56 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.694 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 49' ' ' SER . 45.5 t0 -128.17 105.9 8.69 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.668 179.956 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.448 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 . . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.448 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -77.31 -2.21 33.73 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.124 0.488 . . . . 0.0 110.695 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -97.28 -23.21 16.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.101 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -68.45 -27.7 66.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.469 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.9 pt -62.18 -48.86 86.45 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.548 -179.763 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 67.13 -133.47 31.16 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 179.801 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -60.2 -53.62 63.21 Favored Pre-proline 0 C--O 1.223 -0.314 0 O-C-N 122.474 -0.427 . . . . 0.0 110.465 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.41 ' HD2' ' O ' ' A' ' 5' ' ' ILE . 21.3 Cg_exo -43.45 -26.88 1.12 Allowed 'Trans proline' 0 N--CA 1.504 2.124 0 C-N-CA 122.766 2.31 . . . . 0.0 112.585 178.325 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.65 -26.48 24.86 Favored Glycine 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 176.702 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.442 ' N ' ' CD1' ' A' ' 11' ' ' ILE . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.436 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.436 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -70.54 -18.43 33.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.0 t -92.74 -28.15 16.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.916 -179.671 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -79.36 -33.65 42.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 120.936 0.398 . . . . 0.0 110.713 -179.768 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.458 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 1.3 mp -58.49 -62.35 5.81 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.577 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.7 Cg_endo -51.16 -35.16 50.99 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.475 2.116 . . . . 0.0 111.663 -179.628 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -74.48 -32.05 62.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.8 mt -69.84 -41.0 75.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.844 0.354 . . . . 0.0 110.768 -179.742 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.488 ' CG2' ' N ' ' A' ' 49' ' ' SER . 2.4 p -80.91 160.28 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-O 121.161 0.505 . . . . 0.0 109.883 179.453 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.488 ' N ' ' CG2' ' A' ' 48' ' ' VAL . 0.7 OUTLIER 77.32 -28.17 0.17 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.362 -179.914 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.482 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 62.9 38.35 96.41 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.0 t0 43.99 80.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 110.919 -179.989 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttp . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.438 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 65.7 m-85 -78.6 -4.23 47.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.179 -0.918 . . . . 0.0 110.753 -179.793 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -97.76 -24.42 15.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.055 179.761 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -67.43 -33.41 75.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.556 179.651 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.559 ' CG1' ' H ' ' A' ' 6' ' ' GLY . 3.1 pt -49.92 -61.29 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' H ' ' CG1' ' A' ' 5' ' ' ILE . . . 98.65 -148.34 18.81 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.066 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.535 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -47.92 -47.54 63.55 Favored Pre-proline 0 C--O 1.217 -0.621 0 CA-C-O 118.837 -0.602 . . . . 0.0 109.84 178.738 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 1.9 Cg_endo -36.99 -43.32 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.835 1.69 . . . . 0.0 111.97 179.278 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -60.55 -36.84 92.28 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.852 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.48 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.488 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.424 HG21 HD13 ' A' ' 19' ' ' ILE . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -71.8 -10.54 26.55 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.4 t -91.82 -11.44 36.52 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.949 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -88.59 -16.31 32.86 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.239 -179.384 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.439 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.5 mt -75.6 -55.0 2.15 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.962 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -40.24 -43.31 3.82 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 121.627 1.552 . . . . 0.0 111.706 177.432 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.447 ' O ' ' OG ' ' A' ' 49' ' ' SER . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -75.41 -31.92 60.56 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.34 -43.76 69.58 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.052 0.453 . . . . 0.0 110.69 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.3 -31.53 34.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.004 179.892 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 45' ' ' LYS . 34.5 m -54.63 -34.14 61.67 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 -179.336 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.58 80.49 0.03 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 49' ' ' SER . 51.2 t0 -68.31 140.07 55.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.359 . . . . 0.0 110.736 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.724 179.849 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.669 ' N ' HD21 ' A' ' 4' ' ' ASN . 96.1 mtp . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.405 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.3 m-85 -78.36 4.78 12.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.548 179.853 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -100.97 -24.91 14.24 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.344 179.897 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.669 HD21 ' N ' ' A' ' 1' ' ' MET . 48.4 m-80 -69.99 -20.62 63.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.726 -179.864 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.9 pt -63.92 -44.55 98.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 -179.783 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 71.28 -136.68 25.33 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.674 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -68.85 -46.08 32.35 Favored Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 122.767 -0.255 . . . . 0.0 110.329 179.083 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.464 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.0 Cg_exo -40.82 -37.4 2.35 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.678 1.586 . . . . 0.0 112.243 -179.967 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.54 -27.52 59.1 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.452 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.435 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -68.29 -19.39 44.1 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -99.97 6.58 45.13 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.115 -179.819 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -108.36 -27.57 9.9 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.583 -179.577 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.3 mp -78.25 -62.89 0.47 Allowed Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.596 -0.274 . . . . 0.0 110.564 179.694 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -56.97 -29.52 82.9 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.084 1.856 . . . . 0.0 111.422 -179.648 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -75.66 -33.38 60.43 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.5 mt -70.25 -43.63 70.16 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.975 0.417 . . . . 0.0 110.955 -179.629 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.0 p -70.33 -45.8 73.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.848 179.831 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.471 ' O ' ' N ' ' A' ' 51' ' ' ASP . 33.6 p -70.76 -16.75 62.78 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.478 -179.48 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.39 68.49 0.1 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.775 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' N ' ' O ' ' A' ' 49' ' ' SER . 91.7 m-20 -69.37 142.73 53.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.859 0.361 . . . . 0.0 110.696 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.467 -179.894 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.532 ' N ' ' OD1' ' A' ' 4' ' ' ASN . 97.2 mtp . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.401 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.6 m-85 -79.27 -1.25 35.75 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 121.012 0.435 . . . . 0.0 110.515 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.8 -23.8 13.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.289 -179.938 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 1' ' ' MET . 10.4 m120 -74.97 -14.75 60.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.401 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -65.38 -44.03 94.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.086 -179.887 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.23 -136.39 26.72 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.3 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.28 -45.03 13.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 C-N-CA 121.156 -0.217 . . . . 0.0 110.695 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.473 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.7 Cg_exo -41.44 -29.81 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.451 1.434 . . . . 0.0 111.205 179.07 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.57 -29.27 27.41 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.238 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.534 ' N ' ' O ' ' A' ' 7' ' ' ILE . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.503 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.52 -17.9 33.82 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.9 t -92.62 -7.99 45.43 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.971 179.947 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -96.02 -33.47 12.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.27 179.914 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.497 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -65.26 -48.61 68.2 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.378 -179.441 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.4 Cg_exo -56.37 -37.73 96.47 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.662 2.241 . . . . 0.0 111.678 179.437 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.406 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -77.54 -28.67 51.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 69.8 mt -71.9 -21.1 61.69 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.956 0.408 . . . . 0.0 111.292 -179.605 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.406 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 4.3 m -57.05 -38.43 60.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.491 -178.909 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.421 ' OG ' ' N ' ' A' ' 50' ' ' GLY . 20.9 p -95.4 -54.71 3.3 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.597 -179.923 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.421 ' N ' ' OG ' ' A' ' 49' ' ' SER . . . 62.36 36.18 92.71 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.843 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.1 t0 -150.5 132.73 15.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.87 0.367 . . . . 0.0 110.729 -179.862 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 97.2 mt-10 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.665 179.91 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.703 ' N ' HD21 ' A' ' 4' ' ' ASN . 79.4 mtp . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -84.74 -1.28 56.05 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 110.707 -179.942 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.68 -23.91 13.79 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.504 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.703 HD21 ' N ' ' A' ' 1' ' ' MET . 56.8 m-80 -78.12 -14.23 59.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.799 -180.0 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.1 pt -62.86 -43.44 98.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.75 -179.885 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.03 -135.13 27.7 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -71.38 -45.06 13.54 Favored Pre-proline 0 C--N 1.33 -0.272 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.222 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.524 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.8 Cg_exo -40.54 -29.93 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 121.524 1.483 . . . . 0.0 111.713 179.574 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.29 -26.03 29.38 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.252 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.471 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo -72.11 -17.99 27.63 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.3 t -91.85 -20.51 21.39 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.642 -179.904 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -85.19 -33.17 22.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.052 0.453 . . . . 0.0 110.715 -179.766 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.498 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 12.3 mt -60.46 -56.16 38.04 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.793 179.237 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.5 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 21.4 Cg_endo -57.19 -31.44 90.6 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.306 2.004 . . . . 0.0 111.756 -179.838 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.73 -30.22 59.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -69.71 -37.99 76.77 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.926 0.393 . . . . 0.0 111.072 -179.093 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.2 m -44.97 147.5 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.312 -179.883 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.8 m 58.99 14.61 3.46 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.695 -179.996 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.39 37.83 2.76 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.916 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 41.0 p-10 -86.16 112.64 21.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.877 0.37 . . . . 0.0 110.49 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 55.9 mp0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.434 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.434 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -78.28 -1.32 32.48 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.762 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -101.65 -23.3 14.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.379 179.903 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -74.68 -16.07 60.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.65 -179.763 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.402 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.2 pt -65.55 -44.32 93.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.196 -179.725 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.9 -136.44 25.63 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 -179.208 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.535 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.75 -44.81 12.23 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.952 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.465 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 85.8 Cg_exo -42.26 -30.53 1.43 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 121.108 1.205 . . . . 0.0 111.13 178.899 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.73 -29.57 31.86 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 178.951 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.535 ' N ' ' O ' ' A' ' 7' ' ' ILE . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.485 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.485 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.57 -13.71 32.87 Favored 'Trans proline' 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 t -89.95 -10.1 46.33 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.479 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 15.0 mmmt -94.07 -28.72 15.57 Favored 'General case' 0 C--O 1.222 -0.39 0 N-CA-C 112.861 0.689 . . . . 0.0 112.861 -178.583 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.496 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 13.6 mt -68.03 -53.81 18.45 Favored Pre-proline 0 CA--C 1.54 0.577 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.694 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.496 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 9.8 Cg_exo -37.05 -56.16 0.81 Allowed 'Trans proline' 0 C--N 1.316 -1.139 0 C-N-CA 122.403 2.068 . . . . 0.0 112.066 176.496 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . 0.461 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -76.23 -32.06 58.71 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.404 ' O ' ' N ' ' A' ' 50' ' ' GLY . 56.1 mt -69.85 -33.85 72.83 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.917 0.389 . . . . 0.0 111.308 -179.23 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 4.2 m -43.16 -37.26 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.72 -179.06 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -61.48 -44.18 97.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.041 179.671 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LEU . . . 51.6 32.81 32.52 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.88 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -170.12 100.66 0.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.701 0.286 . . . . 0.0 110.859 -179.85 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.757 179.886 . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.685 ' N ' HD21 ' A' ' 4' ' ' ASN . 77.7 mtm . . . . . 0 N--CA 1.487 1.416 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -84.5 1.23 46.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.609 -179.832 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -103.43 -23.96 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.628 179.918 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.685 HD21 ' N ' ' A' ' 1' ' ' MET . 61.7 m-80 -79.34 -14.4 59.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.1 pt -64.68 -43.1 96.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.427 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.764 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.96 -135.08 24.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.329 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -70.88 -46.02 15.75 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 110.132 -0.322 . . . . 0.0 110.132 178.463 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.8 Cg_exo -39.83 -36.91 1.39 Allowed 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.709 1.606 . . . . 0.0 112.491 -179.617 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.1 -26.36 58.08 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.651 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.437 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.426 ' O ' ' N ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo -72.23 -14.06 28.45 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -96.96 -6.06 36.43 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.886 -179.688 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 17.0 mmmt -98.43 -27.0 14.27 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.206 179.562 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.512 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -72.03 -48.31 10.81 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.953 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.1 Cg_exo -55.21 -38.29 93.74 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.648 2.232 . . . . 0.0 111.353 179.643 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.431 ' CD1' ' HZ2' ' A' ' 41' ' ' LYS . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.431 ' HZ2' ' CD1' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.412 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -76.4 -31.71 58.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.489 ' O ' ' O ' ' A' ' 48' ' ' VAL . 69.5 mt -71.34 -20.5 62.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.297 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 47' ' ' LEU . 5.6 m -53.09 -164.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.918 -179.584 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 51' ' ' ASP . 45.8 t -67.09 58.02 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.486 179.714 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -48.09 88.8 0.01 OUTLIER Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.74 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 49' ' ' SER . 43.3 t0 -162.32 170.06 19.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.661 0.267 . . . . 0.0 110.651 179.771 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.68 179.939 . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.063 0.459 . . . . 0.0 110.22 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 2' ' ' PHE . 0.5 OUTLIER -72.32 1.33 7.98 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.305 -178.793 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -102.1 -23.51 14.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.36 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -70.7 -22.63 62.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.521 179.972 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.428 ' CG1' ' H ' ' A' ' 6' ' ' GLY . 3.2 pt -61.32 -57.18 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.317 -179.204 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.428 ' H ' ' CG1' ' A' ' 5' ' ' ILE . . . 93.64 -132.82 11.38 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.245 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -57.45 -50.97 85.11 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-O 119.383 -0.342 . . . . 0.0 110.086 179.002 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.514 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 4.2 Cg_endo -38.49 -31.21 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.077 1.851 . . . . 0.0 110.7 176.994 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -82.55 -32.87 26.56 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.867 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.496 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.44 -19.51 43.03 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -88.46 1.72 54.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.399 -179.947 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.0 mptt -100.0 -12.4 19.77 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.19 179.546 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.588 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.6 mt -75.13 -40.58 3.68 Favored Pre-proline 0 C--N 1.326 -0.452 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.482 179.906 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 26.1 Cg_exo -63.98 -35.6 53.76 Favored 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.56 2.173 . . . . 0.0 111.301 179.293 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.64 -30.51 56.89 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 61.8 mt -69.74 -36.34 75.75 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.865 0.364 . . . . 0.0 111.2 -179.597 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.403 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 4.3 m -41.16 124.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.669 -179.456 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 16.2 m 40.53 55.88 2.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.367 . . . . 0.0 110.681 -179.736 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.408 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -71.41 55.01 1.19 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.519 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 4.0 p-10 44.99 37.6 2.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 179.758 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.518 179.988 . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -78.68 -3.25 43.16 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.767 -179.841 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -95.23 -23.09 17.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.191 179.806 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -67.42 -32.91 74.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.46 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.1 pt -58.77 -49.05 84.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.586 -179.579 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 101.96 -120.23 6.76 Favored Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.697 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.8 tp -92.87 -24.09 0.26 Allowed Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.053 -0.573 . . . . 0.0 111.478 177.324 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.697 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 53.7 Cg_exo -49.89 -39.9 48.94 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.896 1.731 . . . . 0.0 112.384 -178.866 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -62.34 -34.64 89.91 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.848 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.439 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo -71.5 -18.66 29.25 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.8 t -91.0 -24.35 20.11 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.581 -179.966 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tptm -83.61 -28.0 28.78 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.011 0.434 . . . . 0.0 110.961 -179.75 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.51 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 9.3 mt -63.38 -58.37 16.01 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.753 179.533 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.51 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 14.6 Cg_endo -54.23 -36.95 87.7 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.385 2.057 . . . . 0.0 112.249 -179.608 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.7 -33.48 60.35 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 53.2 mt -70.14 -43.0 71.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.953 0.406 . . . . 0.0 110.939 -179.524 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.82 -26.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.745 179.679 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.9 t -60.0 -42.73 94.91 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.703 -179.368 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 90.81 109.88 1.5 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.842 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 43.8 p-10 -90.75 115.01 27.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.787 0.327 . . . . 0.0 110.584 179.886 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' A' ' 51' ' ' ASP . 79.8 tt0 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.696 ' H2 ' HD21 ' A' ' 4' ' ' ASN . 1.5 ptp . . . . . 0 N--CA 1.493 1.696 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.445 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.5 m-85 -78.64 -2.38 38.79 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.69 -179.817 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.03 -23.43 14.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.411 -179.926 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.696 HD21 ' H2 ' ' A' ' 1' ' ' MET . 70.1 m-80 -76.56 -14.32 60.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.717 -179.806 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.7 pt -63.48 -48.75 85.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.383 179.869 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -118.41 5.93 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.026 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.677 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 tp -105.12 -17.31 0.17 Allowed Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 179.306 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.677 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 63.2 Cg_endo -73.51 -52.43 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.944 1.763 . . . . 0.0 112.893 -178.826 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.45 -21.76 35.54 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.749 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.461 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo -69.65 -17.55 38.01 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.9 t -93.37 -25.41 17.71 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.814 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -79.17 -34.25 43.29 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.111 0.481 . . . . 0.0 110.027 179.824 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.419 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 11.6 mt -59.41 -59.41 13.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.759 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo -57.81 -31.0 91.23 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.141 1.894 . . . . 0.0 112.12 -179.107 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.405 ' O ' ' CG2' ' A' ' 48' ' ' VAL . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t -76.21 -32.05 58.76 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.475 ' C ' ' H ' ' A' ' 49' ' ' SER . 66.5 mt -71.22 -22.52 61.99 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.411 -179.314 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.405 ' CG2' ' O ' ' A' ' 45' ' ' LYS . 11.0 m -48.45 -14.76 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.499 -179.021 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.475 ' H ' ' C ' ' A' ' 47' ' ' LEU . 38.5 t -59.54 -42.56 92.61 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.988 -179.912 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.44 160.35 35.81 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.633 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 51.7 p-10 -137.04 36.2 2.57 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.687 179.935 . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.677 ' N ' HD21 ' A' ' 4' ' ' ASN . 96.2 mtp . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.35 0.91 31.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.044 0.45 . . . . 0.0 110.742 -179.865 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.1 m -102.01 -23.91 14.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.696 -179.829 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.677 HD21 ' N ' ' A' ' 1' ' ' MET . 59.0 m-80 -77.7 -14.17 59.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.76 -179.961 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.7 pt -63.51 -43.72 98.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.864 -179.993 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.37 -136.35 30.06 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.495 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.575 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -69.33 -45.19 27.77 Favored Pre-proline 0 N--CA 1.463 0.218 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 178.639 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.508 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.3 Cg_exo -40.96 -30.61 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.459 1.44 . . . . 0.0 111.551 179.211 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.53 -26.04 31.27 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.113 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.575 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' A' ' 11' ' ' ILE . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.471 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.59 -18.19 53.75 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.4 t -87.95 0.18 56.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.555 -179.815 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.31 -2.45 25.53 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.914 -179.824 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.616 ' N ' ' CD2' ' A' ' 26' ' ' LEU . 1.8 mm? -85.4 -39.8 0.62 Allowed Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 22.1 Cg_exo -66.09 -34.72 36.41 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.279 1.986 . . . . 0.0 111.215 178.792 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -75.6 -32.73 60.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.1 mt -70.47 -43.12 70.43 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.985 0.421 . . . . 0.0 111.002 -179.633 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.2 p -73.1 -25.98 22.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.899 179.895 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 49' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 51' ' ' ASP . 5.3 p -48.47 -24.32 1.24 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -61.31 77.77 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.852 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' A' ' 49' ' ' SER . 53.5 p-10 -83.37 172.81 12.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.832 0.348 . . . . 0.0 110.476 179.896 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.612 -179.813 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.942 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.942 HG23 ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.433 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.433 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo . . . . . 0 N--CA 1.496 1.674 0 N-CA-C 111.211 -0.342 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.898 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 11' ' ' ILE . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.539 HD13 ' HG3' ' A' ' 23' ' ' PRO . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.403 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.403 ' CD1' HD13 ' A' ' 20' ' ' ILE . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo . . . . . 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.702 0.209 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo . . . . . 0 N--CA 1.497 1.688 0 CA-C-O 120.693 0.205 . . . . 0.0 111.906 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m . . . . . 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.923 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.477 ' O ' HG22 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.449 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.491 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.491 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.449 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.451 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.5 Cg_exo . . . . . 0 N--CA 1.493 1.453 0 CA-C-O 121.107 0.378 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.013 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.933 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 20' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.541 HG23 ' N ' ' A' ' 21' ' ' PHE . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.541 ' N ' HG23 ' A' ' 20' ' ' ILE . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo . . . . . 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.746 0.228 . . . . 0.0 111.708 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.684 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.488 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.684 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.423 ' HG3' ' H ' ' A' ' 39' ' ' GLU . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.438 ' O ' HG22 ' A' ' 19' ' ' ILE . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.493 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.493 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.456 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.495 ' HB3' HH12 ' A' ' 31' ' ' ARG . 11.8 Cg_exo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.93 -0.45 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.495 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.604 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.6 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.914 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.518 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.914 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.424 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.573 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo . . . . . 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.573 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo . . . . . 0 N--CA 1.48 0.735 0 CA-C-O 120.929 0.304 . . . . 0.0 111.953 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.905 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.905 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.426 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.443 ' HA2' ' HD2' ' A' ' 23' ' ' PRO . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo . . . . . 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 121.081 0.367 . . . . 0.0 111.464 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.62 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.62 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.531 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.531 ' H ' HG23 ' A' ' 20' ' ' ILE . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.458 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HB3' HH12 ' A' ' 31' ' ' ARG . 37.6 Cg_exo . . . . . 0 N--CA 1.496 1.666 0 CA-C-O 121.296 0.457 . . . . 0.0 111.518 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.418 HH12 ' HB3' ' A' ' 27' ' ' PRO . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.931 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.42 ' H ' HG22 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo . . . . . 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.438 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.0 Cg_exo . . . . . 0 N--CA 1.494 1.503 0 CA-C-O 120.961 0.317 . . . . 0.0 111.575 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.403 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.922 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.922 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.452 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.452 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB3' HH12 ' A' ' 31' ' ' ARG . 38.5 Cg_exo . . . . . 0 N--CA 1.497 1.715 0 CA-C-O 121.116 0.382 . . . . 0.0 111.438 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.421 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.557 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.557 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.401 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.401 ' CD1' HD13 ' A' ' 20' ' ' ILE . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo . . . . . 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 37.5 Cg_exo . . . . . 0 N--CA 1.491 1.369 0 CA-C-O 121.242 0.434 . . . . 0.0 111.601 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.54 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.54 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.442 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.423 HG22 ' H ' ' A' ' 19' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.442 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo . . . . . 0 N--CA 1.498 1.779 0 CA-C-O 121.166 0.402 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.621 0 N-CA-C 112.045 -0.422 . . . . 0.0 112.045 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.918 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.422 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo . . . . . 0 N--CA 1.499 1.802 0 CA-C-O 120.719 0.216 . . . . 0.0 112.103 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.709 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.474 ' O ' HG22 ' A' ' 19' ' ' ILE . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.463 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.532 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.532 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.463 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB3' HH12 ' A' ' 31' ' ' ARG . 28.0 Cg_exo . . . . . 0 N--CA 1.495 1.589 0 CA-C-O 121.182 0.409 . . . . 0.0 111.569 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.426 HH12 ' HB3' ' A' ' 27' ' ' PRO . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.913 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.913 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.427 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.441 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.496 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.496 ' H ' HG23 ' A' ' 20' ' ' ILE . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 CA--C 1.547 1.131 0 CA-C-O 120.729 0.22 . . . . 0.0 111.561 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo . . . . . 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.474 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 29.1 Cg_exo . . . . . 0 N--CA 1.498 1.783 0 CA-C-O 121.22 0.425 . . . . 0.0 112.103 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.941 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.941 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.439 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.439 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo . . . . . 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo . . . . . 0 N--CA 1.504 2.115 0 N-CA-C 113.267 0.449 . . . . 0.0 113.267 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo . . . . . 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.404 ' CG ' ' O ' ' A' ' 23' ' ' PRO . 19.1 Cg_endo . . . . . 0 N--CA 1.492 1.386 0 N-CA-C 111.344 -0.291 . . . . 0.0 111.344 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.912 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 20' ' ' ILE . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.409 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 21' ' ' PHE . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.548 ' N ' HG23 ' A' ' 20' ' ' ILE . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo . . . . . 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 7.4 Cg_endo . . . . . 0 N--CA 1.505 2.175 0 CA-C-O 121.37 0.488 . . . . 0.0 112.218 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' H ' ' A' ' 39' ' ' GLU . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m . . . . . 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.452 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.491 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.446 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.515 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.515 ' H ' HG23 ' A' ' 20' ' ' ILE . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.491 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 120.917 0.299 . . . . 0.0 112.361 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.432 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 30.2 Cg_exo . . . . . 0 N--CA 1.494 1.548 0 CA-C-O 121.214 0.422 . . . . 0.0 111.233 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.421 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.705 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' N ' HG23 ' A' ' 20' ' ' ILE . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo . . . . . 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.444 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.2 Cg_endo . . . . . 0 N--CA 1.492 1.404 0 N-CA-C 111.384 -0.276 . . . . 0.0 111.384 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.511 ' N ' HG23 ' A' ' 20' ' ' ILE . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo . . . . . 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_exo . . . . . 0 N--CA 1.492 1.415 0 N-CA-C 111.113 -0.38 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.421 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.432 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.487 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.521 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.521 ' H ' HG23 ' A' ' 20' ' ' ILE . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.487 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.959 0.316 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.93 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.93 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.472 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.464 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.472 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo . . . . . 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.522 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo . . . . . 0 N--CA 1.503 2.068 0 CA-C-O 120.767 0.236 . . . . 0.0 111.9 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.522 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.917 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.503 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 11' ' ' ILE . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.415 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.415 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo . . . . . 0 N--CA 1.497 1.698 0 CA-C-O 121.208 0.42 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' NZ ' ' A' ' 41' ' ' LYS . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.604 ' NZ ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.463 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA2' ' HD3' ' A' ' 23' ' ' PRO . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.477 ' HG3' HD13 ' A' ' 18' ' ' LEU . 16.4 Cg_exo . . . . . 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.1 Cg_exo . . . . . 0 N--CA 1.493 1.48 0 CA-C-O 121.239 0.433 . . . . 0.0 111.706 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.949 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.949 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.445 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo . . . . . 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 CA-C-O 121.017 0.34 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.591 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.591 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.42 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.486 HG23 ' O ' ' A' ' 15' ' ' VAL . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.553 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.553 ' N ' HG23 ' A' ' 20' ' ' ILE . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 10.7 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.704 0.21 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.488 1.179 0 CA-C-O 120.988 0.328 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.953 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.459 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG22 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.459 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.897 0.29 . . . . 0.0 111.422 . . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.697 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.946 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.946 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.437 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.437 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.458 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.4 Cg_exo . . . . . 0 N--CA 1.496 1.673 0 CA-C-O 121.156 0.398 . . . . 0.0 111.678 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.443 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo . . . . . 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.5 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 21.4 Cg_endo . . . . . 0 N--CA 1.498 1.766 0 CA-C-O 120.789 0.245 . . . . 0.0 111.756 . . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.7 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 20' ' ' ILE . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.454 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 15' ' ' VAL . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.523 HG23 ' H ' ' A' ' 21' ' ' PHE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.523 ' H ' HG23 ' A' ' 20' ' ' ILE . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.454 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.485 1.026 0 CA-C-O 120.636 0.182 . . . . 0.0 112.066 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 35' ' ' ARG . . . . . 0.461 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.955 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.955 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.46 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.46 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo . . . . . 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.411 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 38.1 Cg_exo . . . . . 0 N--CA 1.494 1.507 0 CA-C-O 121.156 0.398 . . . . 0.0 111.353 . . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.63 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HZ3' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t . . . . . 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.921 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.475 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.475 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo . . . . . 0 N--CA 1.494 1.559 0 CA-C-O 121.079 0.366 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.406 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.406 ' CD1' HD13 ' A' ' 20' ' ' ILE . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo . . . . . 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 14.6 Cg_endo . . . . . 0 N--CA 1.492 1.394 0 CA-C-O 120.756 0.232 . . . . 0.0 112.249 . . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.906 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.413 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo . . . . . 0 N--CA 1.498 1.789 0 CA-C-O 120.603 0.168 . . . . 0.0 112.12 . . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo . . . . . 0 N--CA 1.494 1.547 0 CA-C-O 121.07 0.362 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 99.3 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -87.29 -3.22 59.03 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.699 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -101.98 -23.64 14.09 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.8 m120 -76.74 -14.43 59.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.742 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -64.36 -43.99 97.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.006 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.72 -137.79 34.78 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.531 -1.028 . . . . 0.0 110.531 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.527 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -65.86 -47.67 64.15 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.711 179.496 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.463 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 95.2 Cg_exo -39.48 -38.61 1.58 Allowed 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 121.487 1.458 . . . . 0.0 112.114 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.81 -29.96 60.33 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.527 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.942 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.942 HG23 ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.433 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.433 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -69.59 -16.26 38.18 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -94.19 0.89 56.04 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.478 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.51 -35.86 9.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.543 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.3 mt -68.95 -43.26 25.82 Favored Pre-proline 0 N--CA 1.446 -0.635 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.564 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 23.5 Cg_exo -67.17 -32.98 32.58 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.292 1.995 . . . . 0.0 111.211 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -75.75 -31.97 59.79 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.9 mt -70.49 -44.13 68.29 Favored 'General case' 0 N--CA 1.455 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.782 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 49' ' ' SER . 7.5 p -71.74 -40.29 69.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.996 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.454 ' N ' HG13 ' A' ' 48' ' ' VAL . 40.3 t -60.94 -44.38 97.34 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.479 -179.332 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 42.38 31.45 0.99 Allowed Glycine 0 CA--C 1.521 0.447 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.405 ' OD1' ' OG ' ' A' ' 49' ' ' SER . 53.9 p-10 -172.28 178.41 2.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.85 0.357 . . . . 0.0 110.605 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.756 179.836 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.9 mtp . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.423 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.0 m-85 -85.12 -3.09 58.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.612 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.71 -24.48 13.74 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.602 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -77.79 -13.65 59.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.658 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.423 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -61.25 -47.83 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.531 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 97.45 -118.89 6.22 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.687 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.8 tp -105.59 -17.85 0.17 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.687 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 62.0 Cg_endo -72.45 -54.19 0.13 Allowed 'Trans proline' 0 N--CA 1.499 1.853 0 C-N-CA 122.133 1.889 . . . . 0.0 112.912 -178.208 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.14 -21.63 32.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.898 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 11' ' ' ILE . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.539 HD13 ' HG3' ' A' ' 23' ' ' PRO . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.403 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.403 ' CD1' HD13 ' A' ' 20' ' ' ILE . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo -83.88 -15.48 6.96 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.78 -18.23 15.23 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 112.859 -1.973 . . . . 0.0 109.045 -179.431 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 55.8 mmtt -96.44 -13.77 22.89 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.444 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 3.2 mt -82.37 -63.36 0.28 Allowed Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.574 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 21.4 Cg_endo -58.88 -32.27 96.98 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 122.168 1.912 . . . . 0.0 111.676 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t -75.51 -32.78 60.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.7 mt -70.35 -43.47 70.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.978 0.418 . . . . 0.0 110.714 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.22 -28.99 26.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.784 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -60.46 -43.85 96.49 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.717 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 148.96 41.62 0.03 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -125.09 107.92 11.28 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.734 0.302 . . . . 0.0 110.751 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.625 179.838 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 98.1 m-85 -79.73 -2.0 41.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -101.93 -24.14 14.05 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.485 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -73.59 -16.14 61.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.551 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.43 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.0 pt -63.71 -47.59 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.34 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.86 -119.79 6.55 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.685 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.6 tp -104.4 -17.68 0.18 Allowed Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 177.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.685 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 60.0 Cg_endo -71.84 -56.33 0.11 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.95 1.767 . . . . 0.0 113.116 -178.231 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -54.71 -21.31 21.75 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo -70.8 -20.29 30.13 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.5 m -93.35 -23.54 18.42 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.82 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -81.99 -29.67 31.99 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 110.526 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.468 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 6.7 mt -64.55 -59.22 11.11 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.039 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo -57.26 -32.15 92.83 Favored 'Trans proline' 0 N--CA 1.497 1.688 0 C-N-CA 122.266 1.977 . . . . 0.0 111.906 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.728 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m -77.2 -28.57 53.96 Favored 'General case' 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 48' ' ' VAL . 66.2 mt -72.36 -21.44 61.3 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.747 0.308 . . . . 0.0 111.465 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.728 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.9 m -55.88 -154.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.261 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.528 ' N ' HG23 ' A' ' 48' ' ' VAL . 72.0 m -67.68 32.83 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.747 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.56 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 51.88 36.9 42.94 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -157.41 175.45 13.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.808 0.337 . . . . 0.0 110.783 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.681 -179.996 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.529 ' O ' ' N ' ' A' ' 3' ' ' SER . 76.5 mtm . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 38.48 23.43 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.924 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.977 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.529 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -120.39 -33.28 3.91 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.175 0.512 . . . . 0.0 109.851 179.665 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -71.85 -14.3 61.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.268 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.408 HG13 ' N ' ' A' ' 6' ' ' GLY . 5.1 pt -60.66 -50.38 80.68 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.484 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 94.64 -120.36 6.39 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.642 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.5 tp -102.79 -21.37 0.2 Allowed Pre-proline 0 CA--C 1.551 1.005 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 55.8 Cg_endo -69.71 -30.07 23.11 Favored 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 121.602 1.535 . . . . 0.0 112.245 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.3 73.63 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.923 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.477 ' O ' HG22 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.449 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.491 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.491 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.449 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.45 -16.99 34.73 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.9 m -95.61 -6.19 40.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.62 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -99.45 -23.47 15.11 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.417 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -76.66 -47.49 3.06 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.933 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.529 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.5 Cg_exo -56.32 -39.16 93.11 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.537 2.158 . . . . 0.0 111.434 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -75.68 -34.04 60.43 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.18 -42.51 72.33 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.047 0.451 . . . . 0.0 111.119 -179.447 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.56 -28.51 31.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.249 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.472 ' C ' ' H ' ' A' ' 51' ' ' ASP . 54.5 p -60.16 -23.11 63.66 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.307 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.95 38.74 0.94 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.472 ' H ' ' C ' ' A' ' 49' ' ' SER . 54.9 p-10 -83.28 170.77 14.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 110.59 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.632 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.0 mmm . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -79.8 -2.54 43.77 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.657 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -98.17 -23.44 15.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.298 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.8 m120 -68.55 -27.2 65.87 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.405 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.46 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 pt -62.09 -48.47 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.674 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 66.18 -136.35 34.87 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.555 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -57.76 -53.65 63.5 Favored Pre-proline 0 C--O 1.22 -0.475 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.596 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -44.81 -23.77 1.0 Allowed 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.495 2.13 . . . . 0.0 112.233 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -91.15 -26.94 20.13 Favored Glycine 0 C--N 1.345 1.066 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 176.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.555 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.933 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 20' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.541 HG23 ' N ' ' A' ' 21' ' ' PHE . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.541 ' N ' HG23 ' A' ' 20' ' ' ILE . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo -70.34 -21.64 30.52 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -92.25 -31.6 15.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.924 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -77.92 -33.6 51.69 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 121.121 0.486 . . . . 0.0 110.557 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.437 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.5 mt -58.1 -61.45 7.44 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.043 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo -58.37 -30.44 91.27 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.206 1.937 . . . . 0.0 111.708 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.684 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.488 ' N ' ' CD ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.684 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.423 ' HG3' ' H ' ' A' ' 39' ' ' GLU . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.416 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.563 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -84.27 -32.95 24.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.722 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.07 -48.6 28.74 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.494 0.664 . . . . 0.0 110.682 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 44' ' ' THR . 11.1 p -51.45 -20.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.426 -0.807 . . . . 0.0 110.073 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.0 p -61.52 -23.7 66.11 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.517 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.429 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 71.86 36.07 61.51 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.72 37.06 1.44 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.937 0.399 . . . . 0.0 110.736 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.485 -179.902 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.29 -0.54 37.01 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.832 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -103.72 -23.77 13.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.269 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -76.25 -14.29 60.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.537 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.3 pt -62.52 -50.49 79.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.465 -179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.13 -145.55 32.28 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -58.15 -54.76 52.34 Favored Pre-proline 0 C--O 1.225 -0.229 0 CA-C-O 118.855 -0.593 . . . . 0.0 109.73 179.133 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.464 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 38.0 Cg_exo -34.01 -38.86 0.14 Allowed 'Trans proline' 0 N--CA 1.487 1.124 0 C-N-CA 121.598 1.532 . . . . 0.0 111.932 178.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -75.73 -34.85 47.65 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.992 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.547 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.438 ' O ' HG22 ' A' ' 19' ' ' ILE . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.493 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.493 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.456 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.73 -13.04 31.91 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.2 t -87.14 -7.55 57.88 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -91.98 -26.4 18.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.3 -178.492 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.506 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.1 mt -67.08 -50.8 39.67 Favored Pre-proline 0 N--CA 1.445 -0.717 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 178.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.8 Cg_exo -43.52 -49.72 7.48 Favored 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 121.01 1.14 . . . . 0.0 110.93 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.495 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.604 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.576 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m -76.99 -28.3 55.02 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.93 -34.56 71.62 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.04 0.448 . . . . 0.0 111.102 -179.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.576 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.5 m -43.46 -45.35 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.67 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.487 ' N ' ' CG2' ' A' ' 48' ' ' VAL . 7.5 t -78.63 -39.82 36.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.18 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.23 31.75 2.86 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.279 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -93.53 110.92 22.49 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.767 0.317 . . . . 0.0 110.661 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.603 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.597 ' O ' ' N ' ' A' ' 3' ' ' SER . 3.5 ttt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 36.79 21.63 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.126 0.489 . . . . 0.0 111.843 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.597 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.5 OUTLIER -122.31 -28.35 4.33 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.817 179.821 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -76.79 -13.96 59.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.752 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 pt -58.97 -51.8 68.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.919 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.93 -135.76 12.91 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -178.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.601 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -81.37 -39.45 1.0 Allowed Pre-proline 0 CA--C 1.553 1.093 0 CA-C-O 118.967 -0.54 . . . . 0.0 112.27 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.601 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 8.7 Cg_endo -47.56 -30.34 11.98 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 CA-C-N 121.142 1.444 . . . . 0.0 112.567 177.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -80.59 -26.71 53.55 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.499 -178.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.914 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.518 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.914 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.424 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.573 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo -53.72 -28.95 49.49 Favored 'Trans proline' 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.9 m -78.07 -11.41 59.91 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.731 -178.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -93.01 -23.41 18.69 Favored 'General case' 0 C--O 1.22 -0.483 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.516 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 19.3 mt -69.05 -53.82 13.29 Favored Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 119.435 -0.906 . . . . 0.0 109.248 178.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.573 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo -36.72 -53.69 1.09 Allowed 'Trans proline' 0 N--CA 1.48 0.735 0 C-N-CA 123.161 2.574 . . . . 0.0 111.953 175.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.36 -32.42 60.84 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 94.0 mt -70.2 -44.03 69.51 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.09 0.472 . . . . 0.0 110.572 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.45 -26.92 22.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.837 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -58.01 -42.74 85.87 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.249 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.77 59.16 4.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -84.65 112.76 20.75 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.859 0.361 . . . . 0.0 110.827 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.647 179.958 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttm . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -84.74 8.68 16.29 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.785 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.06 -25.94 13.56 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.25 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 54.6 m-80 -75.46 -14.86 60.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.866 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -65.31 -43.81 94.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.025 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.49 -135.15 24.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -72.58 -44.7 9.59 Favored Pre-proline 0 C--N 1.327 -0.386 0 O-C-N 122.866 -0.197 . . . . 0.0 110.738 179.345 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.2 Cg_exo -41.82 -30.72 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 C-N-CA 121.382 1.388 . . . . 0.0 111.208 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.24 -27.38 33.61 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.905 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.905 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.426 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.443 ' HA2' ' HD2' ' A' ' 23' ' ' PRO . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo -48.65 -23.5 5.58 Favored 'Trans proline' 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -88.8 -7.65 55.81 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.953 0.406 . . . . 0.0 111.202 -177.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.5 mptt -99.3 -37.77 9.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.701 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.492 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.8 OUTLIER -59.63 -48.64 94.98 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.062 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo -56.61 -36.49 98.06 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.833 2.355 . . . . 0.0 111.464 179.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.62 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.62 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.748 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -77.21 -30.86 54.87 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.4 mt -70.23 -36.84 74.8 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.364 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 45' ' ' LYS . 6.1 m -41.2 114.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.517 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.9 t 38.65 74.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -69.15 36.34 0.31 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.517 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.3 m-20 -103.01 138.49 39.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 110.459 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.417 -179.851 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.9 mtp . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 92.8 m-85 -77.93 -0.04 26.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.51 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -101.42 -23.48 14.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.732 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 16.0 m120 -76.96 -14.9 59.8 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.72 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 2.7 pt -59.69 -58.18 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.458 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 5' ' ' ILE . . . 97.79 -139.77 14.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.625 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -55.9 -53.22 65.49 Favored Pre-proline 0 C--O 1.222 -0.35 0 CA-C-O 118.364 -0.827 . . . . 0.0 109.751 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.468 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 14.0 Cg_exo -33.12 -32.51 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 121.859 1.706 . . . . 0.0 111.175 175.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -80.07 -35.3 27.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 179.72 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.625 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.531 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.531 ' H ' HG23 ' A' ' 20' ' ' ILE . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.07 -17.4 40.72 Favored 'Trans proline' 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 t -93.93 3.34 55.52 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.666 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -103.05 -34.57 8.85 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.528 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.598 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 5.0 mt -67.61 -40.67 26.38 Favored Pre-proline 0 C--N 1.325 -0.461 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.724 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.6 Cg_exo -60.27 -40.43 59.21 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 C-N-CA 122.799 2.332 . . . . 0.0 111.518 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.418 HH12 ' HB3' ' A' ' 27' ' ' PRO . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.777 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m -76.01 -27.44 57.38 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -72.51 -22.06 61.1 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.932 0.396 . . . . 0.0 110.999 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.9 m -61.95 -27.68 42.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 37.6 m -58.35 -40.46 82.28 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.197 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.56 35.44 62.77 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -84.84 115.16 22.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.754 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.879 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.0 mtp . . . . . 0 N--CA 1.488 1.44 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -83.84 -2.19 55.91 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.534 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -102.16 -23.65 14.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.57 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -82.22 -13.07 57.66 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 8.0 pt -59.96 -43.17 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.425 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.46 -136.81 34.41 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.543 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -67.1 -47.14 52.35 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 178.539 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.513 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.2 Cg_exo -39.34 -36.68 0.97 Allowed 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 121.611 1.541 . . . . 0.0 112.212 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.91 -27.93 57.58 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.931 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.42 ' H ' HG22 ' A' ' 20' ' ' ILE . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo -71.3 -17.05 31.2 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 m -96.94 -3.61 41.45 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.962 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -101.28 -22.34 14.65 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.225 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.19 -47.17 2.12 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.539 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.0 Cg_exo -56.0 -40.9 82.11 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.499 2.133 . . . . 0.0 111.575 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.403 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -76.01 -33.4 59.69 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 mt -70.21 -43.61 70.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.007 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.91 -25.1 23.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.718 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.2 t -59.52 -43.58 93.4 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.658 -179.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -112.87 34.81 4.91 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -149.67 113.29 5.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.703 0.287 . . . . 0.0 110.56 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.562 179.918 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.493 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 89.4 m-85 -77.44 -2.92 37.73 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.602 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -102.18 -22.85 14.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.264 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -77.13 -14.53 59.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.493 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.0 pt -62.51 -51.99 65.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.964 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.411 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 92.16 -136.11 13.07 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -178.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -83.1 -38.84 0.76 Allowed Pre-proline 0 CA--C 1.552 1.051 0 CA-C-O 118.254 -0.879 . . . . 0.0 112.51 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 9.7 Cg_endo -48.36 -28.88 12.22 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.0 1.8 . . . . 0.0 112.389 177.386 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -82.65 -25.26 50.93 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 119.984 -1.103 . . . . 0.0 112.267 -178.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.922 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.922 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.452 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.452 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -70.83 -13.2 31.8 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 t -96.73 4.49 51.78 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.352 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -105.98 -30.16 9.49 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.368 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.4 mt -71.91 -40.93 8.5 Favored Pre-proline 0 C--N 1.324 -0.534 0 C-N-CA 120.524 -0.471 . . . . 0.0 110.374 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.5 Cg_exo -61.11 -37.34 75.96 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 122.805 2.337 . . . . 0.0 111.438 179.635 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.421 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.557 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.557 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.34 -32.53 60.91 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.38 -44.4 68.12 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.038 0.447 . . . . 0.0 110.606 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.33 -35.49 57.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.827 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -59.26 -43.57 92.45 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.483 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -97.37 36.28 4.01 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -148.94 120.04 7.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.808 0.337 . . . . 0.0 110.731 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.582 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.6 mtm . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -77.44 2.17 16.92 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-O 120.93 0.395 . . . . 0.0 110.511 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 m -99.91 -24.11 14.75 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.637 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -69.97 -22.66 63.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.494 -179.504 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.2 pt -63.19 -45.47 98.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.27 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.7 -132.77 14.55 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.981 -0.847 . . . . 0.0 110.981 -179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.645 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.1 mp -73.75 -44.2 6.83 Favored Pre-proline 0 C--N 1.325 -0.495 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 177.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.645 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.5 Cg_exo -41.67 -31.05 1.16 Allowed 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.526 2.151 . . . . 0.0 111.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.56 -23.96 37.82 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.401 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.401 ' CD1' HD13 ' A' ' 20' ' ' ILE . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo -72.55 -14.01 27.53 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -98.24 -6.27 31.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.376 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.8 mptt -98.78 -16.01 19.08 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.837 178.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.547 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -83.77 -47.95 0.73 Allowed Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.038 0.447 . . . . 0.0 110.193 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.5 Cg_exo -57.19 -39.33 91.24 Favored 'Trans proline' 0 C--N 1.302 -1.868 0 C-N-CA 122.907 2.405 . . . . 0.0 111.601 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.54 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.54 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.727 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m -76.99 -28.19 54.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 89.5 mt -72.25 -22.11 61.28 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.977 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.727 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.2 m -58.08 -25.61 26.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.625 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.7 t -63.0 -17.64 62.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.442 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.39 38.25 10.08 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.7 t0 -90.1 109.36 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.785 0.326 . . . . 0.0 110.496 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.641 179.828 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.5 ttp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.17 -1.53 23.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.782 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 m -102.64 -23.54 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.152 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.7 m-80 -77.41 -14.21 59.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -63.84 -45.43 97.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 62.9 -142.5 47.78 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.585 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -53.72 -54.37 47.03 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 119.417 -0.325 . . . . 0.0 110.626 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -43.01 -22.38 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 120.879 1.053 . . . . 0.0 111.837 178.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -90.77 -29.1 13.97 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.442 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.423 HG22 ' H ' ' A' ' 19' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.442 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -68.92 -18.28 41.1 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -89.54 -2.82 58.46 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.575 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -100.34 -7.36 24.56 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.841 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.582 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.0 mt -80.7 -41.07 1.2 Allowed Pre-proline 0 C--N 1.325 -0.46 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.43 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 25.1 Cg_exo -64.24 -34.23 57.06 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.764 2.309 . . . . 0.0 111.466 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.734 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -76.51 -28.63 56.47 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.1 mt -70.12 -36.58 74.93 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.989 0.423 . . . . 0.0 110.953 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.734 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.1 m -44.38 150.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.432 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.0 m 55.19 7.73 0.22 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.506 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -78.43 38.7 1.87 Allowed Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.976 -0.849 . . . . 0.0 110.976 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.9 t0 40.91 68.82 0.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.996 0.427 . . . . 0.0 111.018 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.21 179.801 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.5 mmm . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.435 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.2 m-85 -78.27 -2.95 40.39 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.669 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -100.63 -23.6 14.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.31 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -68.89 -24.0 64.27 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.519 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.435 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.4 pt -61.29 -48.19 90.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.671 -179.055 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.0 -112.0 3.47 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -92.62 -57.31 0.23 Allowed Pre-proline 0 CA--C 1.541 0.618 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.979 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.46 ' HD2' ' H ' ' A' ' 7' ' ' ILE . 24.3 Cg_exo -28.83 -43.42 0.08 OUTLIER 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.524 2.149 . . . . 0.0 112.726 178.269 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.23 -35.7 70.34 Favored Glycine 0 CA--C 1.524 0.621 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.045 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.918 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.422 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.82 -15.89 37.05 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.9 t -90.6 -8.63 49.62 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.514 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.9 mmmt -90.88 -24.87 20.09 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.05 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.2 mt -68.23 -50.3 30.14 Favored Pre-proline 0 N--CA 1.445 -0.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.518 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.55 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 27.0 Cg_endo -58.55 -31.57 94.74 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 C-N-CA 121.644 1.562 . . . . 0.0 112.103 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.586 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.0 -31.66 59.05 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.463 ' O ' ' O ' ' A' ' 48' ' ' VAL . 58.2 mt -72.33 -21.75 61.27 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.216 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.658 ' O ' ' N ' ' A' ' 50' ' ' GLY . 20.0 m -40.26 162.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -51.62 72.65 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 O-C-N 123.409 0.443 . . . . 0.0 111.534 -178.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.658 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -81.31 37.71 2.41 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 54.0 p-10 -171.4 81.28 0.07 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.392 179.931 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.6 mtm . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.4 m-85 -83.48 1.01 43.83 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-O 120.935 0.398 . . . . 0.0 110.664 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -100.37 -24.18 14.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.533 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -70.93 -21.07 62.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.634 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.4 pt -62.72 -45.33 99.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.926 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.03 -135.67 19.23 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -73.38 -43.57 7.25 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.527 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 86.6 Cg_exo -43.44 -29.82 2.22 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 121.458 1.438 . . . . 0.0 111.488 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.77 -27.48 31.84 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.709 ' O ' HD23 ' A' ' 10' ' ' LEU . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.474 ' O ' HG22 ' A' ' 19' ' ' ILE . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.463 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.532 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.532 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.463 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.83 -15.86 33.06 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.5 t -94.56 -0.29 54.67 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.893 0.377 . . . . 0.0 110.587 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -102.81 -8.31 20.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.407 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.59 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -84.68 -41.3 0.69 Allowed Pre-proline 0 N--CA 1.45 -0.439 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.17 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 28.0 Cg_exo -62.41 -34.86 75.34 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.793 2.329 . . . . 0.0 111.569 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.426 HH12 ' HB3' ' A' ' 27' ' ' PRO . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.424 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.597 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -78.88 -32.98 46.07 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.726 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.02 -48.73 28.09 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.512 0.672 . . . . 0.0 110.397 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 44' ' ' THR . 9.0 p -58.73 -31.66 44.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.214 -178.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.8 p -66.55 -18.97 65.66 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.612 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 73.34 39.69 50.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -81.11 109.62 15.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.794 0.331 . . . . 0.0 110.563 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.682 -179.875 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 78.4 mtm . . . . . 0 N--CA 1.488 1.466 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -84.84 -2.68 58.06 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.015 0.436 . . . . 0.0 110.746 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.71 -23.57 13.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.619 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 18.1 m120 -78.95 -13.9 59.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.817 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 pt -63.18 -43.78 98.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.083 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.88 -135.59 28.4 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.94 -44.82 11.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.867 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.3 Cg_exo -41.43 -31.53 1.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.309 1.34 . . . . 0.0 111.139 178.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.03 36.09 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.913 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.913 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.427 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.441 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.496 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.496 ' H ' HG23 ' A' ' 20' ' ' ILE . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -71.98 -24.37 20.82 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.86 -6.73 55.54 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.496 -176.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -93.51 -23.56 18.31 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.003 -0.999 . . . . 0.0 111.846 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.519 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.4 mt -69.97 -54.05 10.48 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.611 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -39.14 -50.73 2.68 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 121.732 1.621 . . . . 0.0 111.561 176.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.786 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -77.05 -28.96 54.95 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.6 mt -71.25 -28.3 64.07 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.25 -179.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.7 m -55.87 -31.04 29.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.244 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.486 ' C ' ' H ' ' A' ' 51' ' ' ASP . 43.0 t -162.87 97.19 0.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.305 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.48 35.63 0.82 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.486 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 -120.64 106.11 11.43 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.682 0.277 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.677 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.589 ' O ' ' N ' ' A' ' 3' ' ' SER . 65.4 mmm . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 38.73 19.89 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.338 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.589 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.9 OUTLIER -115.86 -40.2 3.37 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.174 0.511 . . . . 0.0 110.405 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -76.79 -13.49 60.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.833 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.577 HD12 ' HA3' ' A' ' 9' ' ' GLY . 19.3 pt -61.6 -41.42 90.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.43 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 74.65 -134.22 17.17 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.495 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -76.38 -44.17 3.43 Favored Pre-proline 0 CA--C 1.54 0.594 0 C-N-CA 121.124 -0.231 . . . . 0.0 111.083 179.794 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 84.1 Cg_exo -42.13 -39.62 6.02 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 121.683 1.588 . . . . 0.0 112.505 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.577 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -75.0 -27.61 64.1 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo -52.46 -19.73 10.46 Favored 'Trans proline' 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 t -96.79 -15.6 21.25 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.541 0.686 . . . . 0.0 110.5 -178.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 41.8 mmtm -101.32 -12.06 18.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.073 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.511 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.8 mt -86.6 -43.84 0.56 Allowed Pre-proline 0 CA--C 1.541 0.605 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.783 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.511 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 29.1 Cg_exo -60.36 -42.54 40.85 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.633 2.222 . . . . 0.0 112.103 179.479 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.714 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t -75.79 -31.22 59.37 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.24 -32.74 70.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.298 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.2 m -57.85 -27.78 31.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.147 -178.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.507 ' C ' ' H ' ' A' ' 51' ' ' ASP . 17.4 p -173.17 97.73 0.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.254 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.67 37.02 0.59 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.507 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.0 m-20 -78.44 150.86 32.96 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.869 0.366 . . . . 0.0 110.755 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.706 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.8 mtp . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -79.56 3.98 17.24 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.458 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -99.95 -24.38 14.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.361 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -69.22 -22.98 63.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.67 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.1 pt -63.6 -44.91 98.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.072 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.01 -135.88 23.39 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.95 -44.85 15.03 Favored Pre-proline 0 CA--C 1.532 0.286 0 O-C-N 122.871 -0.193 . . . . 0.0 110.566 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -42.32 -31.24 1.69 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 121.297 1.331 . . . . 0.0 111.268 178.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.38 -26.8 34.98 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.941 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.941 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.439 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.439 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -72.59 -6.39 18.95 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.0 t -105.76 -17.67 14.31 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.135 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 3.0 mmmm -96.12 -15.5 22.11 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.432 ' CB ' ' HD3' ' A' ' 27' ' ' PRO . 1.1 mt -83.54 -59.27 0.37 Allowed Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.834 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.432 ' HD3' ' CB ' ' A' ' 26' ' ' LEU . 82.4 Cg_exo -55.39 -33.15 84.6 Favored 'Trans proline' 0 N--CA 1.504 2.115 0 C-N-CA 122.33 2.02 . . . . 0.0 113.267 178.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.71 -31.98 59.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.6 mt -70.43 -43.68 69.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.018 0.437 . . . . 0.0 110.831 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.57 -35.49 56.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.831 179.735 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 40.3 t -60.22 -43.15 96.24 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.361 -179.233 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -98.46 58.1 0.98 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.8 t0 -66.01 135.45 54.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.851 0.357 . . . . 0.0 110.646 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 79.7 mm-40 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.0 mmm . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.413 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.2 m-85 -80.48 -1.7 42.8 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.686 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.3 m -102.34 -23.25 13.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.292 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 31.0 m120 -75.91 -14.49 60.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.814 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.413 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.5 pt -65.16 -43.92 95.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.004 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.13 -134.38 27.02 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -70.41 -46.96 19.61 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.7 Cg_exo -39.43 -38.1 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.695 1.597 . . . . 0.0 112.312 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.38 -27.87 58.8 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo -68.75 -13.0 36.06 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.4 t -107.33 4.15 26.13 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 13.2 mptt -106.92 -27.71 10.53 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.659 0.266 . . . . 0.0 110.682 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.455 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mp -80.5 -63.53 0.34 Allowed Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.684 -0.235 . . . . 0.0 110.615 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -58.14 -28.46 83.88 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.053 1.835 . . . . 0.0 111.344 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.63 -31.97 60.06 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.85 -44.31 66.67 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.924 0.392 . . . . 0.0 110.818 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 49' ' ' SER . 7.7 p -71.11 -43.18 75.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.89 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.481 ' N ' HG13 ' A' ' 48' ' ' VAL . 40.5 t -62.33 -43.74 98.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.608 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.73 32.31 70.6 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' A' ' 52' ' ' GLU . 99.8 m-20 -69.84 142.61 53.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 51' ' ' ASP . 82.1 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.564 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.9 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.1 m-85 -81.62 -1.97 48.53 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.518 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -102.1 -23.28 14.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.49 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -75.12 -14.81 60.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.3 pt -65.76 -44.05 93.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.8 -138.16 31.21 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -67.07 -46.88 52.99 Favored Pre-proline 0 CA--C 1.539 0.531 0 C-N-CA 120.926 -0.31 . . . . 0.0 110.746 179.642 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.46 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 97.1 Cg_exo -40.25 -37.14 1.79 Allowed 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.516 1.477 . . . . 0.0 112.158 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.45 -29.41 58.13 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.406 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.519 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.912 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 20' ' ' ILE . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.409 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 21' ' ' PHE . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.548 ' N ' HG23 ' A' ' 20' ' ' ILE . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo -54.07 -29.64 56.22 Favored 'Trans proline' 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.4 t -74.93 -36.71 62.15 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 6.6 tptt -89.75 -7.42 54.51 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -177.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.479 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 7.7 tp -76.06 -55.2 1.89 Allowed Pre-proline 0 CA--C 1.554 1.131 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 7.4 Cg_endo -55.0 -47.22 27.78 Favored 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.748 2.299 . . . . 0.0 112.218 176.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' H ' ' A' ' 39' ' ' GLU . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.719 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -76.51 -29.69 56.9 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.471 ' O ' ' N ' ' A' ' 50' ' ' GLY . 58.7 mt -70.2 -35.47 73.94 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.93 0.395 . . . . 0.0 111.062 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.1 m -41.45 142.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.531 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.7 t 54.18 5.93 0.09 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.603 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -95.18 38.6 3.07 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -143.54 125.18 14.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.811 0.339 . . . . 0.0 110.529 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.5 tp10 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.459 -179.827 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 ttp . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -78.41 -2.47 38.48 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.851 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.52 -23.37 13.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.266 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -79.15 -13.6 59.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.83 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.7 pt -63.18 -43.5 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.878 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.6 -137.73 39.76 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.53 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -64.75 -48.0 73.99 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.538 179.226 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.9 Cg_exo -38.75 -37.67 0.84 Allowed 'Trans proline' 0 N--CA 1.49 1.274 0 C-N-CA 121.549 1.5 . . . . 0.0 112.226 179.806 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.66 -29.04 58.27 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.498 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.53 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.452 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.491 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.446 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.515 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.515 ' H ' HG23 ' A' ' 20' ' ' ILE . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.491 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -71.31 -12.31 29.67 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.25 -7.22 22.31 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 110.557 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.4 mmmt -101.92 -22.43 14.32 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.803 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.412 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -77.62 -50.74 1.96 Allowed Pre-proline 0 C--N 1.328 -0.329 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.085 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -62.83 -29.31 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.231 1.954 . . . . 0.0 112.361 -179.74 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.736 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.94 -31.52 59.13 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -69.68 -36.5 76.06 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.873 0.368 . . . . 0.0 111.112 -179.331 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.736 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.5 m -43.26 141.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.437 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.463 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.3 m 48.17 29.94 2.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.421 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -70.95 40.16 0.54 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.463 ' H ' ' C ' ' A' ' 49' ' ' SER . 38.5 t70 -85.92 111.24 20.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.831 0.348 . . . . 0.0 110.682 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.663 -179.93 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.3 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -85.08 -2.36 57.91 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 120.981 0.42 . . . . 0.0 110.552 -179.894 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.18 -23.39 14.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.569 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -76.85 -14.39 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.711 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.1 pt -64.96 -43.73 96.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.123 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.81 -137.1 36.2 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.387 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.45 -46.44 48.42 Favored Pre-proline 0 C--N 1.327 -0.392 0 O-C-N 122.659 -0.318 . . . . 0.0 110.939 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.0 Cg_exo -40.56 -32.28 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 121.372 1.381 . . . . 0.0 111.209 178.493 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.12 35.83 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -69.62 -13.7 35.41 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.9 t -96.92 -6.29 36.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.691 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -100.92 -15.81 17.41 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.812 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -83.34 -47.34 0.8 Allowed Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.778 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.2 Cg_exo -60.52 -32.97 94.23 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.233 179.013 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.421 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -75.86 -31.78 59.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.1 mt -70.72 -43.55 68.69 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-O 120.907 0.384 . . . . 0.0 110.603 -179.641 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.54 -28.92 29.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.1 t -61.13 -43.62 98.6 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.584 -179.348 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 146.81 35.33 0.06 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -103.49 110.76 22.91 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.685 0.279 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.607 179.86 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.4 mtp . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -75.22 0.66 15.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.533 -179.728 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -102.34 -23.77 13.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.46 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -77.45 -14.3 59.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.73 179.965 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.6 pt -63.69 -43.48 98.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.732 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 67.19 -135.85 32.11 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -68.86 -46.01 32.15 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 178.604 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.511 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.5 Cg_exo -40.18 -31.42 0.54 Allowed 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 121.415 1.41 . . . . 0.0 111.521 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.73 -27.99 30.53 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.705 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' N ' HG23 ' A' ' 20' ' ' ILE . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo -70.76 -15.97 33.37 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -93.51 -26.08 17.32 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.803 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -72.85 -40.52 65.64 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.14 0.495 . . . . 0.0 109.986 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.45 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.1 mp -56.69 -62.75 4.43 Favored Pre-proline 0 C--N 1.319 -0.738 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.571 -179.671 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 18.2 Cg_endo -57.13 -35.32 98.88 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.037 1.824 . . . . 0.0 111.384 -179.576 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.734 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t -76.76 -31.68 57.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 70.2 mt -70.8 -20.58 62.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.204 -179.227 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.734 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.5 m -56.22 -41.02 68.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.647 -178.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.44 ' N ' HG23 ' A' ' 48' ' ' VAL . 4.3 m -99.85 -8.58 23.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.436 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.54 40.16 1.1 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.696 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.438 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 43.06 93.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.841 -179.932 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mmm . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -82.89 -1.56 52.48 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.522 179.995 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -98.43 -22.24 16.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.153 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.3 m120 -67.45 -30.66 70.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.466 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.49 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.4 pt -59.68 -53.86 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.464 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 94.5 -125.66 8.39 Favored Glycine 0 CA--C 1.53 0.981 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.636 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 11.2 tp -91.87 -26.16 0.28 Allowed Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 113.257 0.836 . . . . 0.0 113.257 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.636 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 33.8 Cg_exo -57.69 -35.15 98.91 Favored 'Trans proline' 0 N--CA 1.5 1.879 0 C-N-CA 122.263 1.976 . . . . 0.0 112.443 179.326 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.88 -30.71 76.5 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.511 ' N ' HG23 ' A' ' 20' ' ' ILE . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -72.9 -25.17 16.88 Favored 'Trans proline' 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.46 7.88 36.61 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.848 -178.168 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.1 mptt -104.86 -42.02 5.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.754 179.696 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.567 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mt -58.21 -41.3 88.88 Favored Pre-proline 0 C--N 1.322 -0.612 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.435 -179.111 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.6 Cg_exo -62.15 -45.99 14.11 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.335 2.024 . . . . 0.0 111.113 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.421 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.688 ' O ' HG22 ' A' ' 48' ' ' VAL . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -76.01 -32.12 59.25 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.46 ' O ' ' N ' ' A' ' 51' ' ' ASP . 56.6 mt -69.55 -38.44 77.46 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.818 0.342 . . . . 0.0 111.25 -179.209 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.688 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.2 m -38.36 129.1 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.647 -179.434 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.462 ' C ' ' H ' ' A' ' 51' ' ' ASP . 1.5 m 66.24 -57.45 0.36 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.368 -179.71 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -78.18 28.46 1.97 Allowed Glycine 0 CA--C 1.52 0.35 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.462 ' H ' ' C ' ' A' ' 49' ' ' SER . 44.0 t0 -83.01 110.4 17.93 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.441 -0.379 . . . . 0.0 110.282 179.464 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tp10 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.451 -179.752 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.6 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -82.47 -3.18 55.32 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 120.97 0.414 . . . . 0.0 110.488 -179.93 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.57 -23.29 13.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.421 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -76.71 -14.35 59.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.751 -179.827 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -64.98 -43.81 96.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.006 -179.761 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.98 -137.4 36.11 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 -179.298 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.26 -46.48 50.52 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 119.49 -0.29 . . . . 0.0 110.816 179.444 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 88.0 Cg_exo -40.81 -30.93 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.076 1.184 . . . . 0.0 111.251 178.5 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -84.73 -28.33 32.42 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 178.927 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.432 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.487 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.521 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.521 ' H ' HG23 ' A' ' 20' ' ' ILE . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.487 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.95 -14.93 32.62 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 t -87.01 -10.91 51.96 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -93.19 -20.41 20.49 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.337 -179.459 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.512 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.6 mt -70.4 -54.32 9.04 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.146 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.1 Cg_exo -38.09 -52.28 1.84 Allowed 'Trans proline' 0 N--CA 1.489 1.24 0 C-N-CA 122.507 2.138 . . . . 0.0 111.329 176.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.428 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.599 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -77.99 -34.72 50.72 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.692 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.2 tm? -73.45 -47.58 40.39 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 121.564 0.697 . . . . 0.0 110.871 -179.615 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 44' ' ' THR . 9.9 p -62.71 -30.93 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.21 -179.032 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -60.9 -42.64 98.42 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.337 179.782 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 80.43 38.46 17.59 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.789 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 59.3 t0 -89.28 110.16 20.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.74 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.332 179.92 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mmm . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -79.28 -3.35 45.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.553 -179.889 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.4 -23.09 13.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.391 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -74.79 -14.95 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.65 -179.808 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.4 pt -66.21 -44.0 91.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.049 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.52 -137.08 28.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.286 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.02 -45.26 22.46 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 119.688 -0.196 . . . . 0.0 110.745 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.6 Cg_exo -41.64 -30.52 1.03 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 121.19 1.26 . . . . 0.0 111.289 178.831 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.59 -27.35 32.72 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 178.972 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.93 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.93 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.472 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.464 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.472 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -71.89 -12.13 28.2 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.9 t -96.86 -15.95 20.98 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.381 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.56 -17.97 30.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.86 179.579 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 mp -78.11 -55.15 1.18 Allowed Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 120.625 -0.43 . . . . 0.0 109.865 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.522 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo -57.47 -30.38 87.99 Favored 'Trans proline' 0 N--CA 1.503 2.068 0 C-N-CA 122.04 1.827 . . . . 0.0 111.9 179.113 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.522 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -75.52 -32.12 60.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.38 -43.58 69.78 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.011 0.434 . . . . 0.0 110.836 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.76 -31.94 38.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.906 179.643 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -59.82 -43.6 94.44 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.528 -179.337 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.435 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 69.87 35.77 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.281 -0.727 . . . . 0.0 111.281 179.596 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.84 36.34 1.32 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.019 0.438 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 . . . . . 0 C--N 1.325 -0.492 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 179.96 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.1 mmm . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -82.88 -0.14 46.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.721 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.0 -23.21 14.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.433 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 30.1 m120 -75.69 -14.65 60.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.882 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.5 pt -65.86 -43.91 92.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.31 -135.72 27.69 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.562 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -70.52 -45.17 18.54 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-O 119.7 -0.19 . . . . 0.0 110.528 178.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.7 Cg_exo -41.15 -31.32 0.83 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 121.32 1.347 . . . . 0.0 111.417 178.698 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.57 -26.79 31.63 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 178.987 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.562 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.917 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 11' ' ' ILE . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.415 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.7 -18.29 53.28 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -85.85 -3.1 58.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.594 -179.875 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.1 mptt -101.27 -1.85 32.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.807 179.752 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.679 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.1 mm? -84.4 -38.29 0.66 Allowed Pre-proline 0 N--CA 1.452 -0.341 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.487 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 24.4 Cg_exo -65.29 -33.84 46.96 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.356 2.037 . . . . 0.0 111.031 178.2 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' NZ ' ' A' ' 41' ' ' LYS . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.604 ' NZ ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.673 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -76.26 -30.81 57.99 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -70.03 -32.59 70.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.964 0.411 . . . . 0.0 111.258 -179.626 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.673 HG22 ' O ' ' A' ' 45' ' ' LYS . 5.1 m -41.48 -37.35 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.732 -179.233 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.465 ' C ' ' H ' ' A' ' 51' ' ' ASP . 98.4 p -173.04 98.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.262 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.2 35.13 1.3 Allowed Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.852 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.465 ' H ' ' C ' ' A' ' 49' ' ' SER . 42.8 p-10 -154.62 111.12 3.27 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.838 0.351 . . . . 0.0 110.725 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.607 179.816 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.7 ttp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -74.49 -0.04 16.26 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.753 -179.866 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -104.2 -23.58 13.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.283 179.664 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -83.93 -13.99 52.08 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.979 -179.792 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.684 HD12 ' HA3' ' A' ' 9' ' ' GLY . 17.8 pt -65.71 -42.38 92.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.018 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.47 -132.73 12.3 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.059 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -79.17 -42.56 1.66 Allowed Pre-proline 0 C--N 1.326 -0.416 0 O-C-N 122.785 -0.244 . . . . 0.0 110.57 179.094 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 82.9 Cg_exo -43.11 -31.5 2.49 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 121.564 1.509 . . . . 0.0 111.398 179.773 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.684 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -84.93 -25.94 39.35 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.037 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.463 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA2' ' HD3' ' A' ' 23' ' ' PRO . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.477 ' HG3' HD13 ' A' ' 18' ' ' LEU . 16.4 Cg_exo -74.8 -19.5 18.3 Favored 'Trans proline' 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.28 -7.95 25.66 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 113.884 -1.507 . . . . 0.0 110.739 -177.004 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -100.11 -20.94 15.76 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.495 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.513 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.5 -48.11 1.87 Allowed Pre-proline 0 CA--C 1.534 0.35 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.513 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.1 Cg_exo -56.3 -39.45 91.19 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.513 2.142 . . . . 0.0 111.706 179.763 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 44' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 48' ' ' VAL . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -77.45 -28.8 52.53 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.735 HD13 ' C ' ' A' ' 47' ' ' LEU . 1.6 tm? -70.8 -43.54 68.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 -179.472 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 44' ' ' THR . 15.5 m -25.61 -40.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-O 121.16 0.505 . . . . 0.0 111.505 -179.446 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.577 ' N ' ' O ' ' A' ' 47' ' ' LEU . 35.7 p -157.28 -40.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.162 178.735 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.24 37.66 94.37 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 54.0 p-10 -66.69 144.21 56.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.048 0.451 . . . . 0.0 110.616 -179.67 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.687 -179.955 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -89.16 7.92 32.75 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.941 -179.653 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.93 -24.08 13.29 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.069 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.2 m-80 -80.44 -14.01 58.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.056 -179.72 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 9.8 pt -65.51 -42.97 94.39 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.914 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.26 -134.8 21.73 Favored Glycine 0 CA--C 1.525 0.719 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.338 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.503 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.5 OUTLIER -73.2 -45.14 8.03 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.649 179.24 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -40.67 -37.97 2.45 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.746 1.63 . . . . 0.0 112.551 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.48 -28.03 60.35 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 179.363 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.949 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.949 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.445 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -69.97 -16.91 36.86 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -92.6 -0.42 57.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.637 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.6 mptt -101.57 -8.38 21.92 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.811 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.583 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -83.49 -41.24 0.8 Allowed Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.442 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 27.2 Cg_exo -63.99 -35.74 52.96 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.716 2.277 . . . . 0.0 111.258 179.095 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.591 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.591 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.709 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -76.7 -30.52 56.73 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.6 mt -69.97 -35.57 74.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.883 0.373 . . . . 0.0 111.191 -179.494 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.709 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.1 m -41.6 130.5 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 -179.449 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.485 ' C ' ' H ' ' A' ' 51' ' ' ASP . 20.1 m 42.43 47.67 4.35 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.589 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.4 37.48 0.56 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.694 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 49' ' ' SER . 45.5 t0 -128.17 105.9 8.69 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.668 179.956 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.411 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 . . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.411 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -77.31 -2.21 33.73 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.124 0.488 . . . . 0.0 110.695 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -97.28 -23.21 16.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.101 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -68.45 -27.7 66.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.469 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.9 pt -62.18 -48.86 86.45 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.548 -179.763 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 67.13 -133.47 31.16 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 179.801 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -60.2 -53.62 63.21 Favored Pre-proline 0 C--O 1.223 -0.314 0 O-C-N 122.474 -0.427 . . . . 0.0 110.465 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.409 ' HD2' ' O ' ' A' ' 5' ' ' ILE . 21.3 Cg_exo -43.45 -26.88 1.12 Allowed 'Trans proline' 0 N--CA 1.504 2.124 0 C-N-CA 122.766 2.31 . . . . 0.0 112.585 178.325 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.65 -26.48 24.86 Favored Glycine 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 176.702 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.42 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.486 HG23 ' O ' ' A' ' 15' ' ' VAL . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.553 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.553 ' N ' HG23 ' A' ' 20' ' ' ILE . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -70.54 -18.43 33.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.0 t -92.74 -28.15 16.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.916 -179.671 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -79.36 -33.65 42.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 120.936 0.398 . . . . 0.0 110.713 -179.768 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.472 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 1.3 mp -58.49 -62.35 5.81 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.577 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.472 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.7 Cg_endo -51.16 -35.16 50.99 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.475 2.116 . . . . 0.0 111.663 -179.628 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -74.48 -32.05 62.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.8 mt -69.84 -41.0 75.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.844 0.354 . . . . 0.0 110.768 -179.742 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.503 HG22 ' N ' ' A' ' 49' ' ' SER . 2.4 p -80.91 160.28 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-O 121.161 0.505 . . . . 0.0 109.883 179.453 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.503 ' N ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER 77.32 -28.17 0.17 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.362 -179.914 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 62.9 38.35 96.41 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.0 t0 43.99 80.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 110.919 -179.989 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttp . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.438 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 65.7 m-85 -78.6 -4.23 47.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.179 -0.918 . . . . 0.0 110.753 -179.793 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -97.76 -24.42 15.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.055 179.761 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 27.9 m120 -67.43 -33.41 75.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.556 179.651 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.516 ' CG1' ' H ' ' A' ' 6' ' ' GLY . 3.1 pt -49.92 -61.29 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.516 ' H ' ' CG1' ' A' ' 5' ' ' ILE . . . 98.65 -148.34 18.81 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.066 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.552 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -47.92 -47.54 63.55 Favored Pre-proline 0 C--O 1.217 -0.621 0 CA-C-O 118.837 -0.602 . . . . 0.0 109.84 178.738 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.552 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 1.9 Cg_endo -36.99 -43.32 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.835 1.69 . . . . 0.0 111.97 179.278 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -60.55 -36.84 92.28 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.852 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.448 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -71.8 -10.54 26.55 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.4 t -91.82 -11.44 36.52 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.949 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -88.59 -16.31 32.86 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.239 -179.384 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.5 mt -75.6 -55.0 2.15 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.962 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -40.24 -43.31 3.82 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 121.627 1.552 . . . . 0.0 111.706 177.432 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -75.41 -31.92 60.56 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.34 -43.76 69.58 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.052 0.453 . . . . 0.0 110.69 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.3 -31.53 34.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.004 179.892 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 51' ' ' ASP . 34.5 m -54.63 -34.14 61.67 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 -179.336 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.58 80.49 0.03 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 49' ' ' SER . 51.2 t0 -68.31 140.07 55.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.359 . . . . 0.0 110.736 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.724 179.849 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.1 mtp . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.405 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.3 m-85 -78.36 4.78 12.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.548 179.853 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -100.97 -24.91 14.24 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.344 179.897 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -69.99 -20.62 63.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.726 -179.864 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.9 pt -63.92 -44.55 98.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 -179.783 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 71.28 -136.68 25.33 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.674 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -68.85 -46.08 32.35 Favored Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 122.767 -0.255 . . . . 0.0 110.329 179.083 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.0 Cg_exo -40.82 -37.4 2.35 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.678 1.586 . . . . 0.0 112.243 -179.967 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.54 -27.52 59.1 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.953 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.459 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG22 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.459 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -68.29 -19.39 44.1 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -99.97 6.58 45.13 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.115 -179.819 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -108.36 -27.57 9.9 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.583 -179.577 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.3 mp -78.25 -62.89 0.47 Allowed Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.596 -0.274 . . . . 0.0 110.564 179.694 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -56.97 -29.52 82.9 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.084 1.856 . . . . 0.0 111.422 -179.648 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -75.66 -33.38 60.43 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.5 mt -70.25 -43.63 70.16 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.975 0.417 . . . . 0.0 110.955 -179.629 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.532 HG13 ' N ' ' A' ' 49' ' ' SER . 7.0 p -70.33 -45.8 73.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.848 179.831 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.532 ' N ' HG13 ' A' ' 48' ' ' VAL . 33.6 p -70.76 -16.75 62.78 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.478 -179.48 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.39 68.49 0.1 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.775 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' N ' ' O ' ' A' ' 49' ' ' SER . 91.7 m-20 -69.37 142.73 53.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.859 0.361 . . . . 0.0 110.696 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.467 -179.894 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.532 ' N ' ' OD1' ' A' ' 4' ' ' ASN . 97.2 mtp . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.401 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.6 m-85 -79.27 -1.25 35.75 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 121.012 0.435 . . . . 0.0 110.515 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.8 -23.8 13.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.289 -179.938 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 1' ' ' MET . 10.4 m120 -74.97 -14.75 60.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.401 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -65.38 -44.03 94.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.086 -179.887 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.23 -136.39 26.72 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.3 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.28 -45.03 13.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 C-N-CA 121.156 -0.217 . . . . 0.0 110.695 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.499 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.7 Cg_exo -41.44 -29.81 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.451 1.434 . . . . 0.0 111.205 179.07 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.57 -29.27 27.41 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.238 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.697 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.946 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.946 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.437 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.437 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.52 -17.9 33.82 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.9 t -92.62 -7.99 45.43 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.971 179.947 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -96.02 -33.47 12.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.27 179.914 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.497 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -65.26 -48.61 68.2 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.378 -179.441 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.4 Cg_exo -56.37 -37.73 96.47 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.662 2.241 . . . . 0.0 111.678 179.437 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.726 ' O ' HG22 ' A' ' 48' ' ' VAL . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -77.54 -28.67 51.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 69.8 mt -71.9 -21.1 61.69 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.956 0.408 . . . . 0.0 111.292 -179.605 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.726 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.3 m -57.05 -38.43 60.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.491 -178.909 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.421 ' OG ' ' N ' ' A' ' 50' ' ' GLY . 20.9 p -95.4 -54.71 3.3 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.597 -179.923 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.421 ' N ' ' OG ' ' A' ' 49' ' ' SER . . . 62.36 36.18 92.71 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.843 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.1 t0 -150.5 132.73 15.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.87 0.367 . . . . 0.0 110.729 -179.862 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 97.2 mt-10 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.665 179.91 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 79.4 mtp . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -84.74 -1.28 56.05 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 110.707 -179.942 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.68 -23.91 13.79 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.504 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -78.12 -14.23 59.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.799 -180.0 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.1 pt -62.86 -43.44 98.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.75 -179.885 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.03 -135.13 27.7 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -71.38 -45.06 13.54 Favored Pre-proline 0 C--N 1.33 -0.272 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.222 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.554 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.8 Cg_exo -40.54 -29.93 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 121.524 1.483 . . . . 0.0 111.713 179.574 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.29 -26.03 29.38 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.252 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.443 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo -72.11 -17.99 27.63 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.3 t -91.85 -20.51 21.39 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.642 -179.904 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -85.19 -33.17 22.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.052 0.453 . . . . 0.0 110.715 -179.766 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 12.3 mt -60.46 -56.16 38.04 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.793 179.237 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 21.4 Cg_endo -57.19 -31.44 90.6 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.306 2.004 . . . . 0.0 111.756 -179.838 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.73 -30.22 59.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -69.71 -37.99 76.77 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.926 0.393 . . . . 0.0 111.072 -179.093 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.2 m -44.97 147.5 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.312 -179.883 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.8 m 58.99 14.61 3.46 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.695 -179.996 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.39 37.83 2.76 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.916 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 41.0 p-10 -86.16 112.64 21.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.877 0.37 . . . . 0.0 110.49 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 55.9 mp0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.402 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.402 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -78.28 -1.32 32.48 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.762 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -101.65 -23.3 14.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.379 179.903 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.5 m-20 -74.68 -16.07 60.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.65 -179.763 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.402 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.2 pt -65.55 -44.32 93.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.196 -179.725 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.9 -136.44 25.63 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 -179.208 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.535 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.75 -44.81 12.23 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.952 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.469 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 85.8 Cg_exo -42.26 -30.53 1.43 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 121.108 1.205 . . . . 0.0 111.13 178.899 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.73 -29.57 31.86 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 178.951 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.7 ' O ' HD23 ' A' ' 10' ' ' LEU . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 20' ' ' ILE . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.454 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 15' ' ' VAL . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.523 HG23 ' H ' ' A' ' 21' ' ' PHE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.523 ' H ' HG23 ' A' ' 20' ' ' ILE . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.454 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.57 -13.71 32.87 Favored 'Trans proline' 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 t -89.95 -10.1 46.33 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.479 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 15.0 mmmt -94.07 -28.72 15.57 Favored 'General case' 0 C--O 1.222 -0.39 0 N-CA-C 112.861 0.689 . . . . 0.0 112.861 -178.583 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.503 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 13.6 mt -68.03 -53.81 18.45 Favored Pre-proline 0 CA--C 1.54 0.577 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.694 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.503 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 9.8 Cg_exo -37.05 -56.16 0.81 Allowed 'Trans proline' 0 C--N 1.316 -1.139 0 C-N-CA 122.403 2.068 . . . . 0.0 112.066 176.496 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 35' ' ' ARG . . . . . 0.461 ' HD3' ' H ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.712 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -76.23 -32.06 58.71 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.404 ' O ' ' N ' ' A' ' 50' ' ' GLY . 56.1 mt -69.85 -33.85 72.83 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.917 0.389 . . . . 0.0 111.308 -179.23 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.2 m -43.16 -37.26 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.72 -179.06 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -61.48 -44.18 97.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.041 179.671 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LEU . . . 51.6 32.81 32.52 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.88 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -170.12 100.66 0.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.701 0.286 . . . . 0.0 110.859 -179.85 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.757 179.886 . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.7 mtm . . . . . 0 N--CA 1.487 1.416 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -84.5 1.23 46.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.609 -179.832 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -103.43 -23.96 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.628 179.918 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.6 m120 -79.34 -14.4 59.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.994 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.1 pt -64.68 -43.1 96.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.427 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.764 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.96 -135.08 24.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.329 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -70.88 -46.02 15.75 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 110.132 -0.322 . . . . 0.0 110.132 178.463 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.8 Cg_exo -39.83 -36.91 1.39 Allowed 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.709 1.606 . . . . 0.0 112.491 -179.617 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.1 -26.36 58.08 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.651 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.955 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.955 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.46 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.46 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo -72.23 -14.06 28.45 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -96.96 -6.06 36.43 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.886 -179.688 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 17.0 mmmt -98.43 -27.0 14.27 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.206 179.562 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.512 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -72.03 -48.31 10.81 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.953 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.1 Cg_exo -55.21 -38.29 93.74 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.648 2.232 . . . . 0.0 111.353 179.643 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.63 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HZ3' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.685 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -76.4 -31.71 58.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.489 ' O ' ' O ' ' A' ' 48' ' ' VAL . 69.5 mt -71.34 -20.5 62.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.297 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 45' ' ' LYS . 5.6 m -53.09 -164.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.918 -179.584 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 51' ' ' ASP . 45.8 t -67.09 58.02 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.486 179.714 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -48.09 88.8 0.01 OUTLIER Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.74 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 49' ' ' SER . 43.3 t0 -162.32 170.06 19.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.661 0.267 . . . . 0.0 110.651 179.771 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.68 179.939 . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.063 0.459 . . . . 0.0 110.22 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.584 ' CD1' ' N ' ' A' ' 2' ' ' PHE . 0.5 OUTLIER -72.32 1.33 7.98 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.305 -178.793 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -102.1 -23.51 14.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.36 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -70.7 -22.63 62.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.521 179.972 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.412 HD11 ' O ' ' A' ' 2' ' ' PHE . 3.2 pt -61.32 -57.18 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.317 -179.204 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.64 -132.82 11.38 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.245 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -57.45 -50.97 85.11 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-O 119.383 -0.342 . . . . 0.0 110.086 179.002 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 4.2 Cg_endo -38.49 -31.21 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.077 1.851 . . . . 0.0 110.7 176.994 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -82.55 -32.87 26.56 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.867 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.921 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.475 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.475 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.44 -19.51 43.03 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -88.46 1.72 54.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.399 -179.947 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.0 mptt -100.0 -12.4 19.77 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.19 179.546 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.588 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.6 mt -75.13 -40.58 3.68 Favored Pre-proline 0 C--N 1.326 -0.452 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.482 179.906 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 26.1 Cg_exo -63.98 -35.6 53.76 Favored 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.56 2.173 . . . . 0.0 111.301 179.293 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.73 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.64 -30.51 56.89 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 61.8 mt -69.74 -36.34 75.75 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.865 0.364 . . . . 0.0 111.2 -179.597 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.3 m -41.16 124.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.669 -179.456 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 16.2 m 40.53 55.88 2.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.367 . . . . 0.0 110.681 -179.736 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.408 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -71.41 55.01 1.19 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.519 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 4.0 p-10 44.99 37.6 2.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 179.758 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.518 179.988 . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -78.68 -3.25 43.16 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.767 -179.841 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -95.23 -23.09 17.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.191 179.806 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -67.42 -32.91 74.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.492 HD12 ' HA3' ' A' ' 9' ' ' GLY . 3.1 pt -58.77 -49.05 84.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.586 -179.579 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 101.96 -120.23 6.76 Favored Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.697 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.8 tp -92.87 -24.09 0.26 Allowed Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.053 -0.573 . . . . 0.0 111.478 177.324 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.697 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 53.7 Cg_exo -49.89 -39.9 48.94 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.896 1.731 . . . . 0.0 112.384 -178.866 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.492 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -62.34 -34.64 89.91 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.848 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.406 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.406 ' CD1' HD13 ' A' ' 20' ' ' ILE . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo -71.5 -18.66 29.25 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.8 t -91.0 -24.35 20.11 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.581 -179.966 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tptm -83.61 -28.0 28.78 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.011 0.434 . . . . 0.0 110.961 -179.75 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.53 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 9.3 mt -63.38 -58.37 16.01 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.753 179.533 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.53 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 14.6 Cg_endo -54.23 -36.95 87.7 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.385 2.057 . . . . 0.0 112.249 -179.608 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.7 -33.48 60.35 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 53.2 mt -70.14 -43.0 71.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.953 0.406 . . . . 0.0 110.939 -179.524 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.82 -26.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.745 179.679 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.9 t -60.0 -42.73 94.91 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.703 -179.368 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 90.81 109.88 1.5 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.842 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 43.8 p-10 -90.75 115.01 27.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.787 0.327 . . . . 0.0 110.584 179.886 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' A' ' 51' ' ' ASP . 79.8 tt0 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.5 ptp . . . . . 0 N--CA 1.493 1.696 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.445 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.5 m-85 -78.64 -2.38 38.79 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.69 -179.817 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.03 -23.43 14.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.411 -179.926 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -76.56 -14.32 60.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.717 -179.806 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.7 pt -63.48 -48.75 85.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.383 179.869 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -118.41 5.93 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.026 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.677 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 tp -105.12 -17.31 0.17 Allowed Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 179.306 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.677 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 63.2 Cg_endo -73.51 -52.43 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.944 1.763 . . . . 0.0 112.893 -178.826 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.45 -21.76 35.54 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.749 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.906 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.413 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo -69.65 -17.55 38.01 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.9 t -93.37 -25.41 17.71 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.814 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -79.17 -34.25 43.29 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.111 0.481 . . . . 0.0 110.027 179.824 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.436 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 11.6 mt -59.41 -59.41 13.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.759 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo -57.81 -31.0 91.23 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.141 1.894 . . . . 0.0 112.12 -179.107 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.676 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t -76.21 -32.05 58.76 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.468 ' C ' ' N ' ' A' ' 49' ' ' SER . 66.5 mt -71.22 -22.52 61.99 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.411 -179.314 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 45' ' ' LYS . 11.0 m -48.45 -14.76 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.499 -179.021 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.468 ' N ' ' C ' ' A' ' 47' ' ' LEU . 38.5 t -59.54 -42.56 92.61 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.988 -179.912 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.44 160.35 35.81 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.633 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 51.7 p-10 -137.04 36.2 2.57 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.687 179.935 . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.2 mtp . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.35 0.91 31.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.044 0.45 . . . . 0.0 110.742 -179.865 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.1 m -102.01 -23.91 14.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.696 -179.829 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.1 m120 -77.7 -14.17 59.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.76 -179.961 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.7 pt -63.51 -43.72 98.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.864 -179.993 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.37 -136.35 30.06 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.495 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.575 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -69.33 -45.19 27.77 Favored Pre-proline 0 N--CA 1.463 0.218 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 178.639 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.3 Cg_exo -40.96 -30.61 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.459 1.44 . . . . 0.0 111.551 179.211 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.53 -26.04 31.27 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.113 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.575 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.471 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.59 -18.19 53.75 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.4 t -87.95 0.18 56.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.555 -179.815 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.31 -2.45 25.53 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.914 -179.824 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.705 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.8 mm? -85.4 -39.8 0.62 Allowed Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 22.1 Cg_exo -66.09 -34.72 36.41 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.279 1.986 . . . . 0.0 111.215 178.792 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -75.6 -32.73 60.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.1 mt -70.47 -43.12 70.43 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.985 0.421 . . . . 0.0 111.002 -179.633 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.2 p -73.1 -25.98 22.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.899 179.895 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 49' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 51' ' ' ASP . 5.3 p -48.47 -24.32 1.24 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -61.31 77.77 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.852 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' A' ' 49' ' ' SER . 53.5 p-10 -83.37 172.81 12.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.832 0.348 . . . . 0.0 110.476 179.896 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.612 -179.813 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.942 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.942 HG23 ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.433 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.433 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo . . . . . 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo . . . . . 0 N--CA 1.496 1.674 0 N-CA-C 111.211 -0.342 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.898 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 11' ' ' ILE . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.539 HD13 ' HG3' ' A' ' 23' ' ' PRO . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.403 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.403 ' CD1' HD13 ' A' ' 20' ' ' ILE . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo . . . . . 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.702 0.209 . . . . 0.0 111.676 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t . . . . . 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo . . . . . 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo . . . . . 0 N--CA 1.497 1.688 0 CA-C-O 120.693 0.205 . . . . 0.0 111.906 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m . . . . . 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.923 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.477 ' O ' HG22 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.449 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.491 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.491 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.449 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.451 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.5 Cg_exo . . . . . 0 N--CA 1.493 1.453 0 CA-C-O 121.107 0.378 . . . . 0.0 111.434 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 1.013 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.933 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 20' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.541 HG23 ' N ' ' A' ' 21' ' ' PHE . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.541 ' N ' HG23 ' A' ' 20' ' ' ILE . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo . . . . . 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo . . . . . 0 N--CA 1.494 1.52 0 CA-C-O 120.746 0.228 . . . . 0.0 111.708 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.684 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.488 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.684 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.423 ' HG3' ' H ' ' A' ' 39' ' ' GLU . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.656 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.438 ' O ' HG22 ' A' ' 19' ' ' ILE . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.493 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.493 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.456 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.495 ' HB3' HH12 ' A' ' 31' ' ' ARG . 11.8 Cg_exo . . . . . 0 N--CA 1.485 1.018 0 N-CA-C 110.93 -0.45 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.495 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.604 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.6 0 N-CA-C 112.499 -0.241 . . . . 0.0 112.499 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.914 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.914 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.424 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.573 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo . . . . . 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.573 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo . . . . . 0 N--CA 1.48 0.735 0 CA-C-O 120.929 0.304 . . . . 0.0 111.953 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.905 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.905 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.426 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.443 ' HA2' ' HD2' ' A' ' 23' ' ' PRO . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo . . . . . 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo . . . . . 0 N--CA 1.493 1.494 0 CA-C-O 121.081 0.367 . . . . 0.0 111.464 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.62 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.62 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.531 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.531 ' H ' HG23 ' A' ' 20' ' ' ILE . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.458 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo . . . . . 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.418 ' HB3' HH12 ' A' ' 31' ' ' ARG . 37.6 Cg_exo . . . . . 0 N--CA 1.496 1.666 0 CA-C-O 121.296 0.457 . . . . 0.0 111.518 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.418 HH12 ' HB3' ' A' ' 27' ' ' PRO . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.931 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo . . . . . 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.438 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.0 Cg_exo . . . . . 0 N--CA 1.494 1.503 0 CA-C-O 120.961 0.317 . . . . 0.0 111.575 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.403 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.922 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.922 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.452 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.452 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HB3' HH12 ' A' ' 31' ' ' ARG . 38.5 Cg_exo . . . . . 0 N--CA 1.497 1.715 0 CA-C-O 121.116 0.382 . . . . 0.0 111.438 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.421 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.557 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.557 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.401 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.401 ' CD1' HD13 ' A' ' 20' ' ' ILE . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo . . . . . 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.454 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 37.5 Cg_exo . . . . . 0 N--CA 1.491 1.369 0 CA-C-O 121.242 0.434 . . . . 0.0 111.601 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.54 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.54 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.442 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.423 HG22 ' H ' ' A' ' 19' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.442 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo . . . . . 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo . . . . . 0 N--CA 1.498 1.779 0 CA-C-O 121.166 0.402 . . . . 0.0 111.466 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.621 0 N-CA-C 112.045 -0.422 . . . . 0.0 112.045 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.918 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.422 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo . . . . . 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo . . . . . 0 N--CA 1.499 1.802 0 CA-C-O 120.719 0.216 . . . . 0.0 112.103 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.709 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.474 ' O ' HG22 ' A' ' 19' ' ' ILE . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.463 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.532 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.532 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.463 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HB3' HH12 ' A' ' 31' ' ' ARG . 28.0 Cg_exo . . . . . 0 N--CA 1.495 1.589 0 CA-C-O 121.182 0.409 . . . . 0.0 111.569 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.426 HH12 ' HB3' ' A' ' 27' ' ' PRO . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.913 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.913 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.427 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.441 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.496 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.496 ' H ' HG23 ' A' ' 20' ' ' ILE . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo . . . . . 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 CA--C 1.547 1.131 0 CA-C-O 120.729 0.22 . . . . 0.0 111.561 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo . . . . . 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.474 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 29.1 Cg_exo . . . . . 0 N--CA 1.498 1.783 0 CA-C-O 121.22 0.425 . . . . 0.0 112.103 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t . . . . . 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.941 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.941 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.439 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.439 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo . . . . . 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo . . . . . 0 N--CA 1.504 2.115 0 N-CA-C 113.267 0.449 . . . . 0.0 113.267 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo . . . . . 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.404 ' CG ' ' O ' ' A' ' 23' ' ' PRO . 19.1 Cg_endo . . . . . 0 N--CA 1.492 1.386 0 N-CA-C 111.344 -0.291 . . . . 0.0 111.344 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.519 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.912 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 20' ' ' ILE . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.409 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 21' ' ' PHE . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.548 ' N ' HG23 ' A' ' 20' ' ' ILE . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo . . . . . 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 7.4 Cg_endo . . . . . 0 N--CA 1.505 2.175 0 CA-C-O 121.37 0.488 . . . . 0.0 112.218 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' H ' ' A' ' 39' ' ' GLU . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m . . . . . 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.452 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.491 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.446 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.515 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.515 ' H ' HG23 ' A' ' 20' ' ' ILE . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.491 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo . . . . . 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo . . . . . 0 N--CA 1.496 1.651 0 CA-C-O 120.917 0.299 . . . . 0.0 112.361 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.432 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 30.2 Cg_exo . . . . . 0 N--CA 1.494 1.548 0 CA-C-O 121.214 0.422 . . . . 0.0 111.233 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.421 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.705 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' N ' HG23 ' A' ' 20' ' ' ILE . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo . . . . . 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.444 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.2 Cg_endo . . . . . 0 N--CA 1.492 1.404 0 N-CA-C 111.384 -0.276 . . . . 0.0 111.384 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t . . . . . 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.511 ' N ' HG23 ' A' ' 20' ' ' ILE . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo . . . . . 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_exo . . . . . 0 N--CA 1.492 1.415 0 N-CA-C 111.113 -0.38 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.421 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.432 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.487 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.521 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.521 ' H ' HG23 ' A' ' 20' ' ' ILE . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.487 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo . . . . . 0 N--CA 1.489 1.24 0 CA-C-O 120.959 0.316 . . . . 0.0 111.329 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.93 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.93 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.472 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.464 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.472 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo . . . . . 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.522 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo . . . . . 0 N--CA 1.503 2.068 0 CA-C-O 120.767 0.236 . . . . 0.0 111.9 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.522 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.917 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.503 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 11' ' ' ILE . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.415 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.415 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo . . . . . 0 N--CA 1.497 1.698 0 CA-C-O 121.208 0.42 . . . . 0.0 111.031 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' NZ ' ' A' ' 41' ' ' LYS . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.604 ' NZ ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m . . . . . 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.463 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA2' ' HD3' ' A' ' 23' ' ' PRO . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.477 ' HG3' HD13 ' A' ' 18' ' ' LEU . 16.4 Cg_exo . . . . . 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.427 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 32.1 Cg_exo . . . . . 0 N--CA 1.493 1.48 0 CA-C-O 121.239 0.433 . . . . 0.0 111.706 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.949 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.949 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.445 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo . . . . . 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo . . . . . 0 N--CA 1.495 1.614 0 CA-C-O 121.017 0.34 . . . . 0.0 111.258 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.591 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.591 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.42 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.486 HG23 ' O ' ' A' ' 15' ' ' VAL . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.553 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.553 ' N ' HG23 ' A' ' 20' ' ' ILE . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo . . . . . 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.425 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 10.7 Cg_endo . . . . . 0 N--CA 1.493 1.443 0 CA-C-O 120.704 0.21 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.488 1.179 0 CA-C-O 120.988 0.328 . . . . 0.0 111.706 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m . . . . . 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.953 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.459 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG22 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.459 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo . . . . . 0 N--CA 1.493 1.468 0 CA-C-O 120.897 0.29 . . . . 0.0 111.422 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t . . . . . 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.697 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.946 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.946 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.437 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.437 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo . . . . . 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.458 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.4 Cg_exo . . . . . 0 N--CA 1.496 1.673 0 CA-C-O 121.156 0.398 . . . . 0.0 111.678 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.443 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo . . . . . 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.5 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 21.4 Cg_endo . . . . . 0 N--CA 1.498 1.766 0 CA-C-O 120.789 0.245 . . . . 0.0 111.756 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.7 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 20' ' ' ILE . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.454 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 15' ' ' VAL . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.523 HG23 ' H ' ' A' ' 21' ' ' PHE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.523 ' H ' HG23 ' A' ' 20' ' ' ILE . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.454 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_exo . . . . . 0 N--CA 1.485 1.026 0 CA-C-O 120.636 0.182 . . . . 0.0 112.066 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . 0.461 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t . . . . . 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.955 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.955 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.46 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.46 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo . . . . . 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.411 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 38.1 Cg_exo . . . . . 0 N--CA 1.494 1.507 0 CA-C-O 121.156 0.398 . . . . 0.0 111.353 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.63 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HZ3' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t . . . . . 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.921 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.475 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.475 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo . . . . . 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_exo . . . . . 0 N--CA 1.494 1.559 0 CA-C-O 121.079 0.366 . . . . 0.0 111.301 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.406 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.406 ' CD1' HD13 ' A' ' 20' ' ' ILE . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo . . . . . 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.477 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 14.6 Cg_endo . . . . . 0 N--CA 1.492 1.394 0 CA-C-O 120.756 0.232 . . . . 0.0 112.249 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.906 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.413 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo . . . . . 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo . . . . . 0 N--CA 1.498 1.789 0 CA-C-O 120.603 0.168 . . . . 0.0 112.12 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t . . . . . 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo . . . . . 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo . . . . . 0 N--CA 1.494 1.547 0 CA-C-O 121.07 0.362 . . . . 0.0 111.215 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.726 ' N ' HD22 ' A' ' 4' ' ' ASN . 99.3 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -87.29 -3.22 59.03 Favored 'General case' 0 N--CA 1.451 -0.424 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.699 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -101.98 -23.64 14.09 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.726 HD22 ' N ' ' A' ' 1' ' ' MET . 51.0 m-80 -76.74 -14.43 59.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.742 -179.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -64.36 -43.99 97.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.006 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.72 -137.79 34.78 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.531 -1.028 . . . . 0.0 110.531 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.527 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -65.86 -47.67 64.15 Favored Pre-proline 0 CA--C 1.539 0.547 0 C-N-CA 120.986 -0.286 . . . . 0.0 110.711 179.496 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.463 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 95.2 Cg_exo -39.48 -38.61 1.58 Allowed 'Trans proline' 0 C--N 1.313 -1.311 0 C-N-CA 121.487 1.458 . . . . 0.0 112.114 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -74.81 -29.96 60.33 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.527 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -63.25 -38.76 92.43 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.423 0.154 . . . . 0.0 111.121 -179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.942 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.58 -44.69 93.79 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.547 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.8 tp -58.69 -44.69 90.37 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.9 mt -66.45 -42.25 90.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.037 0.446 . . . . 0.0 110.306 178.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.1 t80 -57.63 -41.75 82.02 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.083 -177.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.942 HG23 ' O ' ' A' ' 11' ' ' ILE . 23.9 t -57.1 -42.52 79.68 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.82 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.7 mm -52.7 -33.85 19.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.473 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.74 -35.18 57.95 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.11 179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.433 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.9 mt -65.25 -40.57 94.16 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.908 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.41 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.4 tt -60.27 -41.65 87.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 119.754 -0.778 . . . . 0.0 110.225 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -37.36 14.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.801 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.2 m-85 -95.74 -72.43 0.63 Allowed 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 121.162 -0.215 . . . . 0.0 111.158 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.433 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.94 142.93 6.26 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -69.59 -16.26 38.18 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 122.317 2.012 . . . . 0.0 111.922 179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -94.19 0.89 56.04 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.478 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -100.51 -35.86 9.39 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.543 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.3 mt -68.95 -43.26 25.82 Favored Pre-proline 0 N--CA 1.446 -0.635 0 C-N-CA 119.826 -0.75 . . . . 0.0 110.564 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 23.5 Cg_exo -67.17 -32.98 32.58 Favored 'Trans proline' 0 N--CA 1.496 1.674 0 C-N-CA 122.292 1.995 . . . . 0.0 111.211 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -64.91 -41.0 95.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.804 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.3 mt -64.86 -43.69 96.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.518 -179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.69 98.56 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -63.95 -46.78 83.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.348 0.594 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.23 -48.34 80.41 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.817 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.23 -28.54 69.43 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.16 -43.02 83.67 Favored Glycine 0 CA--C 1.526 0.732 0 CA-C-N 114.978 -1.01 . . . . 0.0 111.029 -178.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.8 mmt180 -69.5 -41.81 75.58 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.089 0.471 . . . . 0.0 110.643 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.9 -43.72 95.13 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.8 mt -68.98 -36.55 78.0 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.347 0.594 . . . . 0.0 111.478 -179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.05 -41.99 84.46 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.113 -0.949 . . . . 0.0 110.447 -179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -74.66 -21.39 59.45 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 120.215 -0.594 . . . . 0.0 110.058 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.84 -48.36 77.06 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.853 0.358 . . . . 0.0 111.96 -178.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.77 -34.77 78.65 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.662 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.17 -39.91 93.57 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.042 179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.84 -38.05 79.55 Favored 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.56 -42.33 98.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.997 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.1 tmmm? -52.99 -31.36 40.47 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.045 -0.525 . . . . 0.0 109.872 -178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -75.75 -31.97 59.79 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.091 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.9 mt -70.49 -44.13 68.29 Favored 'General case' 0 N--CA 1.455 -0.182 0 CA-C-O 121.068 0.461 . . . . 0.0 110.782 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.454 HG13 ' N ' ' A' ' 49' ' ' SER . 7.5 p -71.74 -40.29 69.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.996 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.454 ' N ' HG13 ' A' ' 48' ' ' VAL . 40.3 t -60.94 -44.38 97.34 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.479 -179.332 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 42.38 31.45 0.99 Allowed Glycine 0 CA--C 1.521 0.447 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.405 ' OD1' ' OG ' ' A' ' 49' ' ' SER . 53.9 p-10 -172.28 178.41 2.84 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 120.85 0.357 . . . . 0.0 110.605 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.756 179.836 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.721 ' N ' HD22 ' A' ' 4' ' ' ASN . 96.9 mtp . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.423 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.0 m-85 -85.12 -3.09 58.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.612 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.71 -24.48 13.74 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.602 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.721 HD22 ' N ' ' A' ' 1' ' ' MET . 55.4 m-80 -77.79 -13.65 59.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.658 -179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.423 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -61.25 -47.83 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.531 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.401 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 97.45 -118.89 6.22 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -179.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.687 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.8 tp -105.59 -17.85 0.17 Allowed Pre-proline 0 CA--C 1.551 0.986 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.687 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 62.0 Cg_endo -72.45 -54.19 0.13 Allowed 'Trans proline' 0 N--CA 1.499 1.853 0 C-N-CA 122.133 1.889 . . . . 0.0 112.912 -178.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.14 -21.63 32.92 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.74 -41.5 99.22 Favored 'General case' 0 N--CA 1.452 -0.368 0 C-N-CA 120.731 -0.388 . . . . 0.0 110.255 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.898 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.96 -44.45 98.11 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.364 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.344 -179.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.5 tp -59.29 -44.58 92.48 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.455 -0.498 . . . . 0.0 109.721 -179.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -66.41 -41.74 89.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.028 0.442 . . . . 0.0 110.327 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.3 t80 -56.67 -42.45 79.03 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.819 -177.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 11' ' ' ILE . 10.8 t -56.94 -41.81 77.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.395 179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 31.6 mm -53.51 -32.53 20.59 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.877 179.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.07 -35.31 56.71 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.575 0.702 . . . . 0.0 109.926 178.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.539 HD13 ' HG3' ' A' ' 23' ' ' PRO . 27.1 mt -63.74 -41.48 98.03 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.185 -178.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.33 -41.5 84.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.091 -0.643 . . . . 0.0 110.352 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.403 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -83.46 -34.1 10.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.84 179.498 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.403 ' CD1' HD13 ' A' ' 20' ' ' ILE . 57.9 m-85 -98.77 -67.53 0.84 Allowed 'General case' 0 CA--C 1.535 0.389 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 -179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.89 143.38 6.72 Favored Glycine 0 CA--C 1.53 1.025 0 N-CA-C 108.749 -1.74 . . . . 0.0 108.749 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.539 ' HG3' HD13 ' A' ' 18' ' ' LEU . 5.4 Cg_exo -83.88 -15.48 6.96 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 123.299 2.666 . . . . 0.0 110.018 -178.553 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.78 -18.23 15.23 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 112.859 -1.973 . . . . 0.0 109.045 -179.431 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 55.8 mmtt -96.44 -13.77 22.89 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.444 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 3.2 mt -82.37 -63.36 0.28 Allowed Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.574 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 21.4 Cg_endo -58.88 -32.27 96.98 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 122.168 1.912 . . . . 0.0 111.676 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -61.87 -44.92 95.83 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.998 0.428 . . . . 0.0 110.205 179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.0 mt -65.27 -43.35 95.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.292 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.43 -43.57 98.59 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 -179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.7 mtt180 -63.98 -45.44 89.04 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 121.078 0.466 . . . . 0.0 110.604 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.96 -47.85 83.03 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.615 -0.721 . . . . 0.0 109.807 -179.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.16 -29.16 69.97 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.9 85.02 Favored Glycine 0 N--CA 1.445 -0.727 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.881 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.4 mmt180 -65.76 -42.27 91.1 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.015 0.436 . . . . 0.0 110.442 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.83 -43.41 96.31 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.986 179.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.9 mt -69.69 -36.21 75.78 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.324 0.583 . . . . 0.0 111.313 -179.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 16.4 tp -58.17 -41.96 84.99 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.273 -179.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -74.51 -21.13 59.7 Favored 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 120.198 -0.601 . . . . 0.0 110.064 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.7 -48.9 75.25 Favored 'General case' 0 C--N 1.34 0.16 0 CA-C-O 120.922 0.391 . . . . 0.0 111.667 -178.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.85 -34.18 77.77 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.599 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.3 m -64.94 -38.76 92.04 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.854 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.54 -38.78 74.25 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.929 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.38 -43.16 98.39 Favored 'General case' 0 N--CA 1.45 -0.438 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.843 179.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -56.0 -30.35 61.7 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.643 -179.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.1 t -75.51 -32.78 60.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.895 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.7 mt -70.35 -43.47 70.14 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.978 0.418 . . . . 0.0 110.714 -179.435 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -73.22 -28.99 26.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.784 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -60.46 -43.85 96.49 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.717 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 148.96 41.62 0.03 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.041 -0.824 . . . . 0.0 111.041 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -125.09 107.92 11.28 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.734 0.302 . . . . 0.0 110.751 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.625 179.838 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.693 ' N ' HD22 ' A' ' 4' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 98.1 m-85 -79.73 -2.0 41.04 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -101.93 -24.14 14.05 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.485 179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.693 HD22 ' N ' ' A' ' 1' ' ' MET . 37.6 m-80 -73.59 -16.14 61.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.551 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.43 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.0 pt -63.71 -47.59 90.4 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.34 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 97.86 -119.79 6.55 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.685 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 5.6 tp -104.4 -17.68 0.18 Allowed Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 177.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.685 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 60.0 Cg_endo -71.84 -56.33 0.11 Allowed 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 121.95 1.767 . . . . 0.0 113.116 -178.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -54.71 -21.31 21.75 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.75 -41.7 99.33 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.245 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.68 -44.82 97.9 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.345 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.404 -179.693 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 58.0 tp -59.27 -44.73 92.43 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 120.421 -0.512 . . . . 0.0 109.8 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.32 -41.88 89.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.98 0.419 . . . . 0.0 110.222 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.96 -42.67 80.55 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.198 -177.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.6 t -56.49 -42.01 74.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.147 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.423 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.4 mm -53.32 -32.05 19.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 121.202 0.525 . . . . 0.0 109.708 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.7 -35.92 44.26 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.307 179.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.5 mt -64.45 -40.99 96.77 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.853 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.423 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -58.6 -41.55 82.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.067 -0.653 . . . . 0.0 110.341 -179.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.51 -36.13 12.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.567 179.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -95.14 -76.64 0.49 Allowed 'General case' 0 C--N 1.342 0.25 0 N-CA-C 110.31 -0.255 . . . . 0.0 110.31 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.4 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.92 141.24 5.09 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 110.774 -0.93 . . . . 0.0 110.774 179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.472 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.3 Cg_endo -70.8 -20.29 30.13 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.322 2.015 . . . . 0.0 112.114 -179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.5 m -93.35 -23.54 18.42 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.82 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -81.99 -29.67 31.99 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.035 0.445 . . . . 0.0 110.526 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.468 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 6.7 mt -64.55 -59.22 11.11 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.039 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.472 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 17.8 Cg_endo -57.26 -32.15 92.83 Favored 'Trans proline' 0 N--CA 1.497 1.688 0 C-N-CA 122.266 1.977 . . . . 0.0 111.906 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -64.04 -43.49 95.4 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.949 0.404 . . . . 0.0 110.516 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.3 mt -64.67 -43.26 96.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.16 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.79 98.51 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 -179.734 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.553 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 80.8 mtt180 -64.13 -44.96 90.61 Favored 'General case' 0 CA--C 1.511 -0.526 0 CA-C-O 121.206 0.527 . . . . 0.0 110.637 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.89 -47.12 86.38 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.769 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -29.47 70.27 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.455 178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -44.43 84.92 Favored Glycine 0 N--CA 1.443 -0.853 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.804 -178.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.553 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 18.6 mmt-85 -66.93 -41.62 86.7 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.883 0.373 . . . . 0.0 110.666 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.73 -43.56 96.16 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.897 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.8 mt -69.01 -36.58 77.95 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.26 0.552 . . . . 0.0 111.472 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 22.7 tp -57.87 -41.83 83.29 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.302 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -75.35 -21.44 58.35 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.157 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.56 -48.93 75.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 120.784 0.326 . . . . 0.0 111.724 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.44 -34.38 78.15 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 121.222 0.534 . . . . 0.0 110.529 -179.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.3 m -64.9 -39.57 93.73 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.73 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.82 -37.93 76.4 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.158 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -62.61 -42.68 99.72 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.796 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.728 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.6 tmmm? -53.28 -29.63 34.18 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.915 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.2 m -77.2 -28.57 53.96 Favored 'General case' 0 C--N 1.321 -0.667 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.176 179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.476 ' O ' ' O ' ' A' ' 48' ' ' VAL . 66.2 mt -72.36 -21.44 61.3 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.747 0.308 . . . . 0.0 111.465 -179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.728 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.9 m -55.88 -154.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.261 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.528 ' N ' HG23 ' A' ' 48' ' ' VAL . 72.0 m -67.68 32.83 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.861 -0.335 . . . . 0.0 110.747 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.56 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 51.88 36.9 42.94 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -157.41 175.45 13.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.808 0.337 . . . . 0.0 110.783 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.681 -179.996 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.529 ' O ' ' N ' ' A' ' 3' ' ' SER . 76.5 mtm . . . . . 0 N--CA 1.483 1.196 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 38.48 23.43 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.924 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.977 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.529 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -120.39 -33.28 3.91 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.175 0.512 . . . . 0.0 109.851 179.665 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 49.8 m-80 -71.85 -14.3 61.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.268 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.408 HG13 ' N ' ' A' ' 6' ' ' GLY . 5.1 pt -60.66 -50.38 80.68 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.484 179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.408 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 94.64 -120.36 6.39 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.642 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.5 tp -102.79 -21.37 0.2 Allowed Pre-proline 0 CA--C 1.551 1.005 0 N-CA-C 113.254 0.835 . . . . 0.0 113.254 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.642 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 55.8 Cg_endo -69.71 -30.07 23.11 Favored 'Trans proline' 0 N--CA 1.495 1.606 0 C-N-CA 121.602 1.535 . . . . 0.0 112.245 -178.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -73.19 -25.3 73.63 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.25 -41.38 99.06 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.704 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.923 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.79 -44.49 97.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.375 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.574 -179.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.9 tp -59.15 -44.85 92.11 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.05 -41.99 90.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.084 0.469 . . . . 0.0 110.479 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -56.64 -42.12 78.34 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.985 -177.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.923 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.0 t -57.95 -42.57 82.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.129 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.477 ' O ' HG22 ' A' ' 19' ' ' ILE . 32.8 mm -51.94 -29.62 11.48 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.491 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.909 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.84 -35.71 24.0 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.452 -0.794 . . . . 0.0 109.44 179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.449 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.08 -41.55 94.94 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 111.911 0.338 . . . . 0.0 111.911 -179.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.491 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.4 tp -58.37 -41.66 81.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.275 -0.57 . . . . 0.0 109.883 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.491 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.16 -38.27 14.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.001 179.032 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -93.8 -71.3 0.66 Allowed 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 121.132 -0.227 . . . . 0.0 110.925 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.449 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.72 141.23 5.77 Favored Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.451 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.45 -16.99 34.73 Favored 'Trans proline' 0 N--CA 1.496 1.623 0 C-N-CA 122.49 2.127 . . . . 0.0 112.229 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.9 m -95.61 -6.19 40.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.62 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.1 mmmm -99.45 -23.47 15.11 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.417 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -76.66 -47.49 3.06 Favored Pre-proline 0 CA--C 1.533 0.324 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 179.933 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.529 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.5 Cg_exo -56.32 -39.16 93.11 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 122.537 2.158 . . . . 0.0 111.434 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -62.33 -43.16 99.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.618 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.51 -43.57 94.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.275 179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.471 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.88 -43.65 99.04 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 -179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 66.3 mtt180 -64.65 -46.88 80.63 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-O 121.297 0.57 . . . . 0.0 110.419 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.72 -40.74 96.15 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.342 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -75.72 -28.11 58.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.017 178.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.58 -53.08 40.96 Favored Glycine 0 N--CA 1.447 -0.584 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.609 -177.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.51 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.5 mpt_? -63.58 -42.68 98.28 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.594 0.235 . . . . 0.0 111.148 -179.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -64.22 -43.47 94.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.829 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 61.1 mt -72.9 -34.38 66.62 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.658 0.742 . . . . 0.0 111.393 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.9 tp -58.41 -39.67 80.36 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.466 -1.243 . . . . 0.0 110.245 -179.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -78.55 -22.07 47.8 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.283 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -67.22 -48.28 68.31 Favored 'General case' 0 C--N 1.34 0.167 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.65 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.65 -34.39 77.75 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.672 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -65.41 -39.57 92.32 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.619 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.79 -42.19 67.39 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.253 178.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.03 -42.58 99.81 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.133 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -53.37 -29.56 35.09 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -75.68 -34.04 60.43 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.143 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 52.5 mt -70.18 -42.51 72.33 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.047 0.451 . . . . 0.0 111.119 -179.447 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.56 -28.51 31.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.249 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.472 ' C ' ' H ' ' A' ' 51' ' ' ASP . 54.5 p -60.16 -23.11 63.66 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.307 -179.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.95 38.74 0.94 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.472 ' H ' ' C ' ' A' ' 49' ' ' SER . 54.9 p-10 -83.28 170.77 14.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.852 0.358 . . . . 0.0 110.59 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.632 -179.979 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.0 mmm . . . . . 0 N--CA 1.489 1.495 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.4 m-85 -79.8 -2.54 43.77 Favored 'General case' 0 N--CA 1.45 -0.459 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.657 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -98.17 -23.44 15.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.298 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -68.55 -27.2 65.87 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.405 179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.46 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 pt -62.09 -48.47 88.33 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.749 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.674 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 66.18 -136.35 34.87 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.597 -1.001 . . . . 0.0 110.597 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.555 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -57.76 -53.65 63.5 Favored Pre-proline 0 C--O 1.22 -0.475 0 C-N-CA 120.604 -0.438 . . . . 0.0 110.596 -179.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_exo -44.81 -23.77 1.0 Allowed 'Trans proline' 0 N--CA 1.501 1.916 0 C-N-CA 122.495 2.13 . . . . 0.0 112.233 178.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -91.15 -26.94 20.13 Favored Glycine 0 C--N 1.345 1.066 0 N-CA-C 108.183 -1.967 . . . . 0.0 108.183 176.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.555 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.5 tt -62.3 -41.87 98.88 Favored 'General case' 0 C--N 1.347 0.485 0 CA-C-N 115.009 -0.595 . . . . 0.0 111.528 179.341 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.933 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.49 -44.46 96.47 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 121.078 -0.249 . . . . 0.0 110.664 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.7 tp -58.63 -45.91 88.24 Favored 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.53 -42.26 92.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.043 0.449 . . . . 0.0 110.325 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -57.0 -42.81 80.99 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.271 -177.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.933 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -55.94 -42.13 70.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.993 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.428 ' O ' HG22 ' A' ' 20' ' ' ILE . 27.8 mm -54.19 -32.72 23.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.839 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.67 -31.74 52.73 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.339 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.7 mt -70.76 -43.78 68.1 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.825 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.9 tt -58.27 -44.08 87.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.633 -179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.541 HG23 ' N ' ' A' ' 21' ' ' PHE . 3.1 tt -73.45 -54.82 14.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.413 177.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.541 ' N ' HG23 ' A' ' 20' ' ' ILE . 19.4 m-85 -83.69 -76.37 0.29 Allowed 'General case' 0 CA--C 1.53 0.181 0 N-CA-C 111.746 0.276 . . . . 0.0 111.746 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 126.82 143.72 5.89 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.8 Cg_endo -70.34 -21.64 30.52 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 122.382 2.055 . . . . 0.0 111.978 179.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -92.25 -31.6 15.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.924 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 tptm -77.92 -33.6 51.69 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 121.121 0.486 . . . . 0.0 110.557 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.437 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.5 mt -58.1 -61.45 7.44 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.043 -179.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.46 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.7 Cg_endo -58.37 -30.44 91.27 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.206 1.937 . . . . 0.0 111.708 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.83 -42.74 94.71 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.663 179.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 86.8 mt -64.56 -43.39 96.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.459 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.45 -43.63 98.54 Favored Glycine 0 CA--C 1.523 0.537 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 79.6 mtt180 -64.63 -47.72 77.5 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-O 121.126 0.489 . . . . 0.0 110.61 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.07 -40.45 95.85 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -72.54 -27.72 62.41 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.023 178.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.684 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -53.8 -51.53 48.55 Favored Glycine 0 N--CA 1.444 -0.792 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.315 -177.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.488 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.8 mpt_? -62.92 -40.26 97.06 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.567 0.223 . . . . 0.0 110.893 -179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -64.41 -42.16 96.23 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.22 0.534 . . . . 0.0 109.928 178.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.1 mt -62.93 -36.13 82.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.975 -179.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.684 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.6 mm? -58.45 -35.33 71.96 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.992 179.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.423 ' HG3' ' H ' ' A' ' 39' ' ' GLU . 1.9 mt-10 -77.6 -23.21 49.94 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.05 -179.084 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.63 -48.48 72.07 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-O 120.94 0.4 . . . . 0.0 111.799 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.39 -34.27 77.37 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.62 -178.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.9 m -64.99 -39.27 93.22 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.952 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.416 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.04 -38.9 72.55 Favored 'General case' 0 CA--C 1.517 -0.323 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.563 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.7 m -62.8 -43.65 98.23 Favored 'General case' 0 N--CA 1.447 -0.598 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.622 179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -60.52 -40.73 92.53 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.94 0.4 . . . . 0.0 110.551 -179.221 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -84.27 -32.95 24.14 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.003 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.722 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.07 -48.6 28.74 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.494 0.664 . . . . 0.0 110.682 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.563 HG12 ' O ' ' A' ' 44' ' ' THR . 11.1 p -51.45 -20.26 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.426 -0.807 . . . . 0.0 110.073 -178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.0 p -61.52 -23.7 66.11 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.517 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.429 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 71.86 36.07 61.51 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.429 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.72 37.06 1.44 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.937 0.399 . . . . 0.0 110.736 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.485 -179.902 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.466 ' N ' HD22 ' A' ' 4' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.29 -0.54 37.01 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.832 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -103.72 -23.77 13.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.269 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.466 HD22 ' N ' ' A' ' 1' ' ' MET . 55.0 m-80 -76.25 -14.29 60.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.537 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.3 pt -62.52 -50.49 79.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 120.691 -0.404 . . . . 0.0 111.465 -179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.13 -145.55 32.28 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -58.15 -54.76 52.34 Favored Pre-proline 0 C--O 1.225 -0.229 0 CA-C-O 118.855 -0.593 . . . . 0.0 109.73 179.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.464 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 38.0 Cg_exo -34.01 -38.86 0.14 Allowed 'Trans proline' 0 N--CA 1.487 1.124 0 C-N-CA 121.598 1.532 . . . . 0.0 111.932 178.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -75.73 -34.85 47.65 Favored Glycine 0 CA--C 1.524 0.656 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.992 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.547 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.1 tt -62.54 -38.6 90.65 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.922 -0.139 . . . . 0.0 111.296 -179.165 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.0 -44.81 92.03 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.457 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.8 tp -58.7 -45.14 90.19 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.309 -0.556 . . . . 0.0 109.587 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.84 -42.36 92.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.061 0.457 . . . . 0.0 110.319 178.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.09 -41.71 79.38 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.877 -177.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -57.74 -42.57 82.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.135 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.438 ' O ' HG22 ' A' ' 19' ' ' ILE . 33.1 mm -52.11 -29.69 12.19 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.554 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.573 179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.55 -36.67 23.82 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.824 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.456 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.5 mt -65.36 -41.71 93.55 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.849 -179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.493 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.8 tp -59.05 -42.37 86.17 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 C-N-CA 120.074 -0.65 . . . . 0.0 109.785 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.493 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -80.75 -38.66 17.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.099 178.682 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -95.58 -71.29 0.68 Allowed 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 121.037 -0.265 . . . . 0.0 110.986 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.456 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.89 141.76 6.0 Favored Glycine 0 CA--C 1.533 1.167 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 179.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -70.73 -13.04 31.91 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.63 2.22 . . . . 0.0 111.839 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 37.2 t -87.14 -7.55 57.88 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -91.98 -26.4 18.41 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.3 -178.492 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.506 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.1 mt -67.08 -50.8 39.67 Favored Pre-proline 0 N--CA 1.445 -0.717 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 178.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.506 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.8 Cg_exo -43.52 -49.72 7.48 Favored 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 121.01 1.14 . . . . 0.0 110.93 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.3 tt0 -62.17 -43.92 97.76 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.316 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.6 mt -65.38 -43.42 94.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.31 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.55 98.04 Favored Glycine 0 CA--C 1.521 0.407 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.495 HH12 ' HB3' ' A' ' 27' ' ' PRO . 62.6 mtt85 -63.57 -48.98 75.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.05 0.452 . . . . 0.0 110.399 179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.56 -43.43 98.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.61 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -66.98 -27.69 67.65 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.642 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.17 -48.19 64.56 Favored Glycine 0 N--CA 1.446 -0.693 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.413 -177.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.489 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.7 OUTLIER -65.14 -41.65 94.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.558 0.218 . . . . 0.0 110.956 179.997 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -64.12 -42.51 96.82 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.422 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -64.83 -37.57 88.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.63 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 39.9 mt -58.84 -36.38 74.47 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.604 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -74.3 -24.06 59.18 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.178 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -67.72 -50.83 55.37 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -178.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.604 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.71 -34.73 79.0 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.155 0.502 . . . . 0.0 110.516 -179.138 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.02 -40.15 94.46 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.763 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.79 -40.32 79.71 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.266 0.555 . . . . 0.0 109.584 178.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -63.56 -44.0 95.4 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.091 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.576 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -55.54 -30.59 61.01 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.413 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.9 m -76.99 -28.3 55.02 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.432 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.93 -34.56 71.62 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.04 0.448 . . . . 0.0 111.102 -179.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.576 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.5 m -43.46 -45.35 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.67 -178.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.487 ' N ' ' CG2' ' A' ' 48' ' ' VAL . 7.5 t -78.63 -39.82 36.08 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.707 -0.679 . . . . 0.0 110.18 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -82.23 31.75 2.86 Favored Glycine 0 CA--C 1.52 0.38 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.279 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -93.53 110.92 22.49 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 120.767 0.317 . . . . 0.0 110.661 179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.603 179.925 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.597 ' O ' ' N ' ' A' ' 3' ' ' SER . 3.5 ttt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 36.79 21.63 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.082 0 CA-C-O 121.126 0.489 . . . . 0.0 111.843 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.597 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.5 OUTLIER -122.31 -28.35 4.33 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.817 179.821 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 57.8 m-80 -76.79 -13.96 59.97 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.752 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.7 pt -58.97 -51.8 68.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.919 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.93 -135.76 12.91 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -178.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.601 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -81.37 -39.45 1.0 Allowed Pre-proline 0 CA--C 1.553 1.093 0 CA-C-O 118.967 -0.54 . . . . 0.0 112.27 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.601 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 8.7 Cg_endo -47.56 -30.34 11.98 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 CA-C-N 121.142 1.444 . . . . 0.0 112.567 177.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -80.59 -26.71 53.55 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.499 -178.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.2 tt -62.74 -39.65 94.79 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 119.911 -0.716 . . . . 0.0 110.739 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.914 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.0 98.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.698 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.518 HD13 ' O ' ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.51 -45.53 91.45 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.337 -0.545 . . . . 0.0 109.597 -179.254 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.1 mt -64.78 -42.18 94.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.492 178.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -56.95 -42.59 80.35 Favored 'General case' 0 N--CA 1.437 -1.121 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.51 -177.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.914 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.5 t -56.81 -41.03 74.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.455 0.645 . . . . 0.0 110.51 179.629 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.424 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 35.0 mm -53.42 -35.41 24.85 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.939 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.424 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.34 -34.9 63.54 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.59 178.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 18.7 mt -64.29 -41.44 96.89 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.575 -178.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.424 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -60.31 -41.18 86.19 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 119.841 -0.744 . . . . 0.0 109.864 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.84 -34.21 11.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.063 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.8 m-85 -99.23 -79.57 0.48 Allowed 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 119.399 -0.334 . . . . 0.0 110.456 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 127.96 123.76 2.63 Favored Glycine 0 CA--C 1.552 2.377 0 C-N-CA 120.77 -0.729 . . . . 0.0 113.289 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.573 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.3 Cg_endo -53.72 -28.95 49.49 Favored 'Trans proline' 0 N--CA 1.506 2.238 0 C-N-CA 122.736 2.291 . . . . 0.0 112.967 177.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 6.9 m -78.07 -11.41 59.91 Favored 'General case' 0 C--N 1.316 -0.856 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.731 -178.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.4 tptm -93.01 -23.41 18.69 Favored 'General case' 0 C--O 1.22 -0.483 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.516 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 19.3 mt -69.05 -53.82 13.29 Favored Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 119.435 -0.906 . . . . 0.0 109.248 178.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.573 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 11.8 Cg_exo -36.72 -53.69 1.09 Allowed 'Trans proline' 0 N--CA 1.48 0.735 0 C-N-CA 123.161 2.574 . . . . 0.0 111.953 175.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.1 tt0 -63.73 -43.52 96.29 Favored 'General case' 0 C--N 1.333 -0.141 0 CA-C-O 120.961 0.41 . . . . 0.0 111.196 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.1 mt -65.58 -43.53 94.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.529 179.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.2 -43.52 98.35 Favored Glycine 0 CA--C 1.519 0.295 0 N-CA-C 110.697 -0.961 . . . . 0.0 110.697 -179.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 83.5 mtt180 -63.22 -51.11 67.58 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.271 0.557 . . . . 0.0 110.817 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.25 -49.27 77.78 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.834 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.59 -28.39 69.1 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.99 -44.66 82.95 Favored Glycine 0 CA--C 1.526 0.723 0 CA-C-N 115.065 -0.97 . . . . 0.0 111.17 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -67.88 -40.69 83.53 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.793 0.33 . . . . 0.0 110.858 179.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.57 -43.31 97.36 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.254 179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.0 mt -70.71 -35.78 72.92 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 121.437 0.637 . . . . 0.0 111.362 -179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 36.9 tp -58.24 -41.49 84.27 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.404 -179.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -75.7 -21.5 57.5 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.012 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.24 -48.51 75.51 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-O 120.953 0.406 . . . . 0.0 111.885 -178.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.64 -34.74 78.52 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.672 -179.127 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.8 m -65.08 -40.27 94.4 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.935 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -42.38 64.64 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.123 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.6 -42.78 98.22 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.321 179.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.63 -31.21 46.42 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.391 0.615 . . . . 0.0 109.83 -178.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.36 -32.42 60.84 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.03 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 94.0 mt -70.2 -44.03 69.51 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-O 121.09 0.472 . . . . 0.0 110.572 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.1 p -73.45 -26.92 22.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.837 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -58.01 -42.74 85.87 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.249 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.77 59.16 4.87 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -84.65 112.76 20.75 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.859 0.361 . . . . 0.0 110.827 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.647 179.958 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttm . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.5 m-85 -84.74 8.68 16.29 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.785 -179.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.06 -25.94 13.56 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.25 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 54.6 m-80 -75.46 -14.86 60.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.866 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -65.31 -43.81 94.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.025 -179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.49 -135.15 24.99 Favored Glycine 0 CA--C 1.527 0.813 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -72.58 -44.7 9.59 Favored Pre-proline 0 C--N 1.327 -0.386 0 O-C-N 122.866 -0.197 . . . . 0.0 110.738 179.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.2 Cg_exo -41.82 -30.72 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 C-N-CA 121.382 1.388 . . . . 0.0 111.208 179.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.24 -27.38 33.61 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.023 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.7 tt -62.09 -41.51 98.27 Favored 'General case' 0 N--CA 1.453 -0.322 0 C-N-CA 121.043 -0.263 . . . . 0.0 110.77 -179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.905 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.55 -45.63 96.83 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.284 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.539 -179.284 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 tt -60.11 -44.06 95.13 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.245 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.8 mt -65.54 -42.84 93.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.063 0.459 . . . . 0.0 110.495 178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.22 -41.72 80.01 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.753 -177.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.905 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.6 t -57.33 -41.59 78.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.285 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.416 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.9 mm -52.31 -34.2 18.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-N 116.029 -0.532 . . . . 0.0 109.842 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.75 -35.08 62.61 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.005 178.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.426 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 25.1 mt -65.57 -42.33 91.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.353 -178.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.416 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.4 tt -59.51 -42.9 89.45 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 120.226 -0.59 . . . . 0.0 109.905 -179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -78.65 -37.09 20.41 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.417 178.428 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.8 m-85 -99.76 -75.74 0.56 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-O 119.127 -0.464 . . . . 0.0 111.233 179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.443 ' HA2' ' HD2' ' A' ' 23' ' ' PRO . . . 121.8 123.92 2.99 Favored Glycine 0 CA--C 1.544 1.864 0 CA-C-O 119.007 -0.885 . . . . 0.0 112.586 178.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.537 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 9.9 Cg_endo -48.65 -23.5 5.58 Favored 'Trans proline' 0 N--CA 1.504 2.143 0 C-N-CA 124.252 3.301 . . . . 0.0 113.195 178.072 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.6 t -88.8 -7.65 55.81 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 120.953 0.406 . . . . 0.0 111.202 -177.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 9.5 mptt -99.3 -37.77 9.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.745 -0.662 . . . . 0.0 110.701 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.492 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.8 OUTLIER -59.63 -48.64 94.98 Favored Pre-proline 0 CA--C 1.541 0.604 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.062 -179.431 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.537 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 31.7 Cg_exo -56.61 -36.49 98.06 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.833 2.355 . . . . 0.0 111.464 179.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -62.76 -42.0 99.48 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.62 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.9 -43.66 96.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.343 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.79 -43.7 98.86 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 78.8 mtt180 -63.94 -47.82 78.97 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.295 0.569 . . . . 0.0 110.646 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.39 -48.17 82.48 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.695 -179.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.94 69.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.387 0.613 . . . . 0.0 109.361 178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.04 -45.74 80.53 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 115.134 -0.939 . . . . 0.0 111.104 -178.249 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.1 mmm-85 -66.69 -40.17 88.4 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.924 0.392 . . . . 0.0 110.633 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.53 -42.78 98.41 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.048 179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 33.7 mt -73.2 -33.7 65.54 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.537 0.684 . . . . 0.0 111.313 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.62 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.3 tp -57.94 -39.32 77.78 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.191 -179.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -77.84 -23.2 49.02 Favored 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 120.294 -0.562 . . . . 0.0 110.166 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -70.4 -48.96 53.74 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.915 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.62 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -62.77 -34.77 77.94 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.084 0.469 . . . . 0.0 110.559 -178.973 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.8 m -65.35 -40.11 93.18 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.572 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.87 -42.67 60.4 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.232 179.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -64.01 -43.47 95.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.163 179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.748 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.93 -27.55 31.49 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.018 -179.115 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -77.21 -30.86 54.87 Favored 'General case' 0 C--N 1.32 -0.709 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.901 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.4 mt -70.23 -36.84 74.8 Favored 'General case' 0 C--O 1.231 0.111 0 CA-C-N 116.469 -0.332 . . . . 0.0 111.364 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.748 HG22 ' O ' ' A' ' 45' ' ' LYS . 6.1 m -41.2 114.69 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 -179.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.517 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.9 t 38.65 74.98 0.08 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.879 -179.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -69.15 36.34 0.31 Allowed Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.517 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.3 m-20 -103.01 138.49 39.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.771 0.32 . . . . 0.0 110.459 179.676 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 51.2 tp10 . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.417 -179.851 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.736 ' N ' HD22 ' A' ' 4' ' ' ASN . 95.9 mtp . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 92.8 m-85 -77.93 -0.04 26.05 Favored 'General case' 0 N--CA 1.45 -0.475 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.51 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -101.42 -23.48 14.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.732 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.736 HD22 ' N ' ' A' ' 1' ' ' MET . 51.3 m-80 -76.96 -14.9 59.8 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.72 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 2.7 pt -59.69 -58.18 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.458 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' H ' HG13 ' A' ' 5' ' ' ILE . . . 97.79 -139.77 14.66 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.625 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -55.9 -53.22 65.49 Favored Pre-proline 0 C--O 1.222 -0.35 0 CA-C-O 118.364 -0.827 . . . . 0.0 109.751 178.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.468 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 14.0 Cg_exo -33.12 -32.51 0.05 OUTLIER 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 121.859 1.706 . . . . 0.0 111.175 175.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.514 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -80.07 -35.3 27.73 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 179.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.625 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -61.36 -40.0 92.69 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 111.69 0.255 . . . . 0.0 111.69 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.948 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.13 -44.57 95.45 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.409 0 CA-C-N 116.714 -0.221 . . . . 0.0 110.475 -178.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.8 tp -58.76 -44.74 90.69 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.479 -0.488 . . . . 0.0 109.704 -179.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.27 -42.19 90.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.138 0.494 . . . . 0.0 110.315 178.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.15 -42.06 80.32 Favored 'General case' 0 N--CA 1.441 -0.915 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.054 -177.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.948 HG23 ' O ' ' A' ' 11' ' ' ILE . 20.0 t -57.28 -42.23 79.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.034 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.2 mm -52.89 -34.22 20.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.566 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.04 -31.97 56.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.088 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.9 mt -69.86 -42.04 74.03 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.201 -0.454 . . . . 0.0 112.003 -179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 6.0 tt -58.34 -41.47 81.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 C-N-CA 120.0 -0.68 . . . . 0.0 109.638 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.531 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.75 -56.64 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.959 178.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.531 ' H ' HG23 ' A' ' 20' ' ' ILE . 38.6 m-85 -78.83 -71.34 0.44 Allowed 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 121.0 -0.28 . . . . 0.0 111.697 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.11 144.61 7.01 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -69.07 -17.4 40.72 Favored 'Trans proline' 0 N--CA 1.494 1.513 0 C-N-CA 122.562 2.174 . . . . 0.0 111.9 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 t -93.93 3.34 55.52 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.666 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -103.05 -34.57 8.85 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.528 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.598 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 5.0 mt -67.61 -40.67 26.38 Favored Pre-proline 0 C--N 1.325 -0.461 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.724 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.6 Cg_exo -60.27 -40.43 59.21 Favored 'Trans proline' 0 N--CA 1.496 1.666 0 C-N-CA 122.799 2.332 . . . . 0.0 111.518 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -66.4 -42.21 88.19 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.132 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.74 -43.07 96.54 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.457 -179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.414 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.51 -43.44 98.82 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.764 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.418 HH12 ' HB3' ' A' ' 27' ' ' PRO . 58.9 mtt85 -63.47 -48.95 75.58 Favored 'General case' 0 CA--C 1.513 -0.451 0 CA-C-O 121.37 0.605 . . . . 0.0 110.642 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.23 -49.17 78.22 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.72 -179.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.75 -28.51 69.09 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 178.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.92 -44.87 82.29 Favored Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.993 -1.003 . . . . 0.0 111.162 -178.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.3 mmm180 -67.11 -41.0 86.96 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.798 0.332 . . . . 0.0 110.544 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.81 -43.37 96.48 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.217 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -71.14 -35.34 71.68 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.456 0.646 . . . . 0.0 111.288 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 19.9 tp -57.96 -41.48 82.95 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.287 -179.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -75.95 -21.86 56.58 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.09 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.79 74.9 Favored 'General case' 0 CA--C 1.528 0.1 0 CA-C-O 120.886 0.374 . . . . 0.0 111.728 -178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.75 -34.59 78.52 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.206 0.527 . . . . 0.0 110.776 -179.062 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.6 m -65.18 -39.63 93.16 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.823 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.63 -38.15 80.28 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 178.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.3 m -62.91 -44.18 96.79 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.038 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.777 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -56.67 -30.26 63.19 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.032 -179.332 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.3 m -76.01 -27.44 57.38 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.127 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -72.51 -22.06 61.1 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.932 0.396 . . . . 0.0 110.999 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.777 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.9 m -61.95 -27.68 42.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 37.6 m -58.35 -40.46 82.28 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.197 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.56 35.44 62.77 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -84.84 115.16 22.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.782 0.325 . . . . 0.0 110.754 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.879 179.923 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.718 ' N ' HD22 ' A' ' 4' ' ' ASN . 96.0 mtp . . . . . 0 N--CA 1.488 1.44 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -83.84 -2.19 55.91 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.534 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -102.16 -23.65 14.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.57 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.718 HD22 ' N ' ' A' ' 1' ' ' MET . 64.1 m-80 -82.22 -13.07 57.66 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.856 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 8.0 pt -59.96 -43.17 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.425 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 66.46 -136.81 34.41 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.543 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -67.1 -47.14 52.35 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 178.539 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.513 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.2 Cg_exo -39.34 -36.68 0.97 Allowed 'Trans proline' 0 N--CA 1.488 1.178 0 C-N-CA 121.611 1.541 . . . . 0.0 112.212 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.91 -27.93 57.58 Favored Glycine 0 CA--C 1.528 0.868 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.543 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.3 tt -63.26 -38.99 93.33 Favored 'General case' 0 C--N 1.333 -0.129 0 CA-C-O 120.591 0.234 . . . . 0.0 110.866 -179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.931 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.42 -45.08 93.85 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.386 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 52.0 tp -59.36 -44.83 92.64 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.88 -41.88 90.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 O-C-N 123.343 0.402 . . . . 0.0 110.203 178.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -57.13 -42.36 80.8 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.964 -0.562 . . . . 0.0 109.932 -177.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.931 HG23 ' O ' ' A' ' 11' ' ' ILE . 12.8 t -57.08 -42.05 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.228 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.0 mm -52.53 -31.83 16.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 121.268 0.556 . . . . 0.0 109.758 179.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.51 -35.5 46.25 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.277 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 18.0 mt -65.02 -41.48 95.26 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.932 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.418 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.29 -41.84 82.21 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 C-N-CA 120.261 -0.576 . . . . 0.0 110.35 -179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -82.21 -35.84 13.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.4 179.421 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -97.64 -74.05 0.59 Allowed 'General case' 0 C--N 1.343 0.286 0 C-N-CA 121.036 -0.265 . . . . 0.0 110.655 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.5 143.42 5.6 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.438 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.2 Cg_endo -71.3 -17.05 31.2 Favored 'Trans proline' 0 N--CA 1.492 1.427 0 C-N-CA 122.552 2.168 . . . . 0.0 112.129 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.9 m -96.94 -3.61 41.45 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.962 -179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -101.28 -22.34 14.65 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.225 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.19 -47.17 2.12 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.79 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.539 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.0 Cg_exo -56.0 -40.9 82.11 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 122.499 2.133 . . . . 0.0 111.575 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -64.72 -44.25 90.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.928 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -65.63 -42.67 93.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 120.992 0.425 . . . . 0.0 110.283 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.87 -43.26 98.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.9 mtt-85 -63.75 -45.79 88.23 Favored 'General case' 0 CA--C 1.513 -0.45 0 CA-C-O 121.0 0.429 . . . . 0.0 110.704 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -49.25 76.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.805 -179.124 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.57 -28.6 69.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.587 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.79 -43.36 80.66 Favored Glycine 0 N--CA 1.444 -0.779 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -178.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 7.4 mmt85 -66.87 -42.99 84.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.943 0.402 . . . . 0.0 110.736 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.07 -43.17 96.27 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.042 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.4 mt -69.5 -36.48 76.52 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-O 121.185 0.517 . . . . 0.0 111.431 -179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.403 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.2 tp -58.0 -41.35 82.88 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.343 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -75.46 -21.32 58.2 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.164 -179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.92 74.56 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.791 0.329 . . . . 0.0 111.689 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.56 -34.53 78.47 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.292 -179.299 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.2 m -65.06 -41.81 94.77 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.008 179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.72 -40.8 69.22 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.427 179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.2 -41.76 99.21 Favored 'General case' 0 N--CA 1.452 -0.335 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.93 179.138 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -53.38 -29.88 36.92 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.407 0.622 . . . . 0.0 109.805 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.2 t -76.01 -33.4 59.69 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.711 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.7 mt -70.21 -43.61 70.33 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.007 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.4 p -71.91 -25.1 23.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.718 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.2 t -59.52 -43.58 93.4 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.658 -179.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -112.87 34.81 4.91 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -149.67 113.29 5.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.703 0.287 . . . . 0.0 110.56 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 19.2 pt-20 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.927 -1.035 . . . . 0.0 110.562 179.918 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.7 ttp . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.493 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 89.4 m-85 -77.44 -2.92 37.73 Favored 'General case' 0 N--CA 1.447 -0.583 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.602 -179.544 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.2 m -102.18 -22.85 14.11 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.264 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -77.13 -14.53 59.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.001 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.493 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.0 pt -62.51 -51.99 65.35 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.964 179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.411 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 92.16 -136.11 13.07 Favored Glycine 0 CA--C 1.522 0.477 0 N-CA-C 109.269 -1.532 . . . . 0.0 109.269 -178.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.4 tp -83.1 -38.84 0.76 Allowed Pre-proline 0 CA--C 1.552 1.051 0 CA-C-O 118.254 -0.879 . . . . 0.0 112.51 178.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.574 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 9.7 Cg_endo -48.36 -28.88 12.22 Favored 'Trans proline' 0 N--CA 1.497 1.685 0 C-N-CA 122.0 1.8 . . . . 0.0 112.389 177.386 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -82.65 -25.26 50.93 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 119.984 -1.103 . . . . 0.0 112.267 -178.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.3 tt -63.09 -39.86 95.94 Favored 'General case' 0 N--CA 1.443 -0.803 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.41 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.922 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.72 -45.08 98.27 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.485 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.71 -179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.6 tp -58.93 -45.69 89.77 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.571 -0.452 . . . . 0.0 109.821 -179.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.7 mm -65.45 -42.09 92.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 121.064 0.459 . . . . 0.0 110.284 178.533 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.2 t80 -56.79 -42.13 78.93 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.137 -177.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.922 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.18 -42.2 79.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.167 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.27 -33.31 20.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.693 179.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.29 -35.26 55.19 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.949 178.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.452 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.2 mt -64.98 -40.63 95.27 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.937 -178.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.3 tt -60.27 -41.46 87.08 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.219 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.24 -37.61 14.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.791 179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -95.63 -72.39 0.63 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.084 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.452 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 120.63 142.81 6.62 Favored Glycine 0 CA--C 1.533 1.173 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -70.83 -13.2 31.8 Favored 'Trans proline' 0 N--CA 1.494 1.537 0 C-N-CA 122.337 2.025 . . . . 0.0 111.671 179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.5 t -96.73 4.49 51.78 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.352 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -105.98 -30.16 9.49 Favored 'General case' 0 N--CA 1.456 -0.132 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.368 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.4 mt -71.91 -40.93 8.5 Favored Pre-proline 0 C--N 1.324 -0.534 0 C-N-CA 120.524 -0.471 . . . . 0.0 110.374 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.601 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.5 Cg_exo -61.11 -37.34 75.96 Favored 'Trans proline' 0 N--CA 1.497 1.715 0 C-N-CA 122.805 2.337 . . . . 0.0 111.438 179.635 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 74.2 tt0 -65.8 -40.96 92.4 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.965 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.86 -43.23 96.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.337 -179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.0 -43.33 98.29 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.421 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.1 mtt85 -63.66 -48.88 75.41 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 121.15 0.5 . . . . 0.0 110.476 179.892 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.06 -42.12 97.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.56 -179.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.16 -27.92 66.84 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.827 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.56 -48.88 63.24 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.396 -177.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 2.7 mpt_? -65.01 -42.26 94.59 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.517 0.198 . . . . 0.0 111.059 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -64.44 -42.57 95.91 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.451 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.8 mt -64.35 -37.32 87.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.315 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.557 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 35.3 mt -58.82 -35.75 73.38 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.662 -0.699 . . . . 0.0 109.555 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -75.38 -23.93 57.18 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.267 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -69.46 -50.81 42.02 Favored 'General case' 0 N--CA 1.454 -0.245 0 CA-C-O 120.886 0.374 . . . . 0.0 111.819 -178.594 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.557 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.22 -34.58 77.97 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.127 0.489 . . . . 0.0 110.655 -179.153 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.2 m -65.18 -40.36 94.17 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.965 179.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.18 -41.14 74.13 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.86 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.62 -43.5 96.68 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.263 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 tmmm? -55.11 -30.74 60.36 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.303 0.573 . . . . 0.0 109.77 -178.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.34 -32.53 60.91 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.948 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.38 -44.4 68.12 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.038 0.447 . . . . 0.0 110.606 -179.435 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -71.33 -35.49 57.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.827 179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -59.26 -43.57 92.45 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.483 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -97.37 36.28 4.01 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -148.94 120.04 7.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.808 0.337 . . . . 0.0 110.731 179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.582 179.835 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.717 ' N ' HD22 ' A' ' 4' ' ' ASN . 77.6 mtm . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -77.44 2.17 16.92 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-O 120.93 0.395 . . . . 0.0 110.511 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 m -99.91 -24.11 14.75 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.637 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.717 HD22 ' N ' ' A' ' 1' ' ' MET . 44.0 m-80 -69.97 -22.66 63.13 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.494 -179.504 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.2 pt -63.19 -45.47 98.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -179.27 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 74.7 -132.77 14.55 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.981 -0.847 . . . . 0.0 110.981 -179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.645 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 1.1 mp -73.75 -44.2 6.83 Favored Pre-proline 0 C--N 1.325 -0.495 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 177.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.645 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.5 Cg_exo -41.67 -31.05 1.16 Allowed 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.526 2.151 . . . . 0.0 111.714 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.56 -23.96 37.82 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 178.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.06 -41.49 99.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 120.89 0.376 . . . . 0.0 110.567 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.79 -44.46 94.02 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.548 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.014 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.1 tp -59.1 -44.84 91.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -66.6 -41.86 88.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.116 177.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 4.8 t80 -57.06 -40.94 77.82 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 -177.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.4 t -58.54 -41.95 83.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.178 -179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.9 mm -52.04 -31.71 14.33 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.528 179.149 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.96 -34.98 38.3 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.34 0.59 . . . . 0.0 110.363 178.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 22' ' ' GLY . 19.4 mt -64.5 -43.83 92.86 Favored 'General case' 0 CA--C 1.508 -0.657 0 O-C-N 122.051 -0.406 . . . . 0.0 111.448 -178.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.0 tt -55.92 -40.25 61.54 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.769 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.401 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -85.68 -34.72 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.026 0.441 . . . . 0.0 110.553 -179.667 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.401 ' CD1' HD13 ' A' ' 20' ' ' ILE . 52.5 m-85 -99.47 -71.67 0.69 Allowed 'General case' 0 CA--C 1.513 -0.467 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.064 -179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' A' ' 18' ' ' LEU . . . 123.17 147.18 7.29 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.454 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 64.3 Cg_endo -72.55 -14.01 27.53 Favored 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 122.902 2.401 . . . . 0.0 111.88 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -98.24 -6.27 31.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.376 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.8 mptt -98.78 -16.01 19.08 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.837 178.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.547 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -83.77 -47.95 0.73 Allowed Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.038 0.447 . . . . 0.0 110.193 -179.225 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 37.5 Cg_exo -57.19 -39.33 91.24 Favored 'Trans proline' 0 C--N 1.302 -1.868 0 C-N-CA 122.907 2.405 . . . . 0.0 111.601 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -62.52 -42.52 99.57 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.258 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.3 mt -67.27 -42.18 87.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.123 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.34 -42.84 99.88 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 32.8 mtt-85 -63.79 -50.05 70.51 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 120.919 -0.312 . . . . 0.0 110.767 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.49 -47.59 84.91 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.918 -179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.44 -29.46 70.14 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.021 0.439 . . . . 0.0 109.857 177.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -56.22 -45.12 88.78 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.04 -41.6 90.65 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.976 0.417 . . . . 0.0 110.334 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -63.25 -42.71 99.21 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.786 179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 16.3 mt -72.02 -33.93 68.44 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 121.694 0.759 . . . . 0.0 111.003 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.54 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 10.8 tp -58.19 -40.58 81.89 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.194 -178.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -76.79 -22.4 53.73 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.971 0.415 . . . . 0.0 110.239 -179.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -50.77 64.91 Favored 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.571 -179.211 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.54 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.06 -34.32 77.33 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.425 -178.991 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.1 m -65.09 -39.36 93.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.923 -0.58 . . . . 0.0 109.998 179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.58 -38.77 67.78 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.385 178.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -62.47 -43.5 98.66 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-O 120.951 0.405 . . . . 0.0 110.291 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.727 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.84 -29.91 43.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.802 -178.444 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.7 m -76.99 -28.19 54.98 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 120.984 0.421 . . . . 0.0 110.827 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 89.5 mt -72.25 -22.11 61.28 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.977 -179.221 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.727 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.2 m -58.08 -25.61 26.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.625 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.7 t -63.0 -17.64 62.41 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.442 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.39 38.25 10.08 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 53.7 t0 -90.1 109.36 20.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.785 0.326 . . . . 0.0 110.496 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.641 179.828 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.5 ttp . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -75.17 -1.53 23.61 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.782 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.4 m -102.64 -23.54 13.84 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.152 179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.7 m-80 -77.41 -14.21 59.76 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.788 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.2 pt -63.84 -45.43 97.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 62.9 -142.5 47.78 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.585 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -53.72 -54.37 47.03 Favored Pre-proline 0 C--N 1.332 -0.163 0 CA-C-O 119.417 -0.325 . . . . 0.0 110.626 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo -43.01 -22.38 0.28 Allowed 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 120.879 1.053 . . . . 0.0 111.837 178.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -90.77 -29.1 13.97 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.78 -40.19 96.06 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.584 -0.308 . . . . 0.0 111.2 179.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.53 -45.09 97.63 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.576 -178.426 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.3 tp -58.59 -44.78 89.97 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.39 -41.89 89.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.04 0.447 . . . . 0.0 110.283 178.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -57.36 -42.07 81.35 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.082 -177.484 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -56.83 -42.27 77.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.06 179.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 30.5 mm -53.42 -33.2 21.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.837 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.93 -36.62 56.45 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.115 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.442 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 9.4 mt -63.98 -40.93 97.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.915 -178.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.423 HG22 ' H ' ' A' ' 19' ' ' ILE . 5.5 tt -60.11 -41.44 86.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.967 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.315 -179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.88 -37.75 14.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.75 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -95.38 -72.95 0.6 Allowed 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.037 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.442 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.92 142.19 6.09 Favored Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -68.92 -18.28 41.1 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 122.28 1.987 . . . . 0.0 111.63 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -89.54 -2.82 58.46 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.575 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.4 mptt -100.34 -7.36 24.56 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.841 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.582 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.0 mt -80.7 -41.07 1.2 Allowed Pre-proline 0 C--N 1.325 -0.46 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.43 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 25.1 Cg_exo -64.24 -34.23 57.06 Favored 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.764 2.309 . . . . 0.0 111.466 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -65.28 -39.87 93.14 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.883 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.5 -43.44 96.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.54 -43.62 98.66 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.74 -48.72 75.86 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.24 0.543 . . . . 0.0 110.562 179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.18 -47.79 84.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.489 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.68 -29.07 69.57 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.368 178.219 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.08 -45.52 81.6 Favored Glycine 0 CA--C 1.525 0.716 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.197 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -66.53 -40.33 89.08 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.877 0.37 . . . . 0.0 110.549 179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.74 -42.66 97.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.069 179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.7 mt -72.65 -33.99 66.96 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.669 0.747 . . . . 0.0 111.305 -179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.7 tp -58.74 -40.21 83.13 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.834 -1.075 . . . . 0.0 110.216 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.23 -22.35 55.3 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.339 -0.544 . . . . 0.0 110.131 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.48 -48.19 76.16 Favored 'General case' 0 C--N 1.339 0.129 0 N-CA-C 111.914 0.339 . . . . 0.0 111.914 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.43 -34.67 78.74 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.045 0.45 . . . . 0.0 110.662 -178.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -65.28 -40.19 93.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.809 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.68 -39.59 76.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.958 179.048 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.07 -43.22 99.17 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.185 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.734 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.2 tmmm? -53.83 -30.0 43.37 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.068 -179.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.0 m -76.51 -28.63 56.47 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.136 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.1 mt -70.12 -36.58 74.93 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.989 0.423 . . . . 0.0 110.953 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.734 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.1 m -44.38 150.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.432 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 2.0 m 55.19 7.73 0.22 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.506 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -78.43 38.7 1.87 Allowed Glycine 0 CA--C 1.522 0.515 0 N-CA-C 110.976 -0.849 . . . . 0.0 110.976 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.9 t0 40.91 68.82 0.39 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.996 0.427 . . . . 0.0 111.018 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.955 -1.022 . . . . 0.0 111.21 179.801 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.5 mmm . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.435 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 93.2 m-85 -78.27 -2.95 40.39 Favored 'General case' 0 N--CA 1.449 -0.479 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.669 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.0 m -100.63 -23.6 14.62 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.31 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 43.5 m-80 -68.89 -24.0 64.27 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.519 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.435 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 3.4 pt -61.29 -48.19 90.07 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.671 -179.055 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 76.0 -112.0 3.47 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mm -92.62 -57.31 0.23 Allowed Pre-proline 0 CA--C 1.541 0.618 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.979 179.586 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.46 ' HD2' ' H ' ' A' ' 7' ' ' ILE . 24.3 Cg_exo -28.83 -43.42 0.08 OUTLIER 'Trans proline' 0 N--CA 1.498 1.739 0 C-N-CA 122.524 2.149 . . . . 0.0 112.726 178.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -70.23 -35.7 70.34 Favored Glycine 0 CA--C 1.524 0.621 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.045 -179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.563 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.25 -39.44 90.37 Favored 'General case' 0 C--N 1.32 -0.68 0 O-C-N 122.826 -0.22 . . . . 0.0 111.42 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.918 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.46 -45.89 96.14 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.41 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 39.5 tp -60.1 -43.71 95.38 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 120.598 -0.441 . . . . 0.0 109.84 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.31 -43.17 95.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.592 178.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.99 -42.13 84.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.001 -177.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.918 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.6 t -55.63 -41.26 63.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.005 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.2 mm -53.9 -36.58 30.99 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.777 179.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.28 -32.7 66.85 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.517 0.675 . . . . 0.0 110.118 179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 17.6 mt -63.95 -39.13 93.44 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.656 -178.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.12 -41.92 81.84 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.118 -179.603 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.422 ' N ' HG12 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.24 -37.5 12.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.935 -179.888 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -94.17 -75.73 0.5 Allowed 'General case' 0 C--O 1.23 0.073 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.744 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.97 143.34 6.52 Favored Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 179.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -69.82 -15.89 37.05 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.436 2.091 . . . . 0.0 111.919 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.9 t -90.6 -8.63 49.62 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.514 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 16.9 mmmt -90.88 -24.87 20.09 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.05 -179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.2 mt -68.23 -50.3 30.14 Favored Pre-proline 0 N--CA 1.445 -0.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.518 178.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.55 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 27.0 Cg_endo -58.55 -31.57 94.74 Favored 'Trans proline' 0 N--CA 1.499 1.802 0 C-N-CA 121.644 1.562 . . . . 0.0 112.103 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -65.79 -41.56 91.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.971 0.415 . . . . 0.0 110.911 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.5 mt -64.71 -43.79 96.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.515 -179.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.66 -43.5 98.94 Favored Glycine 0 CA--C 1.521 0.418 0 N-CA-C 110.659 -0.977 . . . . 0.0 110.659 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 85.9 mtt180 -63.65 -46.99 83.14 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.169 0.509 . . . . 0.0 110.699 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.08 -47.8 83.03 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.667 -179.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.69 69.49 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.29 -43.58 84.4 Favored Glycine 0 CA--C 1.526 0.733 0 CA-C-N 114.987 -1.006 . . . . 0.0 111.037 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.9 mmt180 -68.19 -41.84 80.82 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.146 0.498 . . . . 0.0 110.526 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.99 -43.75 94.75 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.308 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.01 -36.49 77.83 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.301 0.572 . . . . 0.0 111.563 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 11.9 tp -58.25 -41.58 84.52 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.265 -178.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.73 -21.3 59.44 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.992 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.72 -48.64 76.24 Favored 'General case' 0 N--CA 1.462 0.14 0 CA-C-O 120.955 0.407 . . . . 0.0 111.85 -178.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.41 -35.02 79.54 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.664 -179.142 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.1 m -65.48 -41.25 93.52 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.131 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.98 -39.6 75.85 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.987 179.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.26 -41.56 99.05 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.068 179.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.586 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.4 tmmm? -52.3 -31.38 32.66 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.054 -178.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.0 -31.66 59.05 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.039 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.463 ' O ' ' O ' ' A' ' 48' ' ' VAL . 58.2 mt -72.33 -21.75 61.27 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.216 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.658 ' O ' ' N ' ' A' ' 50' ' ' GLY . 20.0 m -40.26 162.46 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 -179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 20.1 m -51.62 72.65 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 O-C-N 123.409 0.443 . . . . 0.0 111.534 -178.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.658 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -81.31 37.71 2.41 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 54.0 p-10 -171.4 81.28 0.07 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.871 0.367 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.392 179.931 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.733 ' N ' HD22 ' A' ' 4' ' ' ASN . 77.6 mtm . . . . . 0 N--CA 1.487 1.38 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.4 m-85 -83.48 1.01 43.83 Favored 'General case' 0 N--CA 1.451 -0.4 0 CA-C-O 120.935 0.398 . . . . 0.0 110.664 -179.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -100.37 -24.18 14.58 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.533 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.733 HD22 ' N ' ' A' ' 1' ' ' MET . 42.9 m-80 -70.93 -21.07 62.4 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.634 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.4 pt -62.72 -45.33 99.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.926 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 75.03 -135.67 19.23 Favored Glycine 0 CA--C 1.53 0.971 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -73.38 -43.57 7.25 Favored Pre-proline 0 CA--C 1.531 0.229 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.527 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 86.6 Cg_exo -43.44 -29.82 2.22 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 121.458 1.438 . . . . 0.0 111.488 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.77 -27.48 31.84 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 179.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.709 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.84 -43.01 99.7 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.586 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.68 -45.05 98.2 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.377 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.479 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 56.7 tp -58.23 -46.03 86.66 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.69 -41.32 90.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.01 0.433 . . . . 0.0 110.062 178.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.05 -43.63 82.18 Favored 'General case' 0 N--CA 1.441 -0.892 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.127 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -55.76 -42.17 68.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.306 179.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.474 ' O ' HG22 ' A' ' 19' ' ' ILE . 30.4 mm -52.83 -28.43 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.692 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -84.46 -38.24 20.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.695 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.463 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.4 mt -64.97 -40.52 95.11 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.777 -179.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.532 HG23 ' N ' ' A' ' 20' ' ' ILE . 10.6 tp -58.72 -41.8 83.47 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 C-N-CA 120.352 -0.539 . . . . 0.0 110.097 -179.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.532 ' N ' HG23 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -82.53 -37.29 14.19 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.765 179.12 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.4 m-85 -96.71 -73.25 0.61 Allowed 'General case' 0 C--N 1.341 0.207 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.853 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.463 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 121.74 144.78 6.95 Favored Glycine 0 CA--C 1.532 1.132 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -70.83 -15.86 33.06 Favored 'Trans proline' 0 C--N 1.311 -1.431 0 C-N-CA 122.404 2.069 . . . . 0.0 111.816 179.464 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.5 t -94.56 -0.29 54.67 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.893 0.377 . . . . 0.0 110.587 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -102.81 -8.31 20.89 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.407 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.59 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -84.68 -41.3 0.69 Allowed Pre-proline 0 N--CA 1.45 -0.439 0 C-N-CA 120.922 -0.311 . . . . 0.0 110.17 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.59 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 28.0 Cg_exo -62.41 -34.86 75.34 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.793 2.329 . . . . 0.0 111.569 179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -64.07 -39.18 93.5 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.916 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.1 mt -64.4 -43.19 97.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.112 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.65 -43.84 98.54 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.426 HH12 ' HB3' ' A' ' 27' ' ' PRO . 60.6 mtt85 -64.34 -45.68 86.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.409 . . . . 0.0 110.823 -179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.56 -47.53 83.46 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.62 -179.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.35 -29.07 69.76 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.432 178.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.33 -44.09 84.66 Favored Glycine 0 N--CA 1.443 -0.873 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.894 -178.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -68.5 -43.31 77.11 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.857 0.361 . . . . 0.0 110.726 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -64.14 -43.25 95.82 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.024 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.71 -37.16 79.3 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.229 0.538 . . . . 0.0 111.482 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 42.9 tp -58.17 -41.57 84.16 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.457 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -75.3 -20.91 58.83 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.196 -179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.05 -48.21 77.15 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-O 120.987 0.423 . . . . 0.0 111.733 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.9 -33.96 76.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.685 -179.16 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -64.87 -37.55 88.02 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.845 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.424 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -71.28 -37.06 71.88 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.597 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.6 m -62.5 -42.93 99.83 Favored 'General case' 0 N--CA 1.445 -0.697 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.419 179.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.3 tmmm? -62.31 -43.91 97.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.21 0.528 . . . . 0.0 110.288 -179.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -78.88 -32.98 46.07 Favored 'General case' 0 C--N 1.317 -0.833 0 C-N-CA 120.208 -0.597 . . . . 0.0 111.027 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.726 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.3 tm? -74.02 -48.73 28.09 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-O 121.512 0.672 . . . . 0.0 110.397 -179.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.597 HG12 ' O ' ' A' ' 44' ' ' THR . 9.0 p -58.73 -31.66 44.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.214 -178.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.8 p -66.55 -18.97 65.66 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.612 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 73.34 39.69 50.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -81.11 109.62 15.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.794 0.331 . . . . 0.0 110.563 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.682 -179.875 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.721 ' N ' HD22 ' A' ' 4' ' ' ASN . 78.4 mtm . . . . . 0 N--CA 1.488 1.466 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -84.84 -2.68 58.06 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.015 0.436 . . . . 0.0 110.746 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.71 -23.57 13.81 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.619 -179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.721 HD22 ' N ' ' A' ' 1' ' ' MET . 56.2 m-80 -78.95 -13.9 59.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.817 -179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.3 pt -63.18 -43.78 98.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.083 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.88 -135.59 28.4 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.94 -44.82 11.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 119.703 -0.189 . . . . 0.0 110.867 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.483 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.3 Cg_exo -41.43 -31.53 1.1 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 121.309 1.34 . . . . 0.0 111.139 178.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.03 36.09 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.679 -0.969 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 9.0 tt -61.97 -41.28 97.83 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.066 -0.254 . . . . 0.0 110.758 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.913 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.65 -45.9 96.68 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.549 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.1 tp -59.41 -44.69 92.8 Favored 'General case' 0 C--N 1.323 -0.563 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.242 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.3 mt -65.2 -42.88 95.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.394 179.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -57.18 -42.4 81.11 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.792 -177.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.913 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.9 t -56.7 -41.53 74.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.313 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.0 mm -52.51 -36.13 21.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 C-N-CA 120.417 -0.513 . . . . 0.0 110.142 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.427 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -72.48 -30.61 64.69 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.58 0.705 . . . . 0.0 110.303 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 27.0 mt -68.12 -39.63 82.72 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.534 -0.757 . . . . 0.0 112.186 -178.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.441 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.8 OUTLIER -57.7 -42.92 82.72 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 121.42 0.629 . . . . 0.0 109.398 -179.582 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.496 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.3 tt -79.67 -54.7 10.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 114.958 -1.019 . . . . 0.0 110.236 178.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.496 ' H ' HG23 ' A' ' 20' ' ' ILE . 37.9 m-85 -79.42 -75.54 0.24 Allowed 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.818 -178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 130.14 142.24 5.14 Favored Glycine 0 CA--C 1.543 1.799 0 N-CA-C 110.664 -0.975 . . . . 0.0 110.664 179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -71.98 -24.37 20.82 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.289 1.993 . . . . 0.0 111.093 178.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.86 -6.73 55.54 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 114.259 -1.337 . . . . 0.0 110.496 -176.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -93.51 -23.56 18.31 Favored 'General case' 0 C--O 1.221 -0.443 0 CA-C-N 115.003 -0.999 . . . . 0.0 111.846 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.519 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.4 mt -69.97 -54.05 10.48 Favored Pre-proline 0 CA--C 1.545 0.77 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 178.611 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.519 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -39.14 -50.73 2.68 Favored 'Trans proline' 0 CA--C 1.547 1.131 0 C-N-CA 121.732 1.621 . . . . 0.0 111.561 176.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -63.42 -42.95 98.73 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 111.094 -179.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.2 mt -65.49 -43.62 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.369 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.23 -43.42 98.5 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.523 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 87.4 mtt180 -63.88 -45.96 87.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.243 0.544 . . . . 0.0 110.537 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -46.41 89.56 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.76 -179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.24 -28.37 69.31 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 178.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.96 -44.43 82.62 Favored Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.98 -178.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.4 mmt-85 -66.27 -42.39 88.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 110.541 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.95 -43.82 94.64 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.418 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.44 -35.91 73.65 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.357 0.598 . . . . 0.0 111.36 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 12.3 tp -57.99 -41.73 83.66 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.196 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -74.37 -21.79 59.5 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.094 -0.642 . . . . 0.0 110.121 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.11 -49.06 73.67 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-O 120.873 0.368 . . . . 0.0 111.796 -178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.16 -34.65 78.57 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.524 -179.217 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 43.8 m -65.27 -41.13 94.52 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.83 179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.06 -42.65 66.0 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.994 178.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.95 -43.58 95.39 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.209 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.786 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.68 -28.68 34.88 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.957 -179.028 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -77.05 -28.96 54.95 Favored 'General case' 0 C--N 1.32 -0.715 0 C-N-CA 120.688 -0.405 . . . . 0.0 111.042 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.6 mt -71.25 -28.3 64.07 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 120.814 0.34 . . . . 0.0 111.25 -179.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.786 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.7 m -55.87 -31.04 29.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.244 -178.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.486 ' C ' ' H ' ' A' ' 51' ' ' ASP . 43.0 t -162.87 97.19 0.94 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.305 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -73.48 35.63 0.82 Allowed Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.486 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 -120.64 106.11 11.43 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.682 0.277 . . . . 0.0 110.54 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.677 -179.93 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.589 ' O ' ' N ' ' A' ' 3' ' ' SER . 65.4 mmm . . . . . 0 N--CA 1.487 1.411 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 38.73 19.89 0.0 OUTLIER 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.338 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.589 ' N ' ' O ' ' A' ' 1' ' ' MET . 0.9 OUTLIER -115.86 -40.2 3.37 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 121.174 0.511 . . . . 0.0 110.405 179.903 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 42.1 m-80 -76.79 -13.49 60.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.833 -179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.577 HD12 ' HA3' ' A' ' 9' ' ' GLY . 19.3 pt -61.6 -41.42 90.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.242 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.43 ' N ' HG13 ' A' ' 5' ' ' ILE . . . 74.65 -134.22 17.17 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.495 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 0.5 OUTLIER -76.38 -44.17 3.43 Favored Pre-proline 0 CA--C 1.54 0.594 0 C-N-CA 121.124 -0.231 . . . . 0.0 111.083 179.794 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.495 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 84.1 Cg_exo -42.13 -39.62 6.02 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 121.683 1.588 . . . . 0.0 112.505 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.577 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -75.0 -27.61 64.1 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -64.03 -39.04 93.22 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.491 0.186 . . . . 0.0 111.087 -179.406 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.05 -44.84 95.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.429 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.277 -179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.4 tp -58.96 -44.83 91.55 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -179.839 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.16 -42.47 91.24 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 O-C-N 123.45 0.469 . . . . 0.0 110.437 178.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -57.05 -42.88 81.37 Favored 'General case' 0 N--CA 1.437 -1.11 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.47 -177.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -55.27 -41.9 63.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.575 179.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.429 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.3 mm -54.54 -34.29 28.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.793 179.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.28 -34.76 61.36 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.581 0.705 . . . . 0.0 109.647 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 20.8 mt -64.23 -41.5 96.97 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.273 -177.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.9 -41.12 84.83 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 C-N-CA 120.183 -0.607 . . . . 0.0 109.906 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -83.73 -32.64 8.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.046 179.302 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -99.3 -75.78 0.56 Allowed 'General case' 0 C--N 1.347 0.496 0 CA-C-O 119.321 -0.371 . . . . 0.0 110.314 179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 123.03 121.36 2.66 Favored Glycine 0 CA--C 1.547 2.043 0 CA-C-O 118.811 -0.994 . . . . 0.0 112.685 177.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.474 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 10.1 Cg_endo -52.46 -19.73 10.46 Favored 'Trans proline' 0 N--CA 1.508 2.357 0 C-N-CA 122.529 2.153 . . . . 0.0 112.886 177.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 t -96.79 -15.6 21.25 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 121.541 0.686 . . . . 0.0 110.5 -178.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 41.8 mmtm -101.32 -12.06 18.95 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.073 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.511 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 3.8 mt -86.6 -43.84 0.56 Allowed Pre-proline 0 CA--C 1.541 0.605 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.783 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.511 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 29.1 Cg_exo -60.36 -42.54 40.85 Favored 'Trans proline' 0 N--CA 1.498 1.783 0 C-N-CA 122.633 2.222 . . . . 0.0 112.103 179.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -61.45 -44.96 96.2 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.875 -179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 73.9 mt -68.47 -40.77 82.63 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.266 178.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.17 -42.96 97.41 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 27.1 mtt-85 -65.07 -44.43 88.98 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.217 0.532 . . . . 0.0 110.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.09 -37.75 86.23 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.502 -179.308 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.37 -36.86 45.48 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.682 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -63.26 -48.45 79.2 Favored Glycine 0 CA--C 1.527 0.835 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.631 -178.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 6.8 ppt_? -69.81 -37.9 76.4 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.565 0.698 . . . . 0.0 111.336 -179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.1 m -62.44 -41.84 99.02 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.04 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 39.5 mt -69.07 -33.1 73.01 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.432 0.634 . . . . 0.0 111.257 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.94 -38.81 76.64 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.188 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -81.57 -21.68 38.28 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.548 -0.461 . . . . 0.0 110.501 -178.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -72.22 -46.23 57.02 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.699 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.93 -35.07 78.88 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.965 0.412 . . . . 0.0 110.786 -178.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 49.2 m -65.86 -41.59 91.46 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.806 179.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.8 -43.93 62.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.089 178.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.2 -43.73 97.33 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.208 179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.714 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -56.31 -26.91 53.87 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.263 0.554 . . . . 0.0 109.64 -179.783 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.7 t -75.79 -31.22 59.37 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.994 -179.437 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 56.3 mt -70.24 -32.74 70.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.298 -179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 45' ' ' LYS . 2.2 m -57.85 -27.78 31.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.147 -178.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.507 ' C ' ' H ' ' A' ' 51' ' ' ASP . 17.4 p -173.17 97.73 0.12 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.254 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.67 37.02 0.59 Allowed Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.507 ' H ' ' C ' ' A' ' 49' ' ' SER . 99.0 m-20 -78.44 150.86 32.96 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.869 0.366 . . . . 0.0 110.755 179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.706 -179.997 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.703 ' N ' HD22 ' A' ' 4' ' ' ASN . 95.8 mtp . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -79.56 3.98 17.24 Favored 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.458 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -99.95 -24.38 14.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.361 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.703 HD22 ' N ' ' A' ' 1' ' ' MET . 44.1 m-80 -69.22 -22.98 63.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.67 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.1 pt -63.6 -44.91 98.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.072 -179.524 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.01 -135.88 23.39 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.549 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.95 -44.85 15.03 Favored Pre-proline 0 CA--C 1.532 0.286 0 O-C-N 122.871 -0.193 . . . . 0.0 110.566 179.204 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.504 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -42.32 -31.24 1.69 Allowed 'Trans proline' 0 C--N 1.309 -1.543 0 C-N-CA 121.297 1.331 . . . . 0.0 111.268 178.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.38 -26.8 34.98 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 178.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -62.1 -41.27 98.04 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-O 120.677 0.275 . . . . 0.0 110.778 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.941 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.78 -44.61 97.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.392 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.563 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.5 tp -58.51 -45.98 87.65 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.703 -0.481 . . . . 0.0 109.703 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.6 mm -65.42 -42.15 92.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.086 0.47 . . . . 0.0 110.296 178.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -56.97 -42.49 80.28 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.128 -177.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.941 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.5 t -56.88 -42.36 78.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.962 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.8 mm -52.34 -31.66 15.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.793 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -35.81 34.25 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.01 178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.439 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.0 mt -65.48 -42.05 92.64 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.701 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.5 tt -58.71 -41.83 83.47 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.853 0 C-N-CA 120.013 -0.675 . . . . 0.0 110.21 -179.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.5 -37.62 15.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.748 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -95.86 -70.86 0.7 Allowed 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 121.114 -0.235 . . . . 0.0 110.791 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.439 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.48 143.03 6.21 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 68.3 Cg_endo -72.59 -6.39 18.95 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.363 2.042 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.0 t -105.76 -17.67 14.31 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.135 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 3.0 mmmm -96.12 -15.5 22.11 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.432 ' CB ' ' HD3' ' A' ' 27' ' ' PRO . 1.1 mt -83.54 -59.27 0.37 Allowed Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.834 -179.412 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.432 ' HD3' ' CB ' ' A' ' 26' ' ' LEU . 82.4 Cg_exo -55.39 -33.15 84.6 Favored 'Trans proline' 0 N--CA 1.504 2.115 0 C-N-CA 122.33 2.02 . . . . 0.0 113.267 178.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -61.78 -43.35 99.02 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.425 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.7 mt -65.92 -43.6 92.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.96 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.506 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.17 -43.17 98.66 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 43.3 mtt-85 -65.78 -48.58 71.32 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-O 121.281 0.562 . . . . 0.0 110.816 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.86 -39.33 91.5 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.6 -179.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -78.69 -27.48 45.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.035 178.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.95 -53.22 41.34 Favored Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.411 -177.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.539 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.56 -42.77 98.34 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.337 0.113 . . . . 0.0 111.136 179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.3 m -64.25 -43.38 95.09 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.361 0.6 . . . . 0.0 109.718 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 55.7 mt -73.3 -34.75 65.9 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.311 -179.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 20.5 tp -58.14 -40.79 82.24 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.828 -1.078 . . . . 0.0 109.977 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.84 -21.9 54.36 Favored 'General case' 0 C--N 1.315 -0.929 0 C-N-CA 120.473 -0.491 . . . . 0.0 110.156 -179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.5 -48.41 75.28 Favored 'General case' 0 C--N 1.339 0.124 0 CA-C-O 120.952 0.406 . . . . 0.0 111.573 -178.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.39 -34.39 78.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.633 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 53.7 m -65.34 -39.85 92.92 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.71 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.44 -38.39 77.81 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.034 178.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.01 -42.14 99.74 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.981 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.0 tmmm? -53.1 -31.08 40.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.008 -178.668 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.71 -31.98 59.88 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.892 -179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.6 mt -70.43 -43.68 69.44 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.018 0.437 . . . . 0.0 110.831 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.57 -35.49 56.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.831 179.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 40.3 t -60.22 -43.15 96.24 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.361 -179.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -98.46 58.1 0.98 Allowed Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.8 t0 -66.01 135.45 54.71 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.851 0.357 . . . . 0.0 110.646 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 79.7 mm-40 . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.0 mmm . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.413 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.2 m-85 -80.48 -1.7 42.8 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.686 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.3 m -102.34 -23.25 13.99 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.292 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.3 m-80 -75.91 -14.49 60.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.814 -179.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.413 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.5 pt -65.16 -43.92 95.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.004 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.13 -134.38 27.02 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 -179.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.532 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -70.41 -46.96 19.61 Favored Pre-proline 0 CA--C 1.543 0.7 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.666 179.318 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.484 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.7 Cg_exo -39.43 -38.1 1.4 Allowed 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 121.695 1.597 . . . . 0.0 112.312 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.38 -27.87 58.8 Favored Glycine 0 CA--C 1.528 0.846 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.333 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.532 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.2 tt -63.88 -39.21 93.66 Favored 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 121.219 -0.192 . . . . 0.0 111.074 -179.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.944 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.07 -44.69 95.48 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.391 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 -179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 7.2 mt -58.95 -45.24 90.94 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.581 -0.448 . . . . 0.0 110.023 179.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.4 mt -65.91 -42.29 91.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.825 0 CA-C-O 121.109 0.48 . . . . 0.0 110.327 178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -57.44 -42.38 82.34 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.233 -177.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.944 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.2 t -56.95 -41.07 76.17 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.243 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 32.8 mm -53.69 -34.9 25.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.498 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.0 -34.84 62.0 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.84 178.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.47 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.8 mt -65.15 -41.73 94.47 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.179 -178.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.43 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -59.73 -42.28 88.17 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 C-N-CA 119.794 -0.762 . . . . 0.0 110.013 -179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.91 -38.04 18.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.707 178.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -96.4 -72.78 0.62 Allowed 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 121.21 -0.196 . . . . 0.0 111.115 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.99 145.48 5.95 Favored Glycine 0 CA--C 1.53 1.002 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' O ' ' CG ' ' A' ' 27' ' ' PRO . 50.6 Cg_endo -68.75 -13.0 36.06 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 C-N-CA 122.456 2.104 . . . . 0.0 111.954 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.4 t -107.33 4.15 26.13 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.023 -179.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 13.2 mptt -106.92 -27.71 10.53 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.659 0.266 . . . . 0.0 110.682 -179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.455 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mp -80.5 -63.53 0.34 Allowed Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 116.684 -0.235 . . . . 0.0 110.615 179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -58.14 -28.46 83.88 Favored 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.053 1.835 . . . . 0.0 111.344 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -64.87 -43.31 93.35 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.403 179.27 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.7 mt -65.38 -42.65 94.08 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.518 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.557 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.42 -43.04 97.75 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 -179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 52.0 mtt180 -66.17 -46.91 75.73 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.386 0.613 . . . . 0.0 110.61 179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.8 -38.89 89.78 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.715 -179.187 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -82.39 -28.05 31.68 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.956 178.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.557 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.9 -55.09 29.58 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.613 -177.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.507 ' N ' ' NE ' ' A' ' 35' ' ' ARG . 0.0 OUTLIER -63.12 -43.15 99.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.496 0.188 . . . . 0.0 111.062 -179.939 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.4 m -64.42 -42.89 95.78 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-O 121.262 0.553 . . . . 0.0 109.939 179.431 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 65.7 mt -74.66 -33.97 62.61 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.538 0.685 . . . . 0.0 111.385 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 21.8 tp -58.34 -39.63 79.99 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.012 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -77.11 -22.88 52.02 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.075 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.72 -48.13 72.99 Favored 'General case' 0 N--CA 1.457 -0.108 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.916 -179.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -34.32 77.83 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.608 -178.617 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 41.4 m -65.04 -40.05 94.23 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.933 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.92 -39.54 72.65 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.029 178.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.2 m -63.51 -43.55 96.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.975 179.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.8 tmmm? -53.98 -31.88 52.24 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.76 -178.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -75.63 -31.97 60.06 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.75 -179.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.0 mt -70.85 -44.31 66.67 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.924 0.392 . . . . 0.0 110.818 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.481 HG13 ' N ' ' A' ' 49' ' ' SER . 7.7 p -71.11 -43.18 75.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.89 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.481 ' N ' HG13 ' A' ' 48' ' ' VAL . 40.5 t -62.33 -43.74 98.12 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.646 -0.707 . . . . 0.0 110.608 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.73 32.31 70.6 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' A' ' 52' ' ' GLU . 99.8 m-20 -69.84 142.61 53.06 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.824 0.345 . . . . 0.0 110.561 179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 51' ' ' ASP . 82.1 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.564 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 77.9 mtm . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.417 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 97.1 m-85 -81.62 -1.97 48.53 Favored 'General case' 0 N--CA 1.45 -0.425 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.518 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.1 m -102.1 -23.28 14.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.49 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -75.12 -14.81 60.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.755 -179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.3 pt -65.76 -44.05 93.27 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.086 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.8 -138.16 31.21 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.516 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -67.07 -46.88 52.99 Favored Pre-proline 0 CA--C 1.539 0.531 0 C-N-CA 120.926 -0.31 . . . . 0.0 110.746 179.642 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.46 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 97.1 Cg_exo -40.25 -37.14 1.79 Allowed 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.516 1.477 . . . . 0.0 112.158 179.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.45 -29.41 58.13 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 179.406 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.516 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -63.4 -39.99 95.99 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.603 0.239 . . . . 0.0 111.194 -179.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.912 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.59 -45.49 97.18 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 -179.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.519 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -59.94 -44.89 94.1 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.475 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.1 mt -64.07 -43.47 97.52 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.452 179.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -57.4 -42.34 82.06 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.388 -177.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.912 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.1 t -56.88 -41.49 76.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.634 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.499 ' O ' HG22 ' A' ' 20' ' ' ILE . 39.3 mm -50.87 -35.14 14.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.661 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.44 ' O ' ' CD2' ' A' ' 21' ' ' PHE . . . -76.3 -30.76 57.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.916 178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.409 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . 19.4 mt -71.79 -45.57 61.13 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.697 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.2 tp -57.91 -43.93 85.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 -179.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 21' ' ' PHE . 5.2 tt -72.83 -53.76 17.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.434 -0.803 . . . . 0.0 109.687 177.245 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.548 ' N ' HG23 ' A' ' 20' ' ' ILE . 13.3 m-85 -86.31 -79.91 0.25 Allowed 'General case' 0 C--O 1.235 0.297 0 CA-C-O 119.186 -0.435 . . . . 0.0 111.238 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 129.43 128.22 3.02 Favored Glycine 0 CA--C 1.559 2.817 0 C-N-CA 120.687 -0.768 . . . . 0.0 113.979 178.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.496 ' O ' ' HD2' ' A' ' 27' ' ' PRO . 11.0 Cg_endo -54.07 -29.64 56.22 Favored 'Trans proline' 0 N--CA 1.512 2.583 0 C-N-CA 122.655 2.237 . . . . 0.0 113.206 177.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 3.4 t -74.93 -36.71 62.15 Favored 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 109.214 -0.661 . . . . 0.0 109.214 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 6.6 tptt -89.75 -7.42 54.51 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -177.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.479 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 7.7 tp -76.06 -55.2 1.89 Allowed Pre-proline 0 CA--C 1.554 1.131 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.496 ' HD2' ' O ' ' A' ' 23' ' ' PRO . 7.4 Cg_endo -55.0 -47.22 27.78 Favored 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.748 2.299 . . . . 0.0 112.218 176.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -59.83 -45.57 91.98 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.59 -0.732 . . . . 0.0 112.399 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 92.0 mt -65.02 -42.35 94.42 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.547 -179.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.64 -43.56 97.61 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 56.4 mtt85 -63.55 -47.44 81.56 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.08 0.467 . . . . 0.0 110.801 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.98 -47.38 85.09 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.694 -179.014 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.82 69.58 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.281 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.43 -43.6 85.1 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 114.975 -1.012 . . . . 0.0 111.025 -178.471 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.5 mmt180 -68.28 -41.07 81.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.149 0.5 . . . . 0.0 110.674 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.65 -43.8 95.71 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.311 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.4 mt -69.13 -35.91 76.91 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.441 0.638 . . . . 0.0 111.499 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.4 tp -58.08 -41.79 84.18 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.997 -1.001 . . . . 0.0 110.427 -178.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.4 ' HG2' ' H ' ' A' ' 39' ' ' GLU . 9.0 pt-20 -75.6 -21.41 57.82 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.026 -179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.47 -48.61 74.61 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-O 120.859 0.361 . . . . 0.0 111.818 -178.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.82 78.89 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.497 -178.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.7 m -65.33 -40.45 93.69 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.758 179.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.37 -40.6 73.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.968 178.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.42 -42.88 98.72 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.173 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.719 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -53.85 -29.76 42.58 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.951 -179.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.4 m -76.51 -29.69 56.9 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.165 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.471 ' O ' ' N ' ' A' ' 50' ' ' GLY . 58.7 mt -70.2 -35.47 73.94 Favored 'General case' 0 C--N 1.333 -0.135 0 CA-C-O 120.93 0.395 . . . . 0.0 111.062 -179.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.719 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.1 m -41.45 142.22 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.531 -179.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.7 t 54.18 5.93 0.09 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.603 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . -95.18 38.6 3.07 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -143.54 125.18 14.94 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.811 0.339 . . . . 0.0 110.529 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 45.5 tp10 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.459 -179.827 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 ttp . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -78.41 -2.47 38.48 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.851 -179.633 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.52 -23.37 13.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.266 179.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 70.0 m-80 -79.15 -13.6 59.62 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.83 -179.939 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.7 pt -63.18 -43.5 98.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.878 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 64.6 -137.73 39.76 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.506 -1.038 . . . . 0.0 110.506 -179.595 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.53 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -64.75 -48.0 73.99 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.538 179.226 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.9 Cg_exo -38.75 -37.67 0.84 Allowed 'Trans proline' 0 N--CA 1.49 1.274 0 C-N-CA 121.549 1.5 . . . . 0.0 112.226 179.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.66 -29.04 58.27 Favored Glycine 0 CA--C 1.528 0.857 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.498 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.53 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -63.48 -39.18 93.78 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.422 0.153 . . . . 0.0 111.06 -179.41 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.11 -45.39 95.82 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.431 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -179.718 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.6 tt -59.85 -44.06 94.31 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.169 179.855 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 mt -65.99 -42.4 91.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.419 178.769 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -57.4 -41.69 80.8 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.089 -177.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.5 t -57.26 -41.99 79.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.077 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.6 mm -52.57 -35.43 20.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.189 179.78 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.452 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.35 -30.31 63.24 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.447 0.642 . . . . 0.0 110.189 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.491 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.9 mt -68.67 -40.11 80.31 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.194 -178.814 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.446 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.46 -42.69 81.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 C-N-CA 119.991 -0.683 . . . . 0.0 109.405 -179.111 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.515 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.2 tt -79.51 -55.36 9.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.982 178.684 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.515 ' H ' HG23 ' A' ' 20' ' ' ILE . 35.4 m-85 -79.71 -73.82 0.33 Allowed 'General case' 0 C--N 1.333 -0.143 0 C-N-CA 120.969 -0.292 . . . . 0.0 111.223 -179.428 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.491 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.19 146.56 8.13 Favored Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.78 -0.928 . . . . 0.0 110.78 179.783 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -71.31 -12.31 29.67 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.63 2.22 . . . . 0.0 111.817 179.619 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -102.25 -7.22 22.31 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.802 0.334 . . . . 0.0 110.557 179.993 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.4 mmmt -101.92 -22.43 14.32 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.803 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.412 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -77.62 -50.74 1.96 Allowed Pre-proline 0 C--N 1.328 -0.329 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.085 -179.959 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 35.5 Cg_exo -62.83 -29.31 76.46 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 122.231 1.954 . . . . 0.0 112.361 -179.74 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -66.79 -40.92 88.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.079 0.466 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 94.7 mt -65.29 -43.13 95.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.823 -179.891 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.35 -43.51 98.55 Favored Glycine 0 CA--C 1.521 0.423 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.387 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 86.8 mtt180 -63.86 -45.56 88.94 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.185 0.517 . . . . 0.0 110.629 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.43 84.63 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.826 -179.126 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.04 -28.9 69.8 Favored 'General case' 0 CA--C 1.515 -0.368 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 178.562 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.39 -44.63 85.01 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.152 -0.931 . . . . 0.0 110.941 -178.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -66.97 -41.6 86.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.037 0.446 . . . . 0.0 110.734 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.78 -43.57 95.99 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.213 179.874 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.1 mt -69.62 -36.11 75.87 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-O 121.3 0.571 . . . . 0.0 111.462 -179.566 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.405 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 13.5 tp -58.3 -41.71 85.05 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.197 -178.872 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -74.72 -21.22 59.49 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 120.108 -0.637 . . . . 0.0 109.959 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.89 -48.59 76.05 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-O 120.83 0.348 . . . . 0.0 111.811 -178.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.405 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.77 -34.43 78.16 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.655 -179.104 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 44.8 m -65.12 -39.29 92.89 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.74 179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.05 -38.68 79.26 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.998 179.018 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.75 -43.62 98.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.058 179.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.736 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -55.45 -27.64 49.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.231 0.539 . . . . 0.0 109.699 -179.576 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.94 -31.52 59.13 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.253 -179.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -69.68 -36.5 76.06 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.873 0.368 . . . . 0.0 111.112 -179.331 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.736 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.5 m -43.26 141.91 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.437 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.463 ' C ' ' H ' ' A' ' 51' ' ' ASP . 2.3 m 48.17 29.94 2.0 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.421 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -70.95 40.16 0.54 Allowed Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 -179.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.463 ' H ' ' C ' ' A' ' 49' ' ' SER . 38.5 t70 -85.92 111.24 20.05 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.831 0.348 . . . . 0.0 110.682 -179.983 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 18.8 pt-20 . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.663 -179.93 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.723 ' N ' HD22 ' A' ' 4' ' ' ASN . 96.3 mtp . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -85.08 -2.36 57.91 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-O 120.981 0.42 . . . . 0.0 110.552 -179.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.18 -23.39 14.04 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.569 -179.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.723 HD22 ' N ' ' A' ' 1' ' ' MET . 47.8 m-80 -76.85 -14.39 59.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.711 179.947 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.1 pt -64.96 -43.73 96.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.123 -179.823 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.81 -137.1 36.2 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 -179.387 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.574 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.45 -46.44 48.42 Favored Pre-proline 0 C--N 1.327 -0.392 0 O-C-N 122.659 -0.318 . . . . 0.0 110.939 179.828 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.48 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.0 Cg_exo -40.56 -32.28 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 121.372 1.381 . . . . 0.0 111.209 178.493 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.87 -28.12 35.83 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.748 -0.941 . . . . 0.0 110.748 178.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.574 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.84 -41.62 98.03 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 121.041 -0.264 . . . . 0.0 110.756 -179.559 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.67 -45.71 97.06 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.351 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.971 -178.669 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.3 tp -59.93 -43.92 94.65 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 -179.777 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.9 mt -65.49 -42.6 93.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 O-C-N 123.503 0.502 . . . . 0.0 110.687 178.642 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -57.22 -41.61 79.78 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.832 -177.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.6 t -58.21 -42.34 83.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.274 179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.412 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 34.0 mm -51.81 -33.76 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.93 179.721 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.43 -35.15 58.68 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.057 178.786 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.7 mt -65.74 -41.43 92.2 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.974 -178.758 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.412 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 5.2 tt -59.45 -41.62 85.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.97 -179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.46 -39.5 17.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.936 178.869 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -94.29 -69.15 0.76 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 121.079 -0.248 . . . . 0.0 111.36 179.875 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.457 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 119.43 143.28 6.99 Favored Glycine 0 CA--C 1.532 1.125 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.432 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -69.62 -13.7 35.41 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.402 2.068 . . . . 0.0 111.375 179.73 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.9 t -96.92 -6.29 36.04 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.691 179.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.6 mptt -100.92 -15.81 17.41 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.812 179.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.524 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -83.34 -47.34 0.8 Allowed Pre-proline 0 CA--C 1.535 0.385 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 179.778 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.524 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.2 Cg_exo -60.52 -32.97 94.23 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.233 179.013 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -63.35 -39.96 95.98 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.855 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 96.8 mt -64.99 -43.21 96.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.44 -179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.9 -43.69 97.82 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.42 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.524 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 63.9 mtt180 -64.86 -43.33 93.34 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.188 0.518 . . . . 0.0 110.297 179.508 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -43.96 97.81 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.799 -179.109 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.85 -28.29 69.45 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 178.211 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.65 -43.84 79.26 Favored Glycine 0 CA--C 1.526 0.75 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.002 -178.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.524 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 21.9 mmt-85 -66.17 -40.01 90.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.3 0.571 . . . . 0.0 110.424 179.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -63.25 -43.42 98.06 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.109 -0.951 . . . . 0.0 109.955 179.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.8 mt -68.69 -36.7 78.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.328 0.585 . . . . 0.0 111.302 -179.783 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.421 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 14.6 tp -58.05 -42.31 85.14 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.329 -178.831 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -73.96 -21.35 60.05 Favored 'General case' 0 C--N 1.312 -1.052 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.036 179.934 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.81 -48.4 77.0 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-O 120.825 0.345 . . . . 0.0 111.922 -178.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.03 -34.08 77.58 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.164 0.507 . . . . 0.0 110.534 -179.133 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 40.5 m -64.96 -38.76 92.03 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.7 179.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.9 -36.76 78.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.554 178.698 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.4 m -63.2 -43.22 98.77 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.755 179.587 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -53.73 -32.14 50.99 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.759 -179.158 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.8 m -75.86 -31.78 59.44 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.888 180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 96.1 mt -70.72 -43.55 68.69 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-O 120.907 0.384 . . . . 0.0 110.603 -179.641 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -72.54 -28.92 29.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.743 179.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 41.1 t -61.13 -43.62 98.6 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.584 -179.348 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 146.81 35.33 0.06 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.581 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -103.49 110.76 22.91 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.685 0.279 . . . . 0.0 110.649 179.707 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.09 -0.957 . . . . 0.0 110.607 179.86 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.708 ' N ' HD22 ' A' ' 4' ' ' ASN . 76.4 mtp . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -75.22 0.66 15.72 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.533 -179.728 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -102.34 -23.77 13.94 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.46 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.708 HD22 ' N ' ' A' ' 1' ' ' MET . 57.3 m-80 -77.45 -14.3 59.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.73 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.6 pt -63.69 -43.48 98.09 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.732 -179.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 67.19 -135.85 32.11 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 -179.493 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.54 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -68.86 -46.01 32.15 Favored Pre-proline 0 CA--C 1.532 0.267 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 178.604 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.511 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 83.5 Cg_exo -40.18 -31.42 0.54 Allowed 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 121.415 1.41 . . . . 0.0 111.521 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.73 -27.99 30.53 Favored Glycine 0 CA--C 1.527 0.828 0 N-CA-C 110.71 -0.956 . . . . 0.0 110.71 179.408 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.705 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.16 -41.69 97.23 Favored 'General case' 0 N--CA 1.455 -0.212 0 O-C-N 122.647 -0.325 . . . . 0.0 110.461 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.925 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.55 97.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.389 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 tp -58.23 -45.8 87.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -179.509 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.5 mm -65.55 -41.49 90.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.074 0.464 . . . . 0.0 110.217 178.187 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.01 -43.24 81.58 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.06 -177.348 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.925 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.56 -42.13 75.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.428 179.876 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 28.8 mm -53.44 -31.65 19.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.298 0.571 . . . . 0.0 109.904 179.699 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.15 -31.85 38.93 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.357 179.316 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.448 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 10.6 mt -70.37 -42.12 72.21 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -179.74 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 7.6 tt -58.41 -41.31 81.18 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 C-N-CA 120.558 -0.457 . . . . 0.0 109.792 -179.689 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -80.61 -55.69 8.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.661 178.286 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' N ' HG23 ' A' ' 20' ' ' ILE . 31.9 m-85 -80.81 -73.48 0.37 Allowed 'General case' 0 N--CA 1.457 -0.118 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.287 -179.4 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 123.95 145.94 6.86 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 110.399 -1.08 . . . . 0.0 110.399 -179.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 62.9 Cg_endo -70.76 -15.97 33.37 Favored 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.613 2.209 . . . . 0.0 111.763 179.626 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.4 t -93.51 -26.08 17.32 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.881 -179.803 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -72.85 -40.52 65.64 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.14 0.495 . . . . 0.0 109.986 179.948 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.45 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 4.1 mp -56.69 -62.75 4.43 Favored Pre-proline 0 C--N 1.319 -0.738 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.571 -179.671 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.45 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 18.2 Cg_endo -57.13 -35.32 98.88 Favored 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.037 1.824 . . . . 0.0 111.384 -179.576 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -69.6 -45.75 67.88 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 66.4 mt -65.24 -41.99 92.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.223 179.58 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.91 -43.01 95.04 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 -179.403 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.9 mtt85 -63.42 -44.62 94.09 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-O 120.944 0.402 . . . . 0.0 110.849 179.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.11 -47.04 86.4 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.816 -178.879 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.53 70.39 Favored 'General case' 0 CA--C 1.515 -0.367 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.71 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.79 -45.13 86.6 Favored Glycine 0 N--CA 1.443 -0.883 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.805 -178.498 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.5 mmt85 -65.43 -41.23 93.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.814 0.34 . . . . 0.0 110.535 179.842 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.58 -43.93 95.53 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.924 179.816 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 21.8 mt -70.35 -35.1 73.35 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.464 0.65 . . . . 0.0 111.365 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 16.0 tp -58.56 -40.51 83.3 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.25 -179.179 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -77.04 -21.98 53.69 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.086 -0.645 . . . . 0.0 110.373 -179.361 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.04 -48.99 71.88 Favored 'General case' 0 C--N 1.339 0.114 0 CA-C-O 120.852 0.358 . . . . 0.0 111.797 -179.121 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.69 -34.24 77.41 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.425 -178.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.1 m -64.9 -39.42 93.5 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.681 179.625 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.92 -39.74 69.28 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.335 179.326 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -62.6 -43.33 99.09 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.804 179.268 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.734 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.83 -28.3 34.73 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.539 -179.408 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t -76.76 -31.68 57.23 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.409 -179.793 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 70.2 mt -70.8 -20.58 62.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.204 -179.227 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.734 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.5 m -56.22 -41.02 68.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.647 -178.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.44 ' N ' HG23 ' A' ' 48' ' ' VAL . 4.3 m -99.85 -8.58 23.92 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.436 179.852 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -74.54 40.16 1.1 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 -179.696 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.438 ' H ' ' C ' ' A' ' 49' ' ' SER . 66.3 t0 43.06 93.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.931 0.396 . . . . 0.0 110.862 -179.976 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.841 -179.932 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 93.8 mmm . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 -82.89 -1.56 52.48 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.522 179.995 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -98.43 -22.24 16.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.153 179.944 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.2 m-80 -67.45 -30.66 70.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.466 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.49 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.4 pt -59.68 -53.86 42.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.464 -179.787 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 94.5 -125.66 8.39 Favored Glycine 0 CA--C 1.53 0.981 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.636 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 11.2 tp -91.87 -26.16 0.28 Allowed Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 113.257 0.836 . . . . 0.0 113.257 179.778 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.636 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 33.8 Cg_exo -57.69 -35.15 98.91 Favored 'Trans proline' 0 N--CA 1.5 1.879 0 C-N-CA 122.263 1.976 . . . . 0.0 112.443 179.326 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -66.88 -30.71 76.5 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.6 tt -62.61 -41.5 99.03 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.72 -0.24 . . . . 0.0 111.078 -179.168 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.939 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.43 -44.8 97.0 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.449 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.512 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.5 tp -59.04 -44.81 91.82 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.762 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.6 mt -66.31 -42.27 90.45 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.3 178.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.7 t80 -56.85 -44.0 81.71 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.649 -177.29 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.939 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -54.82 -42.62 63.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.55 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.3 mm -53.07 -33.5 19.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.285 0.564 . . . . 0.0 109.96 -179.911 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.37 -31.81 54.57 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.381 179.293 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -70.42 -41.48 72.87 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.212 -179.209 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.7 tt -59.17 -41.43 83.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 C-N-CA 120.323 -0.551 . . . . 0.0 109.584 179.947 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.511 HG23 ' N ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -79.36 -54.44 11.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.108 178.306 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.511 ' N ' HG23 ' A' ' 20' ' ' ILE . 52.7 m-85 -82.39 -74.9 0.33 Allowed 'General case' 0 C--O 1.233 0.204 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.831 -178.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.64 142.89 5.09 Favored Glycine 0 CA--C 1.539 1.554 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 179.853 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -72.9 -25.17 16.88 Favored 'Trans proline' 0 N--CA 1.489 1.245 0 CA-C-N 119.377 1.589 . . . . 0.0 111.415 178.684 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.46 7.88 36.61 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.848 -178.168 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 11.1 mptt -104.86 -42.02 5.47 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.754 179.696 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.567 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 4.7 mt -58.21 -41.3 88.88 Favored Pre-proline 0 C--N 1.322 -0.612 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.435 -179.111 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 30.6 Cg_exo -62.15 -45.99 14.11 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.335 2.024 . . . . 0.0 111.113 179.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -67.6 -42.98 81.57 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.951 179.73 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 62.7 mt -65.04 -43.14 96.03 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.732 -0.667 . . . . 0.0 110.471 -179.831 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.98 -43.28 98.3 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.476 -1.049 . . . . 0.0 110.476 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 45.5 mtt-85 -63.33 -46.68 85.5 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 179.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.61 -48.35 81.32 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.721 -179.159 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.48 -28.82 69.48 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.38 -43.54 84.86 Favored Glycine 0 CA--C 1.526 0.735 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.081 -178.302 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.6 mmt180 -66.69 -40.91 88.73 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.989 0.424 . . . . 0.0 110.687 179.916 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.2 m -63.82 -42.11 97.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.494 179.782 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 12.4 mt -63.15 -37.39 87.05 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.852 -179.057 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.421 HD23 ' HZ3' ' A' ' 41' ' ' LYS . 52.9 mt -58.78 -36.42 74.39 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.516 0.674 . . . . 0.0 109.621 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -73.89 -24.34 59.7 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.208 -179.666 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -66.49 -51.35 57.64 Favored 'General case' 0 CA--C 1.528 0.103 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.926 -178.722 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.421 ' HZ3' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -65.31 -34.3 78.01 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.07 0.462 . . . . 0.0 110.446 -179.194 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.9 m -64.89 -38.64 91.65 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.666 179.959 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.55 -41.89 71.87 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.083 178.811 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.27 -44.1 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.99 179.313 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.688 ' O ' HG22 ' A' ' 48' ' ' VAL . 5.2 ttmt -54.93 -27.66 45.0 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.834 -179.678 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -76.01 -32.12 59.25 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.249 -179.27 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.46 ' O ' ' N ' ' A' ' 51' ' ' ASP . 56.6 mt -69.55 -38.44 77.46 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.818 0.342 . . . . 0.0 111.25 -179.209 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.688 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.2 m -38.36 129.1 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.647 -179.434 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.462 ' C ' ' H ' ' A' ' 51' ' ' ASP . 1.5 m 66.24 -57.45 0.36 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.368 -179.71 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -78.18 28.46 1.97 Allowed Glycine 0 CA--C 1.52 0.35 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.462 ' H ' ' C ' ' A' ' 49' ' ' SER . 44.0 t0 -83.01 110.4 17.93 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.441 -0.379 . . . . 0.0 110.282 179.464 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.3 tp10 . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.451 -179.752 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.6 mtp . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -82.47 -3.18 55.32 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-O 120.97 0.414 . . . . 0.0 110.488 -179.93 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.5 m -102.57 -23.29 13.89 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.421 179.919 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -76.71 -14.35 59.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.751 -179.827 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.5 pt -64.98 -43.81 96.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.006 -179.761 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 65.98 -137.4 36.11 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 -179.298 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.565 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -67.26 -46.48 50.52 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 119.49 -0.29 . . . . 0.0 110.816 179.444 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.458 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 88.0 Cg_exo -40.81 -30.93 0.62 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.076 1.184 . . . . 0.0 111.251 178.5 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -84.73 -28.33 32.42 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 178.927 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -62.1 -40.39 95.73 Favored 'General case' 0 N--CA 1.455 -0.218 0 C-N-CA 121.188 -0.205 . . . . 0.0 110.89 -179.718 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.61 -45.62 97.01 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.397 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.766 -179.093 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.2 tp -59.84 -43.94 94.35 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 -179.875 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.5 mt -65.65 -42.37 92.61 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.546 178.662 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -57.74 -41.67 82.35 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.877 -177.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 22.4 t -57.12 -42.08 78.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.882 -179.911 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.8 mm -52.28 -36.05 20.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.187 179.899 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.432 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -73.12 -30.91 63.96 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.364 0.602 . . . . 0.0 110.122 179.54 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.487 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.0 mt -67.69 -40.37 84.38 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.79 -0.641 . . . . 0.0 112.268 -178.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.448 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -57.49 -43.26 82.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 120.014 -0.675 . . . . 0.0 109.265 -179.044 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.521 HG23 ' H ' ' A' ' 21' ' ' PHE . 1.4 tt -79.02 -56.07 8.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.105 178.601 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.521 ' H ' HG23 ' A' ' 20' ' ' ILE . 40.3 m-85 -78.58 -72.64 0.37 Allowed 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.461 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.487 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 117.78 143.76 7.5 Favored Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.8 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.95 -14.93 32.62 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.664 2.243 . . . . 0.0 111.385 179.437 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 t -87.01 -10.91 51.96 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.52 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -93.19 -20.41 20.49 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.337 -179.459 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.512 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 18.6 mt -70.4 -54.32 9.04 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 178.146 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.1 Cg_exo -38.09 -52.28 1.84 Allowed 'Trans proline' 0 N--CA 1.489 1.24 0 C-N-CA 122.507 2.138 . . . . 0.0 111.329 176.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -62.1 -43.55 98.58 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-O 121.045 0.45 . . . . 0.0 111.047 179.807 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 87.4 mt -65.9 -43.41 92.97 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.433 179.59 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.2 -43.62 98.25 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -179.377 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 88.7 mtt180 -63.5 -47.92 79.75 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.119 0.485 . . . . 0.0 110.489 179.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.2 -49.08 77.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.874 -179.18 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.32 -28.1 69.07 Favored 'General case' 0 CA--C 1.515 -0.389 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 178.344 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.81 -43.29 80.91 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.978 -178.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -67.47 -43.23 81.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.191 0.519 . . . . 0.0 110.523 179.841 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.6 m -64.24 -43.92 93.43 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.1 mt -67.29 -37.4 83.34 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 121.379 0.609 . . . . 0.0 111.528 -179.322 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 44.4 tp -58.04 -41.96 84.34 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.936 -178.992 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.17 -20.5 57.48 Favored 'General case' 0 C--N 1.311 -1.108 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.793 179.854 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.61 -48.71 73.89 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.668 -178.701 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.9 -34.51 77.56 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.609 -179.064 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.8 m -65.06 -39.14 92.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.757 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.428 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -69.28 -39.14 78.55 Favored 'General case' 0 CA--C 1.514 -0.407 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.425 178.788 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.599 ' O ' HG12 ' A' ' 48' ' ' VAL . 2.8 m -62.12 -43.69 98.28 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.919 179.77 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 3.5 tmmt? -62.1 -43.36 99.01 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.085 0.469 . . . . 0.0 110.422 -179.392 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -77.99 -34.72 50.72 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.882 179.787 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.692 HD13 ' C ' ' A' ' 47' ' ' LEU . 2.2 tm? -73.45 -47.58 40.39 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-O 121.564 0.697 . . . . 0.0 110.871 -179.615 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.599 HG12 ' O ' ' A' ' 44' ' ' THR . 9.9 p -62.71 -30.93 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.21 -179.032 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 13.4 t -60.9 -42.64 98.42 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.337 179.782 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 80.43 38.46 17.59 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.789 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 59.3 t0 -89.28 110.16 20.96 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.777 0.322 . . . . 0.0 110.74 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.976 -1.012 . . . . 0.0 110.332 179.92 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mmm . . . . . 0 N--CA 1.489 1.512 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 84.6 m-85 -79.28 -3.35 45.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.553 -179.889 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.7 m -102.4 -23.09 13.98 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.391 179.917 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -74.79 -14.95 60.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.65 -179.808 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.4 pt -66.21 -44.0 91.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.049 -179.963 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.52 -137.08 28.6 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.286 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.57 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -70.02 -45.26 22.46 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 119.688 -0.196 . . . . 0.0 110.745 179.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 84.6 Cg_exo -41.64 -30.52 1.03 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 121.19 1.26 . . . . 0.0 111.289 178.831 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.59 -27.35 32.72 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 178.972 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.57 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.36 -40.36 96.17 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 121.008 -0.277 . . . . 0.0 110.801 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.93 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.56 -44.81 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.4 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.822 -179.113 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 43.7 tp -58.95 -44.44 91.42 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.811 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 mt -66.42 -41.73 89.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.186 178.198 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.8 t80 -57.45 -41.94 81.51 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.886 -177.505 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.93 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.8 t -57.38 -41.74 79.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.25 179.726 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 39.8 mm -52.17 -36.63 20.97 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.33 179.931 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -73.89 -31.67 63.23 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.521 0.677 . . . . 0.0 110.122 179.25 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.472 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.6 mt -65.14 -38.85 91.95 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 116.026 -0.533 . . . . 0.0 111.607 -178.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.464 ' H ' HG23 ' A' ' 19' ' ' ILE . 0.6 OUTLIER -58.49 -41.91 83.02 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 C-N-CA 120.168 -0.613 . . . . 0.0 110.106 -179.521 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.42 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -85.13 -38.1 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.15 -179.807 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -93.77 -71.07 0.67 Allowed 'General case' 0 N--CA 1.461 0.123 0 C-N-CA 121.038 -0.265 . . . . 0.0 110.785 179.858 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.472 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.09 144.24 6.74 Favored Glycine 0 CA--C 1.534 1.251 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_endo -71.89 -12.13 28.2 Favored 'Trans proline' 0 N--CA 1.498 1.748 0 C-N-CA 122.564 2.176 . . . . 0.0 111.476 179.333 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.9 t -96.86 -15.95 20.98 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.381 179.747 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.56 -17.97 30.79 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 116.169 -0.468 . . . . 0.0 109.86 179.579 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 mp -78.11 -55.15 1.18 Allowed Pre-proline 0 CA--C 1.541 0.602 0 C-N-CA 120.625 -0.43 . . . . 0.0 109.865 179.925 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.522 ' HB3' HH12 ' A' ' 31' ' ' ARG . 41.1 Cg_exo -57.47 -30.38 87.99 Favored 'Trans proline' 0 N--CA 1.503 2.068 0 C-N-CA 122.04 1.827 . . . . 0.0 111.9 179.113 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -63.9 -42.22 97.5 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.191 0.519 . . . . 0.0 109.608 178.936 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.4 -42.8 94.36 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.655 179.282 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -59.54 -43.35 97.66 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 -179.354 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.522 HH12 ' HB3' ' A' ' 27' ' ' PRO . 59.9 mtt85 -63.59 -49.57 72.85 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.261 0.553 . . . . 0.0 110.572 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.13 -48.4 81.8 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.785 -179.151 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.54 -28.73 69.38 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.14 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -55.17 -45.42 82.46 Favored Glycine 0 CA--C 1.525 0.668 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.082 -178.172 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 27.3 mmm-85 -66.32 -40.97 90.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.841 0.353 . . . . 0.0 110.479 179.691 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.67 -43.14 97.57 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.97 179.516 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.3 mt -70.89 -35.42 72.31 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.475 0.655 . . . . 0.0 111.287 -179.543 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.0 tp -58.15 -41.62 84.13 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.363 -179.104 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -75.49 -21.54 57.96 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 120.31 -0.556 . . . . 0.0 110.031 179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.46 75.74 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.843 0.354 . . . . 0.0 111.803 -178.795 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.38 77.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.544 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.1 m -65.13 -40.05 93.91 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.825 179.753 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -71.31 -40.32 70.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.087 179.049 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.8 m -63.2 -42.1 99.27 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.976 179.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -52.84 -31.67 40.4 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.86 -178.722 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.6 m -75.52 -32.12 60.39 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.1 -179.838 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.38 -43.58 69.78 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 121.011 0.434 . . . . 0.0 110.836 -179.887 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.76 -31.94 38.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.906 179.643 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.6 t -59.82 -43.6 94.44 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.528 -179.337 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.435 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . 69.87 35.77 73.08 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.281 -0.727 . . . . 0.0 111.281 179.596 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.435 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 5.0 p-10 43.84 36.34 1.32 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.019 0.438 . . . . 0.0 110.83 179.885 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 . . . . . 0 C--N 1.325 -0.492 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.474 179.96 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.1 mmm . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -82.88 -0.14 46.88 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.721 179.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.0 -23.21 14.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.433 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 69.7 m-80 -75.69 -14.65 60.35 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.875 -179.882 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 5.5 pt -65.86 -43.91 92.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.31 -135.72 27.69 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.398 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.562 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -70.52 -45.17 18.54 Favored Pre-proline 0 CA--C 1.536 0.404 0 CA-C-O 119.7 -0.19 . . . . 0.0 110.528 178.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.497 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 79.7 Cg_exo -41.15 -31.32 0.83 Allowed 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 121.32 1.347 . . . . 0.0 111.417 178.698 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -86.57 -26.79 31.63 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 178.987 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.562 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.3 tt -61.67 -40.28 94.4 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.924 179.908 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.917 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.09 -44.78 95.76 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.707 -179.158 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.503 ' O ' HD13 ' A' ' 12' ' ' LEU . 0.2 OUTLIER -58.74 -46.28 87.77 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.318 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -64.49 -42.15 94.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 123.606 0.566 . . . . 0.0 110.396 178.857 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.0 t80 -57.52 -42.35 82.67 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.863 -177.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.917 HG23 ' O ' ' A' ' 11' ' ' ILE . 17.0 t -57.2 -41.75 78.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.602 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.3 mm -51.9 -31.48 13.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.786 179.654 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.72 -35.75 29.39 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.734 179.073 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.415 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.0 mt -64.84 -42.23 95.1 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.115 -178.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.4 -43.21 89.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 C-N-CA 120.45 -0.5 . . . . 0.0 109.89 -178.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -38.69 19.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.113 178.662 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -95.94 -70.08 0.73 Allowed 'General case' 0 C--N 1.345 0.401 0 C-N-CA 121.102 -0.239 . . . . 0.0 111.527 -179.839 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.458 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 129.01 143.8 5.61 Favored Glycine 0 C--N 1.342 0.896 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 179.779 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.7 -18.29 53.28 Favored 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.315 2.01 . . . . 0.0 111.578 -179.774 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.2 t -85.85 -3.1 58.83 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.594 -179.875 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 7.1 mptt -101.27 -1.85 32.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.807 179.752 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.679 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.1 mm? -84.4 -38.29 0.66 Allowed Pre-proline 0 N--CA 1.452 -0.341 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 -179.487 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 24.4 Cg_exo -65.29 -33.84 46.96 Favored 'Trans proline' 0 N--CA 1.497 1.698 0 C-N-CA 122.356 2.037 . . . . 0.0 111.031 178.2 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -65.14 -41.69 94.54 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.96 179.93 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.4 mt -64.93 -43.13 96.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.36 -179.869 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.49 -43.78 98.43 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.778 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 51.3 mtt-85 -64.06 -46.42 84.42 Favored 'General case' 0 CA--C 1.513 -0.463 0 CA-C-O 121.147 0.498 . . . . 0.0 110.808 179.911 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.62 -49.93 73.27 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.834 -178.98 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.22 -28.74 69.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.149 178.59 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.39 -43.56 76.4 Favored Glycine 0 N--CA 1.445 -0.755 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.695 -178.039 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 9.5 mmt180 -66.78 -41.52 87.52 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.028 0.442 . . . . 0.0 110.7 179.663 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.48 ' O ' ' N ' ' A' ' 40' ' ' PHE . 2.2 m -63.9 -43.04 97.17 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.95 179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 4.8 mt -60.36 -37.43 80.69 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.783 -178.017 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.604 HD23 ' NZ ' ' A' ' 41' ' ' LYS . 39.8 mt -59.78 -38.42 81.81 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.305 0.574 . . . . 0.0 109.593 179.548 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -87.06 -24.11 24.72 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 179.504 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . 0.48 ' N ' ' O ' ' A' ' 36' ' ' THR . 7.1 t80 -71.34 -47.15 58.26 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.955 -179.248 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.604 ' NZ ' HD23 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.4 -35.41 80.81 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.945 -179.618 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.5 m -65.12 -39.26 92.82 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.475 179.207 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.58 -40.5 73.25 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.57 179.259 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.62 -42.2 98.21 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.887 179.272 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.673 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.06 -29.98 33.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.0 -179.141 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -76.26 -30.81 57.99 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.198 -179.932 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 57.5 mt -70.03 -32.59 70.81 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.964 0.411 . . . . 0.0 111.258 -179.626 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.673 HG22 ' O ' ' A' ' 45' ' ' LYS . 5.1 m -41.48 -37.35 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.732 -179.233 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.465 ' C ' ' H ' ' A' ' 51' ' ' ASP . 98.4 p -173.04 98.88 0.13 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.262 179.912 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -76.2 35.13 1.3 Allowed Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 -179.852 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.465 ' H ' ' C ' ' A' ' 49' ' ' SER . 42.8 p-10 -154.62 111.12 3.27 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.838 0.351 . . . . 0.0 110.725 179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.9 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.607 179.816 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.7 ttp . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -74.49 -0.04 16.26 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.753 -179.866 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 m -104.2 -23.58 13.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.283 179.664 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -83.93 -13.99 52.08 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.979 -179.792 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.684 HD12 ' HA3' ' A' ' 9' ' ' GLY . 17.8 pt -65.71 -42.38 92.45 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.018 179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 77.47 -132.73 12.3 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.059 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.0 OUTLIER -79.17 -42.56 1.66 Allowed Pre-proline 0 C--N 1.326 -0.416 0 O-C-N 122.785 -0.244 . . . . 0.0 110.57 179.094 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.528 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 82.9 Cg_exo -43.11 -31.5 2.49 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 C-N-CA 121.564 1.509 . . . . 0.0 111.398 179.773 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.684 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -84.93 -25.94 39.35 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 179.037 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.536 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.4 tt -62.56 -41.2 98.77 Favored 'General case' 0 N--CA 1.454 -0.23 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.861 -179.911 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.928 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.6 -45.22 97.63 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.446 -179.061 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.9 tp -59.33 -44.28 92.63 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.632 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.9 mt -66.25 -41.79 89.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.319 178.593 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -57.43 -41.52 80.62 Favored 'General case' 0 N--CA 1.436 -1.159 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.751 -177.374 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.928 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.8 t -57.29 -41.71 78.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.119 179.732 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 38.4 mm -52.99 -34.45 20.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.867 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.562 179.691 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.07 -31.64 61.29 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.532 0.682 . . . . 0.0 110.13 179.312 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 23' ' ' PRO . 25.4 mt -64.66 -38.29 90.5 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.41 -178.921 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.463 HG23 ' H ' ' A' ' 19' ' ' ILE . 0.7 OUTLIER -57.98 -42.48 82.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 C-N-CA 120.371 -0.532 . . . . 0.0 110.058 -179.727 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.433 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -85.16 -36.12 10.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.894 -179.991 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 -94.98 -79.8 0.42 Allowed 'General case' 0 C--N 1.345 0.379 0 C-N-CA 121.153 -0.219 . . . . 0.0 110.89 -179.805 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' HA2' ' HD3' ' A' ' 23' ' ' PRO . . . 133.9 142.36 4.7 Favored Glycine 0 CA--C 1.54 1.629 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 178.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.477 ' HG3' HD13 ' A' ' 18' ' ' LEU . 16.4 Cg_exo -74.8 -19.5 18.3 Favored 'Trans proline' 0 N--CA 1.503 2.05 0 C-N-CA 123.145 2.564 . . . . 0.0 112.488 -178.929 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -99.28 -7.95 25.66 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 113.884 -1.507 . . . . 0.0 110.739 -177.004 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -100.11 -20.94 15.76 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.495 178.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.513 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.5 OUTLIER -78.5 -48.11 1.87 Allowed Pre-proline 0 CA--C 1.534 0.35 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -179.712 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.513 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 32.1 Cg_exo -56.3 -39.45 91.19 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.513 2.142 . . . . 0.0 111.706 179.763 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -63.22 -45.08 93.33 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.435 -179.983 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.0 mt -67.74 -42.03 85.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.021 179.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.56 -43.36 97.69 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.544 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 36.3 mtt-85 -63.56 -48.2 78.45 Favored 'General case' 0 CA--C 1.514 -0.425 0 CA-C-O 120.896 0.379 . . . . 0.0 110.753 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.75 -48.52 80.34 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.776 -179.02 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.2 -29.03 69.81 Favored 'General case' 0 C--N 1.327 -0.407 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.32 -45.95 81.42 Favored Glycine 0 CA--C 1.526 0.772 0 CA-C-N 115.209 -0.905 . . . . 0.0 111.036 -178.343 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.1 mmt85 -66.53 -44.52 82.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.051 0.453 . . . . 0.0 110.684 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -64.06 -43.6 94.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.162 179.758 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.1 mt -68.5 -35.93 78.19 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.326 0.584 . . . . 0.0 111.512 -179.615 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 41.6 tp -57.93 -39.39 77.9 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.772 -179.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -81.2 -21.99 39.19 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.366 -179.366 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -68.83 -46.14 69.33 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 120.586 -0.446 . . . . 0.0 111.507 -179.525 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.17 -33.91 76.87 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.051 0.453 . . . . 0.0 110.602 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.95 -33.15 75.17 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.776 179.805 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.438 ' O ' ' CB ' ' A' ' 47' ' ' LEU . . . -83.78 -43.91 14.95 Favored 'General case' 0 CA--C 1.513 -0.464 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.027 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . 0.82 ' O ' HG13 ' A' ' 48' ' ' VAL . 2.0 m -62.03 -46.05 90.89 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 120.813 -0.355 . . . . 0.0 110.159 179.123 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.578 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.2 tmmm? -60.55 -44.87 95.65 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.602 0.564 . . . . 0.0 110.942 -179.444 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -77.45 -28.8 52.53 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.009 -0.541 . . . . 0.0 111.053 -179.633 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.735 HD13 ' C ' ' A' ' 47' ' ' LEU . 1.6 tm? -70.8 -43.54 68.45 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.629 -179.472 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 44' ' ' THR . 15.5 m -25.61 -40.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-O 121.16 0.505 . . . . 0.0 111.505 -179.446 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.577 ' N ' ' O ' ' A' ' 47' ' ' LEU . 35.7 p -157.28 -40.58 0.07 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.162 178.735 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 61.24 37.66 94.37 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 54.0 p-10 -66.69 144.21 56.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.048 0.451 . . . . 0.0 110.616 -179.67 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.687 -179.955 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.9 ttp . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -89.16 7.92 32.75 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.941 -179.653 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -103.93 -24.08 13.29 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.069 179.97 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.2 m-80 -80.44 -14.01 58.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.056 -179.72 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 9.8 pt -65.51 -42.97 94.39 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.457 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.954 -179.914 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 72.26 -134.8 21.73 Favored Glycine 0 CA--C 1.525 0.719 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.338 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.503 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.5 OUTLIER -73.2 -45.14 8.03 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.649 179.24 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.492 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.1 Cg_exo -40.67 -37.97 2.45 Favored 'Trans proline' 0 N--CA 1.495 1.575 0 C-N-CA 121.746 1.63 . . . . 0.0 112.551 -179.943 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -76.48 -28.03 60.35 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 111.076 -0.809 . . . . 0.0 111.076 179.363 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.503 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.7 tt -64.03 -38.95 92.94 Favored 'General case' 0 C--N 1.33 -0.267 0 O-C-N 122.788 -0.242 . . . . 0.0 111.158 -179.513 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.949 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.08 -44.62 95.38 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.413 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.661 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.6 tp -58.5 -44.75 89.56 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.562 -0.532 . . . . 0.0 109.562 -179.865 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.2 mt -66.53 -42.11 89.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 CA-C-O 121.095 0.474 . . . . 0.0 110.239 178.388 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.6 t80 -57.14 -42.14 80.4 Favored 'General case' 0 N--CA 1.439 -1.022 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.142 -177.302 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.949 HG23 ' O ' ' A' ' 11' ' ' ILE . 16.4 t -56.82 -42.19 77.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.257 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 29.6 mm -53.29 -32.67 19.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.992 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.08 -35.67 49.11 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.112 179.124 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.445 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.0 mt -64.19 -40.79 96.83 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.736 -178.967 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.415 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -59.81 -41.69 86.47 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 119.981 -0.687 . . . . 0.0 110.298 -179.527 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -38.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.773 179.262 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -94.53 -72.45 0.62 Allowed 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 121.184 -0.206 . . . . 0.0 111.091 -179.929 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.445 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.21 142.0 6.15 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 179.659 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -69.97 -16.91 36.86 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.225 1.95 . . . . 0.0 111.656 -179.891 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -92.6 -0.42 57.32 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.637 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 8.6 mptt -101.57 -8.38 21.92 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.811 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.583 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 1.4 mt -83.49 -41.24 0.8 Allowed Pre-proline 0 CA--C 1.534 0.362 0 C-N-CA 121.012 -0.275 . . . . 0.0 110.442 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.583 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 27.2 Cg_exo -63.99 -35.74 52.96 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.716 2.277 . . . . 0.0 111.258 179.095 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -64.93 -41.49 95.48 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.695 -179.944 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 93.0 mt -65.09 -43.57 95.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.715 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.327 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -61.01 -43.77 99.03 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -179.73 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 55.3 mtt-85 -63.99 -45.57 88.43 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 121.07 0.462 . . . . 0.0 110.713 179.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.99 -48.75 78.95 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.515 -0.766 . . . . 0.0 109.81 -179.064 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -64.87 -29.13 70.07 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.16 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.79 82.91 Favored Glycine 0 N--CA 1.446 -0.636 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.792 -178.419 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.0 mmt85 -65.76 -42.03 91.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.025 0.44 . . . . 0.0 110.445 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.64 -43.32 97.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.1 179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 19.4 mt -71.13 -34.76 71.33 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.479 0.657 . . . . 0.0 111.28 -179.881 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.591 HD12 ' NZ ' ' A' ' 41' ' ' LYS . 11.0 tp -58.51 -40.63 83.4 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.22 -178.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.0 pt-20 -75.72 -22.79 56.24 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.865 -179.563 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -66.41 -49.75 65.74 Favored 'General case' 0 CA--C 1.53 0.201 0 C-N-CA 120.746 -0.381 . . . . 0.0 112.0 -179.123 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.591 ' NZ ' HD12 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.81 -34.13 77.63 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.354 -178.951 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.3 m -64.89 -36.65 85.05 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.232 179.764 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -75.75 -42.42 50.54 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.485 179.038 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.39 -43.04 98.71 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.02 179.115 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.709 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -53.64 -29.32 37.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.883 -0.598 . . . . 0.0 110.084 -179.381 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.5 m -76.7 -30.52 56.73 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.022 -179.61 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 58.6 mt -69.97 -35.57 74.56 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.883 0.373 . . . . 0.0 111.191 -179.494 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.709 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.1 m -41.6 130.5 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.58 -179.449 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.485 ' C ' ' H ' ' A' ' 51' ' ' ASP . 20.1 m 42.43 47.67 4.35 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.589 -179.961 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -71.4 37.48 0.56 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 111.098 -0.801 . . . . 0.0 111.098 -179.694 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 49' ' ' SER . 45.5 t0 -128.17 105.9 8.69 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.789 0.328 . . . . 0.0 110.424 179.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.668 179.956 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.411 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 . . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.411 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -77.31 -2.21 33.73 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 121.124 0.488 . . . . 0.0 110.695 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -97.28 -23.21 16.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.101 179.823 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -68.45 -27.7 66.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.469 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.9 pt -62.18 -48.86 86.45 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 C-N-CA 120.425 -0.51 . . . . 0.0 110.548 -179.763 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.469 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 67.13 -133.47 31.16 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 179.801 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.3 mp -60.2 -53.62 63.21 Favored Pre-proline 0 C--O 1.223 -0.314 0 O-C-N 122.474 -0.427 . . . . 0.0 110.465 -179.607 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.409 ' HD2' ' O ' ' A' ' 5' ' ' ILE . 21.3 Cg_exo -43.45 -26.88 1.12 Allowed 'Trans proline' 0 N--CA 1.504 2.124 0 C-N-CA 122.766 2.31 . . . . 0.0 112.585 178.325 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -89.65 -26.48 24.86 Favored Glycine 0 N--CA 1.469 0.839 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 176.702 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.548 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.4 tt -62.72 -41.15 99.02 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.265 -0.467 . . . . 0.0 111.266 179.56 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -59.65 -45.39 94.34 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.427 0 C-N-CA 121.003 -0.279 . . . . 0.0 110.67 -179.342 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tp -59.16 -45.23 91.53 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 120.579 -0.448 . . . . 0.0 109.831 -179.513 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.4 mt -65.91 -41.99 91.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-O 121.012 0.434 . . . . 0.0 110.304 178.498 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -56.83 -42.32 79.42 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.261 -177.841 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.4 t -57.67 -42.2 81.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.138 179.767 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.3 mm -52.5 -34.89 19.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.771 -179.881 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.42 ' HB1' ' HD2' ' A' ' 21' ' ' PHE . . . -74.12 -30.36 62.27 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-O 121.322 0.582 . . . . 0.0 110.22 179.73 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.424 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 11.8 mt -69.37 -41.17 76.9 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.064 -178.876 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.486 HG23 ' O ' ' A' ' 15' ' ' VAL . 0.8 OUTLIER -58.51 -43.23 86.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.133 -0.627 . . . . 0.0 109.505 -178.856 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.553 HG23 ' N ' ' A' ' 21' ' ' PHE . 1.5 tt -78.68 -55.28 10.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.021 178.708 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.553 ' N ' HG23 ' A' ' 20' ' ' ILE . 30.7 m-85 -81.42 -75.22 0.29 Allowed 'General case' 0 C--O 1.232 0.172 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.407 -179.21 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.424 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.0 144.69 5.78 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.669 -0.973 . . . . 0.0 110.669 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.425 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 59.7 Cg_endo -70.54 -18.43 33.33 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.603 2.202 . . . . 0.0 111.76 179.68 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.0 t -92.74 -28.15 16.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.916 -179.671 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -79.36 -33.65 42.77 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 120.936 0.398 . . . . 0.0 110.713 -179.768 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.472 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 1.3 mp -58.49 -62.35 5.81 Favored Pre-proline 0 C--N 1.327 -0.378 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.577 -179.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.472 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 10.7 Cg_endo -51.16 -35.16 50.99 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 122.475 2.116 . . . . 0.0 111.663 -179.628 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -62.49 -46.45 88.38 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.023 0.44 . . . . 0.0 110.115 179.421 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 77.8 mt -68.12 -41.2 84.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.194 179.409 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -58.73 -42.55 96.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -179.59 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 46.1 mtt-85 -63.36 -46.37 86.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.796 0.331 . . . . 0.0 110.816 179.811 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -49.98 73.69 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.103 -179.036 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.1 -28.63 69.58 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.499 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -44.23 81.42 Favored Glycine 0 N--CA 1.444 -0.794 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.712 -178.454 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 12.6 mmt180 -65.87 -42.96 89.72 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.033 0.444 . . . . 0.0 110.537 179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.92 -43.25 96.47 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.107 179.638 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.5 mt -70.12 -35.56 74.18 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.197 0.522 . . . . 0.0 111.311 -179.558 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.409 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 34.8 tp -57.95 -41.29 82.54 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.393 -178.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -75.37 -21.48 58.27 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.178 -179.97 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.97 -48.81 74.99 Favored 'General case' 0 C--O 1.231 0.112 0 CA-C-O 121.032 0.444 . . . . 0.0 111.712 -178.894 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.409 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.38 -34.3 77.84 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.43 -179.186 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.0 m -64.71 -39.58 93.89 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.562 -0.744 . . . . 0.0 109.694 179.791 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -72.35 -41.23 66.67 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.334 179.301 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.13 -43.57 98.0 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.877 179.194 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -55.08 -28.62 53.79 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.828 -179.302 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -74.48 -32.05 62.43 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.703 -179.33 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.8 mt -69.84 -41.0 75.51 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.844 0.354 . . . . 0.0 110.768 -179.742 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.503 HG22 ' N ' ' A' ' 49' ' ' SER . 2.4 p -80.91 160.28 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 CA-C-O 121.161 0.505 . . . . 0.0 109.883 179.453 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.503 ' N ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER 77.32 -28.17 0.17 Allowed 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.362 -179.914 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.44 ' H ' ' C ' ' A' ' 48' ' ' VAL . . . 62.9 38.35 96.41 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.0 t0 43.99 80.13 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.865 0.364 . . . . 0.0 110.919 -179.989 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.31 -179.902 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.2 ttp . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.438 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 65.7 m-85 -78.6 -4.23 47.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.179 -0.918 . . . . 0.0 110.753 -179.793 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -97.76 -24.42 15.47 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.055 179.761 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 68.5 m-80 -67.43 -33.41 75.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.556 179.651 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.516 ' CG1' ' H ' ' A' ' 6' ' ' GLY . 3.1 pt -49.92 -61.29 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.867 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.516 ' H ' ' CG1' ' A' ' 5' ' ' ILE . . . 98.65 -148.34 18.81 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -179.066 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.552 ' N ' ' HD2' ' A' ' 8' ' ' PRO . 0.3 OUTLIER -47.92 -47.54 63.55 Favored Pre-proline 0 C--O 1.217 -0.621 0 CA-C-O 118.837 -0.602 . . . . 0.0 109.84 178.738 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.552 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 1.9 Cg_endo -36.99 -43.32 0.95 Allowed 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 121.835 1.69 . . . . 0.0 111.97 179.278 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -60.55 -36.84 92.28 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 111.283 -0.727 . . . . 0.0 111.283 179.852 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.448 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.0 tt -62.91 -40.21 96.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.749 -0.225 . . . . 0.0 110.679 -179.622 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.926 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -59.95 -44.54 94.77 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.458 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 -179.929 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 42.4 tp -58.66 -44.81 90.25 Favored 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.428 -0.509 . . . . 0.0 109.663 -179.687 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 28.7 mt -66.46 -42.03 89.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 121.071 0.462 . . . . 0.0 110.254 178.151 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -57.24 -41.87 80.38 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.103 -177.429 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.926 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.7 t -57.24 -42.19 79.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.099 179.781 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 32.2 mm -52.96 -33.92 19.99 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.667 179.821 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.27 -36.87 58.23 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.196 179.048 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.446 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 8.7 mt -64.27 -40.94 96.99 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.829 -178.94 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.9 tt -60.63 -41.71 89.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.241 -179.668 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.67 -37.6 15.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.598 -0.273 . . . . 0.0 110.775 178.996 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -96.2 -73.0 0.61 Allowed 'General case' 0 C--N 1.342 0.264 0 C-N-CA 121.204 -0.198 . . . . 0.0 110.93 179.851 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 122.2 142.83 6.35 Favored Glycine 0 CA--C 1.534 1.261 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.455 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -71.8 -10.54 26.55 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.618 2.212 . . . . 0.0 112.232 179.962 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 11.4 t -91.82 -11.44 36.52 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.949 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -88.59 -16.31 32.86 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.239 -179.384 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.444 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 22.5 mt -75.6 -55.0 2.15 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.962 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.444 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 11.6 Cg_exo -40.24 -43.31 3.82 Favored 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 121.627 1.552 . . . . 0.0 111.706 177.432 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 78.5 tt0 -65.11 -43.43 92.01 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.541 -179.313 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.16 -43.18 95.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.71 -179.71 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.37 -43.01 97.7 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -179.379 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 57.8 mtt180 -63.24 -46.09 88.54 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 121.157 0.504 . . . . 0.0 110.709 179.771 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.82 -47.12 86.5 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.719 -178.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.11 -29.17 70.01 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.202 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.76 85.31 Favored Glycine 0 CA--C 1.525 0.686 0 CA-C-N 114.916 -1.038 . . . . 0.0 111.007 -178.529 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.3 mmt85 -68.11 -40.95 82.43 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.986 0.422 . . . . 0.0 110.889 -179.983 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.7 m -63.5 -44.29 94.75 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.57 -179.812 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 38.6 mt -67.68 -37.15 81.91 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-O 121.426 0.632 . . . . 0.0 111.466 -179.576 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 38.8 tp -58.06 -41.12 82.67 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.701 -179.18 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -78.31 -20.76 50.8 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.945 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.97 -48.92 72.31 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.702 -178.735 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.03 -34.73 78.68 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.55 -179.13 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.8 m -65.29 -39.72 92.9 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.91 179.723 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -37.73 80.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.226 0.536 . . . . 0.0 109.72 178.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.1 m -63.16 -42.49 99.43 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.162 179.221 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.04 -31.56 42.03 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.94 -178.661 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -75.41 -31.92 60.56 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.136 -179.73 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 55.8 mt -70.34 -43.76 69.58 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-O 121.052 0.453 . . . . 0.0 110.69 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -73.3 -31.53 34.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.004 179.892 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.42 ' O ' ' N ' ' A' ' 51' ' ' ASP . 34.5 m -54.63 -34.14 61.67 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.312 -179.336 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -62.58 80.49 0.03 OUTLIER Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 49' ' ' SER . 51.2 t0 -68.31 140.07 55.93 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.359 . . . . 0.0 110.736 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.724 179.849 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.704 ' N ' HD22 ' A' ' 4' ' ' ASN . 96.1 mtp . . . . . 0 N--CA 1.489 1.509 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.405 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.3 m-85 -78.36 4.78 12.08 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.548 179.853 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -100.97 -24.91 14.24 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.344 179.897 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.704 HD22 ' N ' ' A' ' 1' ' ' MET . 48.4 m-80 -69.99 -20.62 63.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.726 -179.864 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.405 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.9 pt -63.92 -44.55 98.02 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.021 -179.783 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 71.28 -136.68 25.33 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.674 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -68.85 -46.08 32.35 Favored Pre-proline 0 CA--C 1.544 0.734 0 O-C-N 122.767 -0.255 . . . . 0.0 110.329 179.083 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.488 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 86.0 Cg_exo -40.82 -37.4 2.35 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 121.678 1.586 . . . . 0.0 112.243 -179.967 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -77.54 -27.52 59.1 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.356 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.504 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.6 tt -64.13 -39.1 93.31 Favored 'General case' 0 C--N 1.332 -0.178 0 O-C-N 122.975 -0.133 . . . . 0.0 111.045 -179.487 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.953 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -59.86 -44.81 95.04 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.418 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 -179.674 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 47.8 tp -58.5 -45.28 89.09 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.847 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.0 mt -66.11 -42.15 90.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 123.501 0.5 . . . . 0.0 110.241 178.27 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -57.07 -42.58 80.88 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.988 -177.433 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.953 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.2 t -57.21 -42.67 80.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.095 179.812 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 36.0 mm -50.95 -32.77 12.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.834 179.887 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.41 -35.43 47.04 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.181 179.081 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.459 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 15.5 mt -65.13 -40.07 93.94 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.178 -0.465 . . . . 0.0 112.118 -178.741 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.44 ' H ' HG22 ' A' ' 19' ' ' ILE . 0.0 OUTLIER -59.43 -42.18 86.86 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 C-N-CA 120.17 -0.612 . . . . 0.0 110.123 -179.607 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -82.9 -36.99 13.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.921 179.327 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -96.24 -74.5 0.56 Allowed 'General case' 0 C--N 1.344 0.332 0 C-N-CA 121.085 -0.246 . . . . 0.0 110.786 179.61 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.459 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.56 144.89 5.74 Favored Glycine 0 CA--C 1.531 1.043 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.483 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -68.29 -19.39 44.1 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.408 2.072 . . . . 0.0 112.067 -179.788 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 10.9 t -99.97 6.58 45.13 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.115 -179.819 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -108.36 -27.57 9.9 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.564 -0.289 . . . . 0.0 110.583 -179.577 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.449 ' CB ' ' CD ' ' A' ' 27' ' ' PRO . 4.3 mp -78.25 -62.89 0.47 Allowed Pre-proline 0 C--N 1.324 -0.502 0 CA-C-N 116.596 -0.274 . . . . 0.0 110.564 179.694 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.449 ' CD ' ' CB ' ' A' ' 26' ' ' LEU . 19.1 Cg_endo -56.97 -29.52 82.9 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.084 1.856 . . . . 0.0 111.422 -179.648 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -65.51 -44.21 87.67 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.448 179.173 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.68 -42.75 93.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.571 179.744 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -59.95 -43.49 98.07 Favored Glycine 0 CA--C 1.524 0.654 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 -179.485 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . 0.546 ' O ' ' NH1' ' A' ' 35' ' ' ARG . 68.3 mtt180 -63.57 -45.92 88.24 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.118 0.485 . . . . 0.0 110.709 179.91 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.44 -46.97 86.12 Favored 'General case' 0 C--N 1.319 -0.72 0 C-N-CA 120.026 -0.669 . . . . 0.0 109.683 -179.085 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.17 -29.56 70.4 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.391 178.522 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.1 -45.15 83.09 Favored Glycine 0 N--CA 1.447 -0.616 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.878 -178.243 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.546 ' NH1' ' O ' ' A' ' 31' ' ' ARG . 20.1 mmt-85 -66.12 -42.49 89.12 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.915 0.388 . . . . 0.0 110.631 179.899 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.81 -43.69 95.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.919 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.0 mt -69.29 -36.46 77.06 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.185 0.517 . . . . 0.0 111.529 -179.663 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.4 ' O ' ' HG3' ' A' ' 41' ' ' LYS . 29.2 tp -57.67 -41.83 82.34 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.392 -179.128 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -75.25 -21.54 58.51 Favored 'General case' 0 C--N 1.312 -1.053 0 C-N-CA 120.253 -0.579 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.71 -48.41 77.22 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-O 120.849 0.357 . . . . 0.0 111.912 -178.779 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.4 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.0 OUTLIER -64.96 -34.4 78.34 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.538 -179.147 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 39.4 m -64.83 -39.59 93.82 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.888 179.771 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.08 -37.91 78.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.96 179.314 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -62.65 -42.67 99.74 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.933 179.273 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -53.7 -29.99 41.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.013 -179.151 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.5 t -75.66 -33.38 60.43 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.995 -179.314 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.5 mt -70.25 -43.63 70.16 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.975 0.417 . . . . 0.0 110.955 -179.629 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.532 HG13 ' N ' ' A' ' 49' ' ' SER . 7.0 p -70.33 -45.8 73.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.848 179.831 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.532 ' N ' HG13 ' A' ' 48' ' ' VAL . 33.6 p -70.76 -16.75 62.78 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.478 -179.48 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -65.39 68.49 0.1 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.775 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.471 ' N ' ' O ' ' A' ' 49' ' ' SER . 91.7 m-20 -69.37 142.73 53.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.859 0.361 . . . . 0.0 110.696 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.467 -179.894 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.532 ' N ' ' OD1' ' A' ' 4' ' ' ASN . 97.2 mtp . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.401 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.6 m-85 -79.27 -1.25 35.75 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 121.012 0.435 . . . . 0.0 110.515 -179.983 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -102.8 -23.8 13.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.289 -179.938 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.532 ' OD1' ' N ' ' A' ' 1' ' ' MET . 10.4 m120 -74.97 -14.75 60.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 179.977 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.401 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.8 pt -65.38 -44.03 94.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.086 -179.887 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.23 -136.39 26.72 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.3 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.28 -45.03 13.85 Favored Pre-proline 0 C--N 1.329 -0.299 0 C-N-CA 121.156 -0.217 . . . . 0.0 110.695 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.499 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.7 Cg_exo -41.44 -29.81 0.77 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 121.451 1.434 . . . . 0.0 111.205 179.07 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -85.57 -29.27 27.41 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 179.238 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.697 HD23 ' O ' ' A' ' 10' ' ' LEU . 6.0 tt -61.06 -41.26 96.28 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.713 0.292 . . . . 0.0 110.616 -179.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.946 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.82 -44.28 97.24 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.396 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.847 -179.697 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.3 tp -58.04 -46.88 84.63 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -179.324 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 1.8 mp -64.95 -41.59 92.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 121.072 0.463 . . . . 0.0 110.117 178.136 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -57.21 -42.6 81.62 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.146 -177.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.946 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.5 t -57.1 -42.43 79.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.181 179.909 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.7 mm -52.09 -30.82 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.708 179.666 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.94 -36.6 27.82 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.987 179.265 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.437 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 13.6 mt -64.93 -41.17 95.77 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.997 -178.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.4 tp -59.5 -42.7 88.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.869 0 C-N-CA 120.209 -0.596 . . . . 0.0 109.745 -179.375 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.98 -37.37 15.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.933 178.675 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -95.41 -75.13 0.53 Allowed 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 121.176 -0.209 . . . . 0.0 110.695 179.902 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.437 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 127.01 140.88 5.29 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.505 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.458 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 61.5 Cg_endo -70.52 -17.9 33.82 Favored 'Trans proline' 0 N--CA 1.493 1.447 0 C-N-CA 122.297 1.998 . . . . 0.0 111.975 -179.907 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.9 t -92.62 -7.99 45.43 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.971 179.947 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.6 tptm -96.02 -33.47 12.11 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.27 179.914 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.497 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -65.26 -48.61 68.2 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.378 -179.441 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.497 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 31.4 Cg_exo -56.37 -37.73 96.47 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.662 2.241 . . . . 0.0 111.678 179.437 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -63.23 -41.95 99.17 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.889 -179.845 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.07 -43.37 95.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.337 -179.694 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.41 ' O ' ' N ' ' A' ' 34' ' ' GLY . . . -60.5 -43.69 98.53 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.521 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 39.5 mtt-85 -65.49 -45.69 82.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 179.957 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.49 -40.71 97.59 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.576 -179.247 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -76.06 -27.88 57.41 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.549 -0.751 . . . . 0.0 110.035 178.734 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 30' ' ' GLY . . . -54.63 -53.17 40.61 Favored Glycine 0 N--CA 1.447 -0.628 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -177.455 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.508 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 1.4 mpt_? -63.59 -43.23 97.56 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.516 0.198 . . . . 0.0 111.191 -179.894 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.2 m -64.52 -43.25 94.63 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.445 0.641 . . . . 0.0 109.885 179.519 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 62.5 mt -73.35 -34.18 65.48 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 115.613 -0.722 . . . . 0.0 111.319 -179.57 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 27.4 tp -58.33 -39.78 80.37 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.166 -179.425 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -77.61 -22.72 50.37 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.094 -179.693 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.8 -48.22 75.22 Favored 'General case' 0 N--CA 1.457 -0.1 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.819 -179.222 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.51 -34.83 78.64 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.631 -178.864 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.9 m -65.17 -40.76 94.76 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.732 179.669 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -69.78 -39.56 76.56 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.059 179.196 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.5 m -63.22 -43.14 98.97 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.007 179.277 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.726 ' O ' HG22 ' A' ' 48' ' ' VAL . 4.5 tmmt? -53.32 -29.25 32.66 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.121 -179.403 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.3 m -77.54 -28.67 51.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.747 -0.381 . . . . 0.0 111.037 -179.951 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 69.8 mt -71.9 -21.1 61.69 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-O 120.956 0.408 . . . . 0.0 111.292 -179.605 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.726 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.3 m -57.05 -38.43 60.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.491 -178.909 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.421 ' OG ' ' N ' ' A' ' 50' ' ' GLY . 20.9 p -95.4 -54.71 3.3 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.597 -179.923 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.421 ' N ' ' OG ' ' A' ' 49' ' ' SER . . . 62.36 36.18 92.71 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.843 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 52' ' ' GLU . 67.1 t0 -150.5 132.73 15.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.87 0.367 . . . . 0.0 110.729 -179.862 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 51' ' ' ASP . 97.2 mt-10 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.665 179.91 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.745 ' N ' HD22 ' A' ' 4' ' ' ASN . 79.4 mtp . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.1 m-85 -84.74 -1.28 56.05 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 120.923 0.392 . . . . 0.0 110.707 -179.942 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.4 m -102.68 -23.91 13.79 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.504 -179.945 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.745 HD22 ' N ' ' A' ' 1' ' ' MET . 56.8 m-80 -78.12 -14.23 59.56 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.799 -180.0 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.1 pt -62.86 -43.44 98.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.75 -179.885 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.03 -135.13 27.7 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.441 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.576 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -71.38 -45.06 13.54 Favored Pre-proline 0 C--N 1.33 -0.272 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.222 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.554 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 81.8 Cg_exo -40.54 -29.93 0.45 Allowed 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 121.524 1.483 . . . . 0.0 111.713 179.574 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -88.29 -26.03 29.38 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 179.252 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.9 tt -61.81 -39.94 93.51 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 120.743 0.306 . . . . 0.0 110.615 -179.939 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.57 -44.74 97.36 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.201 -179.404 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 41.1 tp -58.57 -45.54 88.82 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.576 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 2.3 mm -65.91 -41.39 89.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.804 0.335 . . . . 0.0 110.448 177.959 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.9 t80 -57.62 -42.46 83.39 Favored 'General case' 0 N--CA 1.44 -0.936 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.163 -177.399 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 18.9 t -56.5 -41.77 73.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.112 -179.897 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 27.2 mm -53.79 -31.36 20.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.88 179.664 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.48 -34.99 35.39 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.982 179.135 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.443 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 14.9 mt -64.37 -41.1 96.88 Favored 'General case' 0 C--N 1.314 -0.946 0 O-C-N 121.957 -0.464 . . . . 0.0 111.684 -179.02 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.421 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.9 tt -57.84 -41.16 79.2 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 C-N-CA 120.107 -0.637 . . . . 0.0 110.581 -179.762 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.414 HG22 ' H ' ' A' ' 20' ' ' ILE . 0.0 OUTLIER -84.84 -35.99 10.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.799 179.785 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -95.28 -74.02 0.57 Allowed 'General case' 0 C--O 1.23 0.072 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.793 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.443 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 125.66 142.65 5.82 Favored Glycine 0 CA--C 1.529 0.943 0 N-CA-C 110.679 -0.968 . . . . 0.0 110.679 179.289 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.5 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 65.3 Cg_endo -72.11 -17.99 27.63 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.313 2.009 . . . . 0.0 111.677 179.479 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.3 t -91.85 -20.51 21.39 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.642 -179.904 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -85.19 -33.17 22.34 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-O 121.052 0.453 . . . . 0.0 110.715 -179.766 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 12.3 mt -60.46 -56.16 38.04 Favored Pre-proline 0 C--N 1.326 -0.456 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.793 179.237 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 21.4 Cg_endo -57.19 -31.44 90.6 Favored 'Trans proline' 0 N--CA 1.498 1.766 0 C-N-CA 122.306 2.004 . . . . 0.0 111.756 -179.838 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -63.62 -43.45 96.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.025 0.44 . . . . 0.0 110.137 179.57 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 79.9 mt -65.07 -42.75 95.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.253 179.697 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.04 -43.4 98.26 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.954 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 40.1 mtt-85 -64.66 -47.79 77.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.976 0.417 . . . . 0.0 110.704 -179.951 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.0 -48.77 80.28 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.783 -179.092 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.55 -28.92 69.51 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.95 -0.568 . . . . 0.0 109.471 178.683 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.4 -45.76 82.56 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.909 -178.266 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 14.9 mmm180 -65.71 -39.99 91.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.685 0.278 . . . . 0.0 110.52 179.681 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.0 m -63.7 -42.84 97.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.616 179.374 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 37.1 mt -72.56 -33.94 67.14 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.418 0.628 . . . . 0.0 111.214 -179.724 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 37.2 tp -58.22 -39.02 77.97 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.272 -179.273 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -78.76 -21.94 47.2 Favored 'General case' 0 C--N 1.313 -1.001 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.367 -179.338 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.86 -48.34 74.63 Favored 'General case' 0 CA--C 1.521 -0.145 0 CA-C-O 121.032 0.444 . . . . 0.0 111.584 -179.214 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.4 -34.0 76.78 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.674 -179.105 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 51.5 m -64.72 -38.55 91.37 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.555 179.846 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.36 -41.18 63.73 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.459 179.101 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.6 m -63.17 -44.08 96.46 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.617 179.126 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.761 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.3 tmmm? -58.2 -27.8 64.22 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.81 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.9 t -75.73 -30.22 59.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.056 -179.637 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -69.71 -37.99 76.77 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.926 0.393 . . . . 0.0 111.072 -179.093 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 45' ' ' LYS . 3.2 m -44.97 147.5 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.312 -179.883 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 1.8 m 58.99 14.61 3.46 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.695 -179.996 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -83.39 37.83 2.76 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.916 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 41.0 p-10 -86.16 112.64 21.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.877 0.37 . . . . 0.0 110.49 179.98 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' A' ' 52' ' ' GLU . 55.9 mp0 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.493 -179.963 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.402 ' CG ' ' H ' ' A' ' 2' ' ' PHE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.402 ' H ' ' CG ' ' A' ' 1' ' ' MET . 97.0 m-85 -78.28 -1.32 32.48 Favored 'General case' 0 N--CA 1.452 -0.339 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.762 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.7 m -101.65 -23.3 14.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.379 179.903 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.4 ' N ' HD22 ' A' ' 4' ' ' ASN . 1.1 m-80 -74.68 -16.07 60.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.65 -179.763 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.402 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.2 pt -65.55 -44.32 93.96 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.196 -179.725 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.9 -136.44 25.63 Favored Glycine 0 CA--C 1.528 0.875 0 N-CA-C 110.424 -1.071 . . . . 0.0 110.424 -179.208 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.535 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -71.75 -44.81 12.23 Favored Pre-proline 0 C--N 1.331 -0.239 0 CA-C-O 119.712 -0.185 . . . . 0.0 110.952 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.469 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 85.8 Cg_exo -42.26 -30.53 1.43 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 C-N-CA 121.108 1.205 . . . . 0.0 111.13 178.899 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -83.73 -29.57 31.86 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.919 -0.873 . . . . 0.0 110.919 178.951 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.7 HD23 ' O ' ' A' ' 10' ' ' LEU . 5.7 tt -61.67 -42.04 98.38 Favored 'General case' 0 N--CA 1.455 -0.216 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.68 -179.623 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.945 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -61.3 -45.02 99.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.708 -179.554 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 tp -58.39 -44.87 89.12 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.913 -0.403 . . . . 0.0 109.913 -179.271 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -66.71 -41.44 88.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-O 121.081 0.467 . . . . 0.0 110.115 178.08 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 9.2 t80 -57.78 -42.92 85.13 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.219 -177.863 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.945 HG23 ' O ' ' A' ' 11' ' ' ILE . 26.0 t -55.77 -42.98 72.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.108 -179.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 37.0 mm -51.63 -35.5 17.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.086 179.809 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 20' ' ' ILE . . . -75.93 -30.51 58.74 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.294 0.568 . . . . 0.0 110.052 179.539 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.454 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.4 mt -69.45 -40.67 77.05 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.147 -179.164 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 15' ' ' VAL . 1.3 pt -58.07 -46.44 88.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 C-N-CA 119.728 -0.789 . . . . 0.0 109.179 -179.175 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.523 HG23 ' H ' ' A' ' 21' ' ' PHE . 2.3 tt -73.2 -54.91 14.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.145 -0.934 . . . . 0.0 109.928 178.123 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.523 ' H ' HG23 ' A' ' 20' ' ' ILE . 27.0 m-85 -82.71 -76.17 0.28 Allowed 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 120.968 -0.293 . . . . 0.0 111.562 -179.163 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.454 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 118.61 145.4 7.76 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 -179.957 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -70.57 -13.71 32.87 Favored 'Trans proline' 0 N--CA 1.496 1.661 0 C-N-CA 122.72 2.28 . . . . 0.0 111.811 179.729 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 t -89.95 -10.1 46.33 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.479 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 15.0 mmmt -94.07 -28.72 15.57 Favored 'General case' 0 C--O 1.222 -0.39 0 N-CA-C 112.861 0.689 . . . . 0.0 112.861 -178.583 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.503 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 13.6 mt -68.03 -53.81 18.45 Favored Pre-proline 0 CA--C 1.54 0.577 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.694 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.503 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 9.8 Cg_exo -37.05 -56.16 0.81 Allowed 'Trans proline' 0 C--N 1.316 -1.139 0 C-N-CA 122.403 2.068 . . . . 0.0 112.066 176.496 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 73.7 tt0 -62.28 -43.14 99.52 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.553 -0.294 . . . . 0.0 111.733 -179.561 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.45 -43.37 94.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.857 0 CA-C-O 120.984 0.421 . . . . 0.0 110.601 179.868 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.15 -43.67 98.13 Favored Glycine 0 CA--C 1.52 0.369 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -179.267 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 63.6 mtt85 -64.58 -45.5 86.75 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.221 0.534 . . . . 0.0 110.3 179.651 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.48 -42.25 98.49 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.509 -178.931 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -28.46 65.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.942 178.408 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.95 -52.13 48.79 Favored Glycine 0 N--CA 1.445 -0.722 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.44 -177.622 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . 0.461 ' CD ' ' N ' ' A' ' 35' ' ' ARG . 0.3 OUTLIER -63.94 -42.52 97.31 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 120.45 0.167 . . . . 0.0 111.084 -179.812 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -64.36 -43.88 93.17 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.391 0.615 . . . . 0.0 109.909 179.533 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -72.25 -35.29 68.76 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.287 -179.505 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.5 tp -58.23 -41.03 83.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.06 -179.452 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -76.15 -21.98 55.94 Favored 'General case' 0 C--N 1.314 -0.957 0 C-N-CA 120.285 -0.566 . . . . 0.0 109.998 179.988 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -64.23 -48.78 74.51 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 120.799 0.333 . . . . 0.0 111.722 -178.744 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.65 -34.53 78.44 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.683 -179.075 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 57.9 m -65.16 -39.56 93.12 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.871 179.913 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -68.41 -38.02 80.86 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.702 179.003 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 2.0 m -62.8 -43.67 98.17 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.075 179.474 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.712 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -54.78 -28.16 46.86 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.388 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.2 t -76.23 -32.06 58.71 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.402 -179.326 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.404 ' O ' ' N ' ' A' ' 50' ' ' GLY . 56.1 mt -69.85 -33.85 72.83 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.917 0.389 . . . . 0.0 111.308 -179.23 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.712 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.2 m -43.16 -37.26 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.72 -179.06 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 11.7 t -61.48 -44.18 97.54 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.041 179.671 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 47' ' ' LEU . . . 51.6 32.81 32.52 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.88 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -170.12 100.66 0.28 Allowed 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.701 0.286 . . . . 0.0 110.859 -179.85 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.757 179.886 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.725 ' N ' HD22 ' A' ' 4' ' ' ASN . 77.7 mtm . . . . . 0 N--CA 1.487 1.416 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -84.5 1.23 46.61 Favored 'General case' 0 N--CA 1.45 -0.451 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.609 -179.832 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.6 m -103.43 -23.96 13.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.628 179.918 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.725 HD22 ' N ' ' A' ' 1' ' ' MET . 61.7 m-80 -79.34 -14.4 59.01 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.928 179.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.1 pt -64.68 -43.1 96.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.427 0 C-N-CA 120.879 -0.328 . . . . 0.0 110.764 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 70.96 -135.08 24.06 Favored Glycine 0 CA--C 1.529 0.948 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.329 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 10' ' ' LEU . 0.6 OUTLIER -70.88 -46.02 15.75 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 110.132 -0.322 . . . . 0.0 110.132 178.463 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.512 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 82.8 Cg_exo -39.83 -36.91 1.39 Allowed 'Trans proline' 0 N--CA 1.49 1.316 0 C-N-CA 121.709 1.606 . . . . 0.0 112.491 -179.617 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -79.1 -26.36 58.08 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.651 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 7' ' ' ILE . 7.2 tt -64.71 -38.68 91.81 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-O 120.625 0.25 . . . . 0.0 111.038 -179.593 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.955 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.27 -44.71 96.26 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.683 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.7 tp -58.62 -44.71 90.05 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 -179.722 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 31.3 mt -66.69 -41.77 88.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.948 0.404 . . . . 0.0 110.32 178.147 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -57.21 -42.87 82.14 Favored 'General case' 0 N--CA 1.439 -1.0 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.187 -177.353 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.955 HG23 ' O ' ' A' ' 11' ' ' ILE . 14.5 t -56.35 -41.84 72.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.227 179.806 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.8 mm -52.41 -30.5 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.806 179.547 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.51 -36.04 26.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.179 178.954 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.46 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 16.1 mt -65.29 -41.76 93.81 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.164 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tp -58.41 -41.94 82.84 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 C-N-CA 120.477 -0.489 . . . . 0.0 110.068 -179.352 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.98 -37.07 14.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.954 179.194 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -97.05 -71.08 0.69 Allowed 'General case' 0 C--N 1.342 0.27 0 C-N-CA 120.971 -0.292 . . . . 0.0 110.605 179.748 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.46 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 124.39 143.93 6.3 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.411 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 71.9 Cg_endo -72.23 -14.06 28.45 Favored 'Trans proline' 0 C--N 1.309 -1.546 0 C-N-CA 122.429 2.086 . . . . 0.0 111.579 179.359 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 23.1 t -96.96 -6.06 36.43 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.886 -179.688 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 17.0 mmmt -98.43 -27.0 14.27 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.206 179.562 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.512 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 0.6 OUTLIER -72.03 -48.31 10.81 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.953 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 38.1 Cg_exo -55.21 -38.29 93.74 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 122.648 2.232 . . . . 0.0 111.353 179.643 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -63.36 -43.23 98.26 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.676 179.608 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 97.0 mt -65.15 -43.29 95.63 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.115 -179.936 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.52 -43.61 98.65 Favored Glycine 0 CA--C 1.52 0.372 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.753 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.3 mtt180 -64.45 -49.45 71.39 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 120.993 0.425 . . . . 0.0 110.766 179.967 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.58 -48.11 82.42 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.806 -178.943 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -29.32 69.77 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.396 0.617 . . . . 0.0 109.385 178.532 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.63 ' O ' HD23 ' A' ' 38' ' ' LEU . . . -55.45 -46.63 80.05 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 114.983 -1.008 . . . . 0.0 110.978 -178.192 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.5 mmm180 -65.01 -37.82 88.91 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.731 0.301 . . . . 0.0 110.502 -179.87 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.3 m -63.73 -42.03 97.95 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.76 179.401 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 14.6 mt -63.3 -35.43 80.33 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.375 0.607 . . . . 0.0 110.965 -179.794 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 34' ' ' GLY . 3.4 mm? -58.88 -34.63 71.86 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.201 179.343 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -78.35 -22.96 47.21 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.033 -179.235 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -67.31 -49.79 62.77 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.474 -178.829 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HZ3' HD13 ' A' ' 38' ' ' LEU . 0.0 OUTLIER -63.87 -33.78 76.47 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.535 -179.325 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 37.4 m -65.34 -34.69 78.92 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.534 179.787 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.57 -42.8 24.25 Favored 'General case' 0 CA--C 1.528 0.126 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.25 179.287 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.4 m -63.28 -42.74 99.12 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.835 178.988 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.685 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.7 OUTLIER -53.36 -28.87 31.4 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.754 -178.958 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.4 t -76.4 -31.71 58.12 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.283 -179.664 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.489 ' O ' ' O ' ' A' ' 48' ' ' VAL . 69.5 mt -71.34 -20.5 62.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.297 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.685 HG22 ' O ' ' A' ' 45' ' ' LYS . 5.6 m -53.09 -164.59 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.918 -179.584 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 51' ' ' ASP . 45.8 t -67.09 58.02 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.486 179.714 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' A' ' 48' ' ' VAL . . . -48.09 88.8 0.01 OUTLIER Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.74 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 49' ' ' SER . 43.3 t0 -162.32 170.06 19.54 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.661 0.267 . . . . 0.0 110.651 179.771 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.68 179.939 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.063 0.459 . . . . 0.0 110.22 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.584 ' N ' ' CD1' ' A' ' 2' ' ' PHE . 0.5 OUTLIER -72.32 1.33 7.98 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.305 -178.793 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.2 m -102.1 -23.51 14.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.36 179.96 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -70.7 -22.63 62.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.521 179.972 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.412 HD11 ' O ' ' A' ' 2' ' ' PHE . 3.2 pt -61.32 -57.18 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.317 -179.204 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.64 -132.82 11.38 Favored Glycine 0 CA--C 1.535 1.294 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.245 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.59 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.1 mp -57.45 -50.97 85.11 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-O 119.383 -0.342 . . . . 0.0 110.086 179.002 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.522 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 4.2 Cg_endo -38.49 -31.21 0.21 Allowed 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 122.077 1.851 . . . . 0.0 110.7 176.994 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 7' ' ' ILE . . . -82.55 -32.87 26.56 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.867 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.59 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.6 tt -61.8 -39.97 93.58 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 121.021 -0.272 . . . . 0.0 111.24 -179.368 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.921 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.4 mp -60.88 -45.47 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.259 -179.356 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 tp -59.25 -44.31 92.4 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.239 -179.65 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.9 mt -65.35 -42.76 94.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.466 178.987 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -57.92 -42.26 84.43 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.177 -177.493 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.921 HG23 ' O ' ' A' ' 11' ' ' ILE . 21.1 t -55.87 -41.17 65.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.826 -179.896 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.5 mm -53.92 -36.01 29.58 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.887 179.533 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -72.3 -33.28 67.29 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.478 0.656 . . . . 0.0 110.133 179.349 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.475 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 19.0 mt -63.41 -39.08 93.53 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.693 -179.071 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.425 ' CG1' ' N ' ' A' ' 20' ' ' ILE . 0.6 OUTLIER -58.11 -42.86 84.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.118 -0.633 . . . . 0.0 110.044 -179.41 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.425 ' N ' ' CG1' ' A' ' 19' ' ' ILE . 0.0 OUTLIER -83.5 -37.51 13.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.812 179.97 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -94.01 -73.75 0.56 Allowed 'General case' 0 C--O 1.231 0.115 0 C-N-CA 121.105 -0.238 . . . . 0.0 110.874 179.862 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.475 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 129.12 142.4 5.31 Favored Glycine 0 CA--C 1.531 1.087 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 179.392 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.44 -19.51 43.03 Favored 'Trans proline' 0 N--CA 1.492 1.43 0 C-N-CA 122.283 1.989 . . . . 0.0 111.858 179.743 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 t -88.46 1.72 54.22 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.399 -179.947 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 10.0 mptt -100.0 -12.4 19.77 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.19 179.546 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.588 ' N ' ' CD ' ' A' ' 27' ' ' PRO . 2.6 mt -75.13 -40.58 3.68 Favored Pre-proline 0 C--N 1.326 -0.452 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.482 179.906 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.588 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 26.1 Cg_exo -63.98 -35.6 53.76 Favored 'Trans proline' 0 N--CA 1.494 1.559 0 C-N-CA 122.56 2.173 . . . . 0.0 111.301 179.293 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 76.7 tt0 -65.93 -41.78 90.91 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.017 -179.824 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.5 mt -64.81 -43.44 96.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.379 -179.934 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.62 -43.76 98.6 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.721 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 44.1 mtt-85 -63.78 -45.39 89.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-O 121.243 0.544 . . . . 0.0 110.646 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.13 -48.21 81.14 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.296 -0.865 . . . . 0.0 109.719 -179.118 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.29 -28.91 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.498 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.13 -44.55 83.71 Favored Glycine 0 N--CA 1.446 -0.684 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.982 -178.335 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -66.83 -42.15 86.27 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.117 0.484 . . . . 0.0 110.511 179.956 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 3.1 m -63.97 -43.34 96.06 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.336 179.812 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 18.3 mt -70.54 -34.96 72.84 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.529 0.681 . . . . 0.0 111.433 -179.67 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 13.4 tp -58.48 -40.98 84.22 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.223 -178.957 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -76.16 -22.16 55.72 Favored 'General case' 0 C--N 1.313 -0.987 0 C-N-CA 120.416 -0.514 . . . . 0.0 110.166 -179.529 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -66.4 -49.93 65.17 Favored 'General case' 0 C--O 1.232 0.157 0 C-N-CA 120.857 -0.337 . . . . 0.0 111.88 -179.109 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.05 -34.78 78.79 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.102 0.477 . . . . 0.0 110.518 -178.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 m -65.06 -40.38 94.62 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.742 179.659 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.11 -40.95 74.6 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.991 179.08 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.7 m -63.67 -43.64 96.1 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.134 179.293 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.73 ' O ' HG22 ' A' ' 48' ' ' VAL . 0.8 OUTLIER -53.91 -28.91 39.66 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.976 -179.135 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.6 m -76.64 -30.51 56.89 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.196 -179.917 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 61.8 mt -69.74 -36.34 75.75 Favored 'General case' 0 C--N 1.333 -0.122 0 CA-C-O 120.865 0.364 . . . . 0.0 111.2 -179.597 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.73 HG22 ' O ' ' A' ' 45' ' ' LYS . 4.3 m -41.16 124.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.669 -179.456 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 16.2 m 40.53 55.88 2.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.87 0.367 . . . . 0.0 110.681 -179.736 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.408 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -71.41 55.01 1.19 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 -179.519 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.408 ' OD1' ' O ' ' A' ' 50' ' ' GLY . 4.0 p-10 44.99 37.6 2.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 179.758 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.518 179.988 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -78.68 -3.25 43.16 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.767 -179.841 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.9 m -95.23 -23.09 17.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.191 179.806 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 13.1 m120 -67.42 -32.91 74.12 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.492 HD12 ' HA3' ' A' ' 9' ' ' GLY . 3.1 pt -58.77 -49.05 84.16 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.567 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.586 -179.579 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' N ' ' CG1' ' A' ' 5' ' ' ILE . . . 101.96 -120.23 6.76 Favored Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.431 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.697 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 10.8 tp -92.87 -24.09 0.26 Allowed Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.053 -0.573 . . . . 0.0 111.478 177.324 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.697 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 53.7 Cg_exo -49.89 -39.9 48.94 Favored 'Trans proline' 0 N--CA 1.495 1.599 0 C-N-CA 121.896 1.731 . . . . 0.0 112.384 -178.866 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.492 ' HA3' HD12 ' A' ' 5' ' ' ILE . . . -62.34 -34.64 89.91 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.848 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.8 tt -62.8 -41.88 99.47 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.618 0.247 . . . . 0.0 110.747 -179.076 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.59 -44.77 97.49 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.423 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -179.549 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 44.4 tp -59.24 -44.16 92.38 Favored 'General case' 0 C--N 1.319 -0.73 0 C-N-CA 120.409 -0.517 . . . . 0.0 109.735 -179.478 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 32.4 mt -67.18 -41.43 86.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 120.977 0.418 . . . . 0.0 110.19 178.318 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -57.42 -42.64 82.73 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.289 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 13.5 t -55.64 -41.59 65.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.125 179.99 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 24.1 mm -54.97 -31.69 25.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.925 179.734 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.29 -36.2 46.93 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.165 178.874 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 14.0 mt -64.0 -41.95 97.31 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 122.103 -0.373 . . . . 0.0 111.669 -178.473 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.427 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.7 tt -57.62 -40.77 77.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 C-N-CA 120.043 -0.663 . . . . 0.0 110.368 -179.867 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.406 HD13 ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -84.72 -33.56 8.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.476 -179.957 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.406 ' CD1' HD13 ' A' ' 20' ' ' ILE . 49.2 m-85 -98.13 -78.83 0.48 Allowed 'General case' 0 CA--C 1.52 -0.19 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.308 179.801 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 131.84 141.18 4.68 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.26 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.477 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 58.0 Cg_endo -71.5 -18.66 29.25 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.533 2.156 . . . . 0.0 111.993 179.261 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.8 t -91.0 -24.35 20.11 Favored 'General case' 0 C--N 1.332 -0.163 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.581 -179.966 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 2.4 tptm -83.61 -28.0 28.78 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 121.011 0.434 . . . . 0.0 110.961 -179.75 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.53 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 9.3 mt -63.38 -58.37 16.01 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.753 179.533 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.53 ' HD2' ' N ' ' A' ' 26' ' ' LEU . 14.6 Cg_endo -54.23 -36.95 87.7 Favored 'Trans proline' 0 N--CA 1.492 1.394 0 C-N-CA 122.385 2.057 . . . . 0.0 112.249 -179.608 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -65.93 -45.68 80.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.122 0.487 . . . . 0.0 111.017 -179.693 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 85.8 mt -65.77 -41.4 90.22 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.19 -179.899 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -57.82 -42.58 94.64 Favored Glycine 0 CA--C 1.521 0.46 0 N-CA-C 110.718 -0.953 . . . . 0.0 110.718 -179.542 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -64.42 -51.81 61.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.992 0.425 . . . . 0.0 110.946 179.988 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.15 -48.79 78.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.054 -179.079 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.56 -27.84 68.73 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.454 178.668 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.85 -42.58 79.86 Favored Glycine 0 N--CA 1.445 -0.749 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -178.574 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 10.7 mmt180 -69.61 -43.94 71.72 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.936 0.398 . . . . 0.0 110.74 -179.819 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.4 m -63.97 -43.57 95.38 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.729 179.696 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.1 mt -69.05 -34.57 75.41 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.026 0.441 . . . . 0.0 111.508 -179.767 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 50.5 tp -58.45 -38.68 78.0 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.372 -179.03 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -81.6 -21.59 38.24 Favored 'General case' 0 C--N 1.313 -0.979 0 C-N-CA 120.602 -0.439 . . . . 0.0 110.499 -178.813 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -68.63 -44.88 73.26 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.443 -179.412 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.8 -34.97 78.38 Favored 'General case' 0 C--N 1.317 -0.821 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.825 -178.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.6 m -65.66 -41.83 92.09 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.895 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -73.18 -39.84 65.29 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.458 179.216 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.09 -40.63 98.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.555 179.25 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -53.27 -30.72 40.04 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.039 -178.655 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.8 t -75.7 -33.48 60.35 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.899 -179.615 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 53.2 mt -70.14 -43.0 71.82 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.953 0.406 . . . . 0.0 110.939 -179.524 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.6 p -72.82 -26.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.745 179.679 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . . . . . . . . . 38.9 t -60.0 -42.73 94.91 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.703 -179.368 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 90.81 109.88 1.5 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 -179.842 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 43.8 p-10 -90.75 115.01 27.5 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.787 0.327 . . . . 0.0 110.584 179.886 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' A' ' 51' ' ' ASP . 79.8 tt0 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.425 179.928 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.633 ' N ' HD22 ' A' ' 4' ' ' ASN . 1.5 ptp . . . . . 0 N--CA 1.493 1.696 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.445 ' O ' ' CD1' ' A' ' 5' ' ' ILE . 96.5 m-85 -78.64 -2.38 38.79 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.69 -179.817 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -102.03 -23.43 14.1 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.411 -179.926 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.633 HD22 ' N ' ' A' ' 1' ' ' MET . 70.1 m-80 -76.56 -14.32 60.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.717 -179.806 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.445 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 4.7 pt -63.48 -48.75 85.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.383 179.869 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -118.41 5.93 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.026 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.677 ' N ' ' CD ' ' A' ' 8' ' ' PRO . 6.2 tp -105.12 -17.31 0.17 Allowed Pre-proline 0 CA--C 1.55 0.95 0 N-CA-C 113.71 1.004 . . . . 0.0 113.71 179.306 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.677 ' CD ' ' N ' ' A' ' 7' ' ' ILE . 63.2 Cg_endo -73.51 -52.43 0.14 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 121.944 1.763 . . . . 0.0 112.893 -178.826 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -56.45 -21.76 35.54 Favored Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 179.749 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.9 tt -63.22 -41.75 99.18 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.092 179.62 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.906 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.2 mp -61.22 -44.64 98.77 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.416 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.625 -179.368 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 46.1 tp -59.32 -44.38 92.6 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 120.47 -0.492 . . . . 0.0 109.823 -179.796 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 30.5 mt -66.14 -42.25 90.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 121.162 0.506 . . . . 0.0 110.461 178.416 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 7.5 t80 -56.88 -42.05 79.12 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.268 -177.389 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.906 HG23 ' O ' ' A' ' 11' ' ' ILE . 11.9 t -57.39 -42.22 80.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.065 179.847 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.8 mm -52.92 -31.63 17.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.695 179.737 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -79.88 -36.64 36.29 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.993 179.067 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.413 ' HA ' ' H ' ' A' ' 22' ' ' GLY . 12.2 mt -64.95 -41.3 95.62 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.986 -178.789 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.3 tp -59.93 -42.79 90.56 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.836 0 C-N-CA 120.055 -0.658 . . . . 0.0 109.717 -179.185 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -80.26 -37.3 17.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.965 178.224 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -95.04 -76.0 0.5 Allowed 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 121.166 -0.214 . . . . 0.0 110.718 179.557 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' A' ' 18' ' ' LEU . . . 128.02 139.45 4.83 Favored Glycine 0 CA--C 1.533 1.217 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 179.434 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.455 ' O ' ' CD ' ' A' ' 27' ' ' PRO . 60.0 Cg_endo -69.65 -17.55 38.01 Favored 'Trans proline' 0 N--CA 1.494 1.518 0 C-N-CA 122.22 1.947 . . . . 0.0 112.221 -179.618 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 22.9 t -93.37 -25.41 17.71 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.814 -179.789 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 1.7 tptm -79.17 -34.25 43.29 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-O 121.111 0.481 . . . . 0.0 110.027 179.824 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.436 ' N ' ' HD2' ' A' ' 27' ' ' PRO . 11.6 mt -59.41 -59.41 13.94 Favored Pre-proline 0 CA--C 1.539 0.536 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.759 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.455 ' CD ' ' O ' ' A' ' 23' ' ' PRO . 18.1 Cg_endo -57.81 -31.0 91.23 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.141 1.894 . . . . 0.0 112.12 -179.107 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -64.16 -42.62 96.67 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.925 0.393 . . . . 0.0 110.462 179.686 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 91.4 mt -64.92 -43.79 96.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.405 -179.699 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.8 -44.08 98.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.831 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 47.4 mtt-85 -63.57 -45.56 89.91 Favored 'General case' 0 CA--C 1.515 -0.397 0 CA-C-O 121.215 0.531 . . . . 0.0 110.512 179.793 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -62.26 -46.74 87.45 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.622 -178.996 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.05 -29.5 70.39 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 178.178 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.98 -44.08 82.77 Favored Glycine 0 N--CA 1.445 -0.735 0 CA-C-N 114.891 -1.049 . . . . 0.0 110.868 -178.467 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 8.2 mmt85 -67.95 -41.63 82.2 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.158 0.504 . . . . 0.0 110.92 -179.959 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.8 m -63.41 -43.68 96.82 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.508 -179.791 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 36.1 mt -69.31 -35.66 76.21 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.411 0.625 . . . . 0.0 111.51 -179.94 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 46.0 tp -58.26 -39.76 80.02 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.687 -179.155 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -80.05 -21.97 42.86 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 120.696 -0.401 . . . . 0.0 110.357 -179.428 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -67.88 -45.59 74.06 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 120.897 -0.321 . . . . 0.0 111.766 -179.42 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.68 -35.04 79.25 Favored 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 120.466 -0.494 . . . . 0.0 110.644 -178.603 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 64.9 m -65.52 -41.63 92.91 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.988 179.714 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -70.95 -41.08 71.56 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.175 179.155 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.9 m -63.09 -42.84 99.71 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.434 -0.803 . . . . 0.0 111.217 179.389 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.676 ' O ' HG22 ' A' ' 48' ' ' VAL . 1.5 tmmm? -53.7 -29.03 37.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.715 -179.324 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 t -76.21 -32.05 58.76 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.038 -179.566 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.468 ' C ' ' N ' ' A' ' 49' ' ' SER . 66.5 mt -71.22 -22.52 61.99 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.411 -179.314 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 45' ' ' LYS . 11.0 m -48.45 -14.76 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.499 -179.021 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.468 ' N ' ' C ' ' A' ' 47' ' ' LEU . 38.5 t -59.54 -42.56 92.61 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.988 -179.912 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 92.44 160.35 35.81 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.834 -0.906 . . . . 0.0 110.834 179.633 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 51.7 p-10 -137.04 36.2 2.57 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.942 0.401 . . . . 0.0 110.678 -179.954 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.687 179.935 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.716 ' N ' HD22 ' A' ' 4' ' ' ASN . 96.2 mtp . . . . . 0 N--CA 1.489 1.483 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -80.35 0.91 31.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.044 0.45 . . . . 0.0 110.742 -179.865 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.1 m -102.01 -23.91 14.05 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.696 -179.829 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.716 HD22 ' N ' ' A' ' 1' ' ' MET . 59.0 m-80 -77.7 -14.17 59.69 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.76 -179.961 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 6.7 pt -63.51 -43.72 98.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.864 -179.993 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 68.37 -136.35 30.06 Favored Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -179.495 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.575 ' O ' ' N ' ' A' ' 10' ' ' LEU . 1.2 mp -69.33 -45.19 27.77 Favored Pre-proline 0 N--CA 1.463 0.218 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 178.639 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.536 ' HD2' ' N ' ' A' ' 7' ' ' ILE . 87.3 Cg_exo -40.96 -30.61 0.61 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 121.459 1.44 . . . . 0.0 111.551 179.211 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.53 -26.04 31.27 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.113 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.575 ' N ' ' O ' ' A' ' 7' ' ' ILE . 8.5 tt -61.66 -40.58 95.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-O 120.677 0.275 . . . . 0.0 110.685 179.934 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.934 ' O ' HG23 ' A' ' 15' ' ' VAL . 1.3 mp -60.46 -44.17 95.73 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.417 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.329 -179.377 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -58.69 -46.23 87.72 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.509 -0.476 . . . . 0.0 110.076 -179.768 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.0 mt -65.14 -41.61 92.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.182 0.515 . . . . 0.0 109.779 178.818 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -57.34 -42.92 82.86 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.575 -0.738 . . . . 0.0 110.442 -177.422 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.934 HG23 ' O ' ' A' ' 11' ' ' ILE . 15.9 t -56.67 -41.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.478 179.739 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 19' ' ' ILE . 33.0 mm -53.09 -34.14 20.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.417 179.889 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.7 -35.74 57.69 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.652 0.739 . . . . 0.0 109.842 178.432 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.455 ' O ' ' N ' ' A' ' 22' ' ' GLY . 14.2 mt -64.24 -42.82 96.35 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.122 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' O ' ' A' ' 16' ' ' ILE . 4.5 tt -58.2 -41.61 81.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.816 0 C-N-CA 120.177 -0.609 . . . . 0.0 110.531 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -81.23 -37.31 15.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.804 179.485 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . . . . . . . . . 58.5 m-85 -97.53 -69.45 0.76 Allowed 'General case' 0 C--O 1.234 0.245 0 C-N-CA 120.996 -0.282 . . . . 0.0 111.234 -179.942 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.471 ' O ' ' CD2' ' A' ' 26' ' ' LEU . . . 128.06 144.31 5.84 Favored Glycine 0 C--N 1.338 0.664 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -66.59 -18.19 53.75 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.534 2.156 . . . . 0.0 112.104 179.988 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.4 t -87.95 0.18 56.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.555 -179.815 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.31 -2.45 25.53 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.914 -179.824 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.705 HD22 ' N ' ' A' ' 26' ' ' LEU . 1.8 mm? -85.4 -39.8 0.62 Allowed Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.598 ' CD ' ' N ' ' A' ' 26' ' ' LEU . 22.1 Cg_exo -66.09 -34.72 36.41 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 122.279 1.986 . . . . 0.0 111.215 178.792 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -64.52 -40.75 96.21 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.107 -179.853 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 95.4 mt -64.5 -43.11 96.85 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.189 179.799 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -60.57 -43.76 98.55 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.694 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 31' ' ' ARG . . . . . . . . . . . . . 72.4 mtt180 -64.73 -47.2 79.12 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.119 0.485 . . . . 0.0 110.686 -179.95 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -61.32 -48.44 81.34 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.785 -179.2 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.84 -28.93 69.35 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.732 178.55 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -55.26 -45.87 81.32 Favored Glycine 0 N--CA 1.444 -0.775 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 -178.127 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 35' ' ' ARG . . . . . . . . . . . . . 15.0 mmm180 -65.83 -41.11 92.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.688 0.28 . . . . 0.0 110.641 179.792 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . . . . . . . . . 2.9 m -63.8 -43.18 97.08 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.696 179.28 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 17.6 mt -71.88 -34.79 69.46 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.331 0.586 . . . . 0.0 111.481 -179.353 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 14.9 tp -58.32 -40.92 83.35 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.973 -179.179 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -75.63 -21.83 57.37 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.372 -179.502 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 40' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -63.76 -49.14 74.13 Favored 'General case' 0 C--N 1.339 0.117 0 CA-C-O 121.004 0.431 . . . . 0.0 111.617 -178.669 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.26 -34.62 78.53 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.588 -179.424 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 38.5 m -65.31 -35.25 80.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -80.15 -41.65 24.97 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.193 179.355 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 44' ' ' THR . . . . . . . . . . . . . 1.3 m -63.66 -40.95 98.12 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.715 178.932 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -52.86 -30.84 36.15 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.163 -178.561 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.8 m -75.6 -32.73 60.43 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.999 179.897 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 51.1 mt -70.47 -43.12 70.43 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.985 0.421 . . . . 0.0 111.002 -179.633 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.2 p -73.1 -25.98 22.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.899 179.895 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 49' ' ' SER . . . . . 0.484 ' O ' ' N ' ' A' ' 51' ' ' ASP . 5.3 p -48.47 -24.32 1.24 Allowed 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.505 -179.008 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -61.31 77.77 0.01 OUTLIER Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.852 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.484 ' N ' ' O ' ' A' ' 49' ' ' SER . 53.5 p-10 -83.37 172.81 12.12 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.832 0.348 . . . . 0.0 110.476 179.896 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.612 -179.813 . . . . . . . . 0 0 . 1 stop_ save_